<SEC-DOCUMENT>0001193125-12-223884.txt : 20120510
<SEC-HEADER>0001193125-12-223884.hdr.sgml : 20120510
<ACCEPTANCE-DATETIME>20120510090108
ACCESSION NUMBER:		0001193125-12-223884
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120510
DATE AS OF CHANGE:		20120510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVI BIOPHARMA INC
		CENTRAL INDEX KEY:			0000873303
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				930797222
		STATE OF INCORPORATION:			OR
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14895
		FILM NUMBER:		12827910

	BUSINESS ADDRESS:	
		STREET 1:		3450 MONTE VILLA PARKWAY
		STREET 2:		SUITE 101
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		425-354-5038

	MAIL ADDRESS:	
		STREET 1:		3450 MONTE VILLA PARKWAY
		STREET 2:		SUITE 101
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIVIRALS INC
		DATE OF NAME CHANGE:	19970123
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d326013d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;10-Q
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Mark One) </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the quarterly period ended March&nbsp;31, 2012 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission file number 001-14895
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AVI BIOPHARMA,&nbsp;INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oregon</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>93-0797222</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3450 Monte Villa Parkway, Suite&nbsp;101, Bothell, Washington</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>98021</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (425)&nbsp;354-5038 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act (Check one): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;Reporting&nbsp;Company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of the latest practicable date.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock with $0.0001 par value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>135,743,787</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Class)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Outstanding as of May&nbsp;1, 2012)</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>AVI BIOPHARMA,&nbsp;INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM&nbsp;10-Q </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_1">PART&nbsp;I - FINANCIAL INFORMATION </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_2">Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_3">Balance Sheets - March&nbsp;31, 2012 and December&nbsp;31, 2011 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_4">Statements of Operations and Comprehensive Income (Loss) - Three Months Ended March&nbsp;
31, 2012 and 2011 and from July&nbsp;22, 1980 (Inception) through March&nbsp;31, 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_5">Statements of Cash Flows - Three Months Ended March&nbsp;31, 2012 and 2011 and from July&nbsp;
22, 1980 (Inception) through March&nbsp;31, 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_6">Notes to Financial Statements (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_8">Quantitative and Qualitative Disclosures about Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_9">Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_10">PART&nbsp;II - OTHER INFORMATION </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_11">Legal Proceedings</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_12">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_13">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_14">Defaults Upon Senior Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_15">Mine Safety Disclosures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_16">Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_17">Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc326013_18">Signatures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_1"></A>PART&nbsp;I &#151; FINANCIAL INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_2"></A>Item&nbsp;1. Financial Statements. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AVI BIOPHARMA, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A Development Stage Company) </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A NAME="toc326013_3"></A>BALANCE SHEETS </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(in thousands, except per share data) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Current Assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and Equipment, net of accumulated depreciation and amortization of $15,982 and $15,765</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Costs, net of accumulated amortization of $2,298 and $2,199</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and Shareholders&#146; Equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued employee compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt, current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant valuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Current Liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and Contingencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt, non-current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; Equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $.0001 par value, 20,000,000 shares authorized; none issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $.0001 par value, 300,000,000 and 200,000,000 shares authorized; 135,743,787 and 135,743,120 issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">341,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deficit accumulated during the development stage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(327,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(309,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Shareholders&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Liabilities and Shareholders&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A NAME="toc326013_4"></A>AVI BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A Development Stage Company) </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">STATEMENTS OF OPERATIONS and COMPREHENSIVE INCOME (LOSS) </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(in thousands, except per share amounts) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">July&nbsp;22,&nbsp;1980</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Inception)&nbsp;through</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March 31, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues from license fees, grants and research contracts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">348,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquired in-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(337,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (loss):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain (loss) on change in warrant valuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realized gain on sale of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Write-down of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(327,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income (loss):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Write-down of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realized gain on sale of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrealized loss on short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(327,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share - basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share - diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of common shares outstanding for computing basic income (loss) per share (in thousands)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of common shares outstanding for computing diluted income (loss) per share (in thousands)</FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A NAME="toc326013_5"></A>AVI BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A Development Stage Company) </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">STATEMENTS OF CASH FLOWS </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(in thousands) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">For&nbsp;the&nbsp;Period</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">July 22, 1980</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Inception)&nbsp;through</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March 31, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(327,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net income (loss) to net cash flows used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on disposal of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realized gain on sale of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Write-down of short-term securities - available-for-sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment charge on real estate owned</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of interest accrued to common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquired in-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase (decrease) on warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Increase) in accounts receivable, other current assets and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase (decrease) in accounts payable, accrued employee compensation, and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(112,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sale of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and
warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">297,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Buyback of common stock pursuant to rescission offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Withdrawal of partnership net assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of convertible debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by (used in) financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">297,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">End of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid during the year for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING ACTIVITIES AND FINANCING ACTIVITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term securities - available-for-sale received in connection with the private offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock and warrants in satisfaction of liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock for building purchase</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumption of long-term debt for building purchase</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock for Ercole assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumption of liabilities for Ercole assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_6"></A>AVI BIOPHARMA,&nbsp;INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ORGANIZATION AND BASIS OF PRESENTATION </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AVI BioPharma, Inc. (the &#147;Company&#148;) is a biopharmaceutical company incorporated in the State of Oregon on
July&nbsp;22, 1980. The Company is focused on the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. Applying the Company&#146;s proprietary platform technologies, the Company is able to
target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. The Company is focused on rapidly advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate,
eteplirsen. In April 2012, the Company announced results from its Phase IIb placebo controlled trial in eteplirsen. Following completion of this study, the Company initiated an open label extension study with the same participants from the original
Phase IIb placebo controlled trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg
hemorrhagic fever viruses for which the Company has historically received and expects to continue to receive significant financial support from U.S. government research contracts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company and its consolidated
subsidiaries. The accompanying unaudited condensed consolidated balance sheet data as of December&nbsp;31, 2011 was derived from audited financial statements not included in this report. The accompanying unaudited condensed consolidated financial
statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and the rules&nbsp;and regulations of the U.S. Securities and Exchange Commission (&#147;SEC&#148;) pertaining to
interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management,
necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial
statements and the notes thereto included in the Company&#146;s annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011. The results of operations for the interim periods presented are not necessarily indicative of the results to
be expected for the full year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since its inception in 1980, the Company has incurred losses of approximately $327.7 million,
substantially all of which resulted from expenditures related to research and development, general and administrative charges and acquired in-process research and development resulting from two acquisitions. The Company has not generated any
material revenue from product sales to date, and there can be no assurance that revenues from product sales will be achieved. Moreover, even if the Company does achieve revenue from product sales, the Company expects to incur operating losses over
the next several years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the periods presented, nearly all of the revenue generated by the Company was derived from
research contracts and grants with the U.S. government. As of March&nbsp;31, 2012, the Company had had substantially completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics
against Ebola and Marburg. Pursuant to this agreement, as of March&nbsp;31, 2012, the Company is currently entitled to receive up to an aggregate of $126.5 million for development of its product candidates, of which $63.9 million has been recognized
as revenue and $62.6 million relates to development that has not yet been completed and has not been billed or recognized as revenue. In addition, if the U.S. government elects to exercise all its options under the agreement, an additional
$161.5&nbsp;million in funding is available. See &#147;Note 6 &#151; U.S. Government Contracts&#148; for additional information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At March&nbsp;31, 2012, cash and cash equivalents were $30.6 million. The Company&#146;s principal sources of liquidity have been equity financings and revenue from its U.S. government research contracts.
The Company&#146;s principal uses of cash have been research and development expenses, general and administrative expenses and other working capital requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company believes it has sufficient cash to fund operations at least through the following 12 months. The Company anticipates receiving continued funding from the U.S. government to pursue the
development of its therapeutics against Ebola and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Marburg, and has assumed certain revenues from these awards in providing this guidance. Should the Company&#146;s funding from the U.S. government cease or be delayed, it would have a significant
negative impact on the Company&#146;s financial condition and on this guidance and the Company would likely be forced to significantly curtail its research and development efforts unless additional funding was obtained. The Company is also likely to
pursue additional funding through public or private financings and cash generated from establishing collaborations or licensing its technology to other companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Estimates and Uncertainties </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of liability classified warrants and stock-based awards,
long lived asset impairment, and revenue recognition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Commitments and Contingencies </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of this report, the Company is not a party to any material legal proceedings with respect to itself, its subsidiaries, or
any of its material properties. In the normal course of business, the Company may from time to time be named as a party to various legal claims, actions and complaints, including matters involving employment, intellectual property, effects from the
use of&nbsp;therapeutics&nbsp;utilizing its technology, professional services or others. It is impossible to predict with certainty whether any resulting liability&nbsp;would have a material adverse effect on the Company&#146;s financial position,
results of operations or cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reclassifications </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain inception to date amounts have been reclassified to conform to current year presentation. These changes did not have a significant
impact on the Company&#146;s net loss, assets, liabilities, shareholders&#146; equity or cash flows. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. NET INCOME (LOSS) PER SHARE </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common
shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares and dilutive common stock equivalent shares outstanding. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of shares of common stock and common stock equivalents&nbsp;outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of common shares outstanding for computing basic earnings per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilutive effect of warrants and stock options after application of the treasury stock method*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of common shares outstanding for computing diluted earnings per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share - basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share - dilutive</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants and stock options to purchase 42,953,909 and 12,572,964 shares of common stock as of March&nbsp;31, 2012 and 2011, respectively, were excluded from the net
income (loss) per share calculation as their effect would have been anti-dilutive. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. FAIR VALUE MEASUREMENTS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company measures at fair value certain financial assets and liabilities in accordance with a hierarchy of valuation techniques
based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company&#146;s market assumptions. There are
three levels of inputs that may be used to measure fair-value: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 1 &#151; quoted prices for identical instruments in active markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2 &#151; quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not
active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 3 &#151; valuations derived from valuation techniques in which one or more significant value drivers are unobservable.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s assets and liabilities measured at fair value on a recurring basis consisted of the
following as of the date indicated: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurement as of March&nbsp;31, 2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;March&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>00000000</B></FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Note 5 &#151; Warrants&#148; for additional information related to the determination of fair value of the warrants and a reconciliation of changes in fair
value. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The carrying amounts reported in the balance sheets for accounts receivable, accounts payable, and other
current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ACCOUNTS RECEIVABLE </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable are stated at invoiced amount and do not bear interest. Because all accounts receivable are from
the U.S. government and historically no amounts have been written off, an allowance for doubtful accounts receivable is not considered necessary. The accounts receivable balance included $2,623,000 and $2,093,000 of U.S. government receivables that
were unbilled at March&nbsp;31, 2012 and December&nbsp;31, 2011, respectively. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. WARRANTS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants issued in connection with the Company&#146;s December 2007, January 2009 and August 2009 financings are
classified as liabilities, as opposed to equity, due to their settlement terms which require settlement in registered shares. Additionally, the settlement terms may result in cash settlement upon the occurrence of certain specified transactions set
forth in the warrant agreements. Warrants classified as liabilities are adjusted to fair value each reporting period with the fair value adjustment recorded in the statement of operations. All other warrants issued by the Company were recorded as
additional paid-in capital and no further adjustments are made. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the warrants classified as liabilities was recorded on the balance sheet
at issuance and is adjusted to fair value at each financial reporting period, with changes in the fair value recorded as a gain or loss in the statement of operations. The fair value is determined using the Black-Scholes option-pricing model, which
requires the use of significant judgment and estimates for the inputs used in the model. The following reflects the weighted-average assumptions for each of the periods indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2%-0.3 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.8%-1.3 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected lives</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7-2.4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7-3.4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65.1%-82.4&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71.4%-88.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares underlying warrants classified as liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,948,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,948,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market value of stock at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market value of stock at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A reconciliation of the change in value of such warrants for the three months ended March&nbsp;31, 2012
is as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:48pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reclassification to shareholders&#146; equity upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes information about warrants outstanding at March&nbsp;31, 2012. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Outstanding&nbsp;Warrants&nbsp;at<BR>March&nbsp;31, 2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average&nbsp;Remaining<BR>Contractual Life (Years)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercisable<BR>Warrants</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$0.0003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">No&nbsp;expiration&nbsp;date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1679</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">238,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">238,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">No expiration date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,124,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,124,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,410,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,410,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.45</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,348,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,348,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,204,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,204,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. U.S. GOVERNMENT CONTRACTS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes revenues from U.S. government research contracts during the period in which the related
expenditures are incurred and presents these revenues and related expenses gross in the consolidated financial statements. In the periods presented, all of the revenue generated by the Company was derived from research contracts with and grants from
the U.S. government. As of March&nbsp;31, 2012, the Company had completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics against Ebola and Marburg. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>July&nbsp;2010 Agreement (Ebola and Marburg) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;14, 2010, the Company was awarded a contract with the U.S. Department of Defense, or DoD, Chemical and Biological Defense Program through the U.S. Army Space and Missile Defense Command for
the advanced development of the Company&#146;s hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, against the Ebola and Marburg viruses, respectively.&nbsp;In February 2012, the Company announced that it received approval from
the FDA to proceed with a single oligomer from AVI-6003, AVI-7288, as the lead product candidate against Marburg virus infection. The contract is structured into four segments for each therapeutic candidate and has an aggregate period of performance
spanning approximately six years if DoD exercises its options for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
all segments.&nbsp;Activities under the first segment began in July 2010 and include Phase I studies in healthy volunteers as well as preclinical studies which are scheduled to be completed in
the second quarter of 2013. The aggregate available funding for the current segments is approximately $126.5 million of which $63.9 million has been recognized to date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After completion of the first segment, and each successive segment, DoD has the option to proceed to the next segment for either or both AVI-6002 and AVI-7288. If DoD exercises its options for all four
segments for both AVI-6002 and AVI-7288 , contract activities would include all clinical and licensure activities necessary to obtain FDA regulatory approval for each therapeutic candidate and would provide for a total funding award to the Company
of up to $288.0 million over a period of six years, of which $161.5 million remains to be funded. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>June&nbsp;2010
Agreement (H1N1/Influenza) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;4, 2010, the Company entered into a contract with the Defense Threat Reduction
Agency&nbsp;to advance the development of AVI-7100 as a medical countermeasure against the pandemic H1N1 influenza virus in cooperation with the Transformational Medical Technologies program of DoD. The period of performance for this contract ended
on June&nbsp;3, 2011 and, as of December&nbsp;31, 2011, the Company has recognized revenue of $12.3 million and does not expect to receive any additional revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the revenue for each of the contracts with the U.S. government for the three months ended March&nbsp;31, 2012 and 2011. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 2010 Agreement <I>(Ebola and Marburg)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;2010 Agreement <I>(H1N1)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other Agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. STOCK COMPENSATION </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, stock options granted prior to December&nbsp;31, 2010 vest over a three year period, with one-third of the
underlying shares vesting on each anniversary of grant, and have a ten year term. Beginning in January 2011, stock options granted generally vest over a four year period, with one-fourth of the underlying shares vesting on the first anniversary of
the grant and 1/48</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of the underlying shares vesting
monthly thereafter, such that the underlying shares will be fully vested on the fourth anniversary of the grant. As of March&nbsp;31, 2012, 13,040,676 shares of common stock remain available for future grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the Company&#146;s stock option activity with respect to the three months ended March&nbsp;31, 2012 follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:48pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Options</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underlying<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Contractual</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Term</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Intrinsic</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,505,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">653,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,409,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,749,052</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,626,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested at March&nbsp;31, 2012 and expected to vest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,202,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,477,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,149,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">609,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted-average fair value per share of stock-based awards granted to employees during
the three months ended March&nbsp;31, 2012 and 2011 was $0.91 and $1.54, respectively. During the three months ended March&nbsp;31, 2012 and 2011, the total intrinsic value of stock options exercised was $280 and $0 respectively, and the total grant
date fair value of stock options that vested was $1,942,000 and $1,089,000, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Valuation Assumptions
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation costs are based on the fair value calculated from the Black-Scholes option-pricing model on
the date of grant for stock options. The fair value of stock grants is amortized as compensation expense on a straight-line basis over the vesting period of the grants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The fair values of stock options granted during the periods presented were measured on the date of grant using the Black-Scholes option-pricing model, with the following assumptions: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected lives</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-based Compensation Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the stock-based compensation expense recognized in the statements of operations is as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;31, 2012, there was $7,526,000 of unrecognized compensation cost related to non-vested
share-based compensation arrangements granted, including stock options and restricted stock. These costs are expected to be recognized over a weighted-average period of 3.1 years. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. INCOME TAXES </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2011, the Company had net deferred tax assets of approximately $116.8 million. The net deferred
tax assets are primarily composed of U.S. federal and state tax net operating loss carryforwards, U.S. federal and state research and development credit carryforwards and share-based compensation expense. Due to uncertainties surrounding the
Company&#146;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset its net deferred tax asset. Additionally, the Internal Revenue Code rules&nbsp;could limit the future use of
its net operating loss and research and development credit carryforwards to offset future taxable income based on ownership changes and the value of the Company&#146;s stock. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. RESTRUCTURING </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, the Company restructured its operations by reducing its workforce by 28%. Restructuring charges
totaling $1,145,000 were recorded in 2011 and included severance and related costs. The charge included $548,000 to research and development expense and $597,000 to general and administrative expense. The restructuring was completed by
January&nbsp;31, 2012 and all severance costs are expected to be paid by July&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in the accrued employee
compensation liability and the balance related to the December 2011 restructuring plan are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;months&nbsp;ending<BR>March 31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at January&nbsp;1, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring charge for severance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severance payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. RECENT ACCOUNTING PRONOUNCEMENTS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April&nbsp;2011, the Financial Accounting Standards Board (&#147;FASB&#148;) issued guidance to achieve common fair
value measurement and disclosure requirements between GAAP and International Financial Reporting Standards. This guidance amends current fair value measurement and disclosure guidance to include increased transparency around valuation inputs and
investment categorization. The guidance is effective for fiscal years and interim periods beginning after December&nbsp;15, 2011. The adoption of this new guidance did not have a material impact on the Company&#146;s financial statements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, the FASB issued guidance regarding presentation of other comprehensive income in the financial statements. This
guidance eliminated the option under GAAP to present other comprehensive income in the statement of changes in equity. Under the guidance, the Company had the option to present the components of net income and comprehensive income in either one or
two consecutive financial statements. The guidance is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2011. The adoption of this new guidance did not have a material impact on the Company&#146;s
financial statements. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_7"></A>Item&nbsp;2.&nbsp;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This section should be read in conjunction with our condensed consolidated financial statements and related
notes included in Part&nbsp;I, Item&nbsp;1 of this Quarterly Report on Form 10-Q and the section contained in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011 under the caption &#147;Part&nbsp;II-Item&nbsp;7 &#151;
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;. This discussion contains certain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E
of the Exchange Act. All statements other than historical or current facts, including, without limitation, statements about our business strategy, plans and objectives of management, and our future prospects, are forward-looking statements and are
sometimes identified by such words as &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;plan,&#148; &#147;estimate,&#148;
&#147;project,&#148; &#147;predict,&#148; and &#147;potential,&#148; and words of similar import. These forward-looking statements include, but are not limited to, statements regarding: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding the development and clinical benefits of our product candidates; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the results of our research and development efforts and the efficacy of our PMO-based chemistries and other RNA-based technology;
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding our ability to become a leading developer and marketer of RNA-based therapeutics;
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the efficacy, potency and utility of our product candidates in the treatment of rare and infectious diseases, and their potential to treat a
broad number of human diseases; </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding the results of preclinical and clinical testing of our product candidates; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our ability to release results by the fourth quarter of 2012 from our Phase IIb extension study for eteplirsen and initiate a pivotal Phase
III clinical trial for eteplirsen in 2013; </I></FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding the timing, completion and receipt of results from our ongoing development programs;
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the receipt of any required approval from the U.S. Food and Drug Administration, or FDA, or other regulatory approval for our products;
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the effect of regulation by FDA and other agencies; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding the markets for our products; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>acceptance of our products, if introduced, in the marketplace; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the impact of competitive products, product development, commercialization and technological difficulties; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations regarding partnering opportunities and other strategic transactions; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the extent of protection that our patents provide and our pending patent applications may provide, if patents issue from such applications,
to our technologies and programs; </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our plans to file additional patent applications to enhance and protect our existing intellectual property portfolio;
</I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our ability to invalidate some or all of the claims covered by patents issued to competitors; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our estimates regarding our future revenues, research and development expenses, other expenses, payments to third parties and changes in
staffing levels; </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our estimates regarding how long our currently available cash and cash equivalents, exclusive of the U.S. government exercising its options
under the 2010 Ebola and Marburg agreement, will be sufficient to finance our operations and statements about our future capital needs; and </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>our expectations about funding from the government and other sources. </I></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially
from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this Quarterly Report in Part&nbsp;II, Item&nbsp;1A &#151; &#147;Risk Factors,&#148; and
elsewhere in this Quarterly Report. These statements, like all statements in this Quarterly Report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. In this report,
&#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;AVI,&#148; and &#147;Company&#148; refers to AVI BioPharma, Inc. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the
treatment of rare and infectious diseases. Applying our proprietary, highly-differentiated and innovative platform technologies, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. We are
primarily focused on rapidly advancing the development of our potentially disease-modifying Duchenne muscular dystrophy drug candidates, including our lead product candidate, eteplirsen. We are also focused on developing therapeutics for the
treatment of infectious diseases, including our lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. By building our infectious disease programs funded by the U.S.
government and leveraging our highly-differentiated, proprietary technology platforms, we are seeking to further develop our research and development competencies and identify additional product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our highly-differentiated RNA-based technologies work at the most fundamental level of biology and potentially could have a meaningful
impact across a broad range of human diseases and disorders. Our lead program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy, or DMD, a rare genetic muscle-wasting disease caused by the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
absence of dystrophin, a protein necessary for muscle function. Currently, there are no disease-modifying therapies available for DMD. Eteplirsen is our lead therapeutic candidate for DMD and if
we are successful in our development efforts, eteplirsen will address a severe unmet medical need. We recently completed a U.S.-based Phase IIb clinical trial for eteplirsen that was initiated in August 2011 and announced results from this trial in
April 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, we announced that treatment with eteplirsen met the primary efficacy endpoint in the Phase IIb
study. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant (p <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 0.002) increase in novel dystrophin (22.5% dystrophin-positive fibers as a percentage of
normal) compared to no increase in the placebo group. Restoration of dystrophin expression and dystrophin positive fibers is believed to be critical for successful disease-modifying treatment of individuals with DMD. In the study, a shorter duration
of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin (0.79% dystrophin-positive fibers as a percentage of normal; p-value NS), despite administration of the drug at a higher dose (50mg/kg once weekly). This
finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced. Eteplirsen was well tolerated at both dose levels through 24 weeks of treatment and there were no treatment-related adverse events, no
serious adverse events, and no treatment discontinuations related to eteplirsen. No significant improvements in clinical outcomes in the treated groups were observed compared to placebo, suggesting that a longer period of observation will be
required to demonstrate clinical effects of eteplirsen versus a placebo control. Following completion of this study, we initiated an open label extension study with the same participants from the original Phase IIb placebo controlled trial. We
anticipate releasing results from the open label extension study in the fourth quarter of 2012 and initiating a pivotal Phase III trial in 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are also leveraging the capabilities of our RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The U.S. Department of Defense, or DoD, has provided
significant financial support for the development of therapeutics against Ebola, Marburg, and influenza viruses, as described in greater detail below under the heading &#147;Government Contracts&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception in 1980, we have incurred losses of approximately $327.7&nbsp;million and substantially all of our revenue has been
derived from research and development contracts with the U.S. government. We have not yet generated any material revenue from product sales and we have incurred expenses related to research and development, general and administrative charges and
acquired in-process research and development resulting from two acquisitions. We expect to continue to incur losses in the future as we continue our research and development efforts and seek approval from various regulatory agencies for our product
candidates, but there can be no assurance that we will obtain approval for our product candidates and achieve revenues from product sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;31, 2012, we had cash and cash equivalents of $30.6&nbsp;million and we anticipate receiving continued funding from the U.S. government to pursue the development of our therapeutics
against Ebola and Marburg. Combined together, we believe these sources provide us with sufficient cash to fund operations at least through the following 12 months. In addition, we are likely to pursue additional funding through public or private
financings and cash generated from establishing collaborations or licensing our technology to other companies. Should our funding from the U.S. government cease or be delayed, it would have a significant negative impact on our financial condition
and on this guidance and we would likely be forced to significantly curtail our research and development efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
likelihood of our long-term success must be considered in light of the expenses, difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products, competitive factors in the marketplace, the
risks associated with U.S. government-sponsored programs, and the complex regulatory environment in which we operate. There can be no assurance that we will ever achieve significant revenues or profitable operations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Contracts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
recognize revenues from U.S. government research contracts during the period in which the related expenditures are incurred and present these revenues and related expenses gross in the consolidated financial statements. In the periods presented, all
of the revenue generated by us was derived from research contracts with and grants from the U.S. government. As of March&nbsp;31, 2012, we had completed all of our significant contracts with the U.S. government except for the July 2010 agreement for
the development of therapeutics against Ebola and Marburg. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>July&nbsp;2010 Agreement (Ebola and Marburg)
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;14, 2010, we were awarded a contract with the U.S. Department of Defense, or DoD, Chemical and Biological
Defense Program through the U.S. Army Space and Missile Defense Command for the advanced development of our hemorrhagic fever virus </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
therapeutic candidates, AVI-6002 and AVI-6003 against the Ebola and Marburg viruses, respectively.&nbsp;In February 2012, we announced that we received approval from the FDA to proceed with a
single oligomer from AVI-6003, AVI-7288, as the lead product candidate against Marburg virus infection. The contract is structured into four segments for each therapeutic candidate and has an aggregate period of performance spanning approximately
six years if DoD exercises its options for all segments.&nbsp;Activities under the first segment began in July 2010 and include Phase I studies in healthy volunteers as well as preclinical studies which are scheduled to be completed in the second
quarter of 2013. The aggregate available funding for the current segments is approximately $126.5 million of which $63.9 million has been recognized to date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After completion of the first segment, and each successive segment, DoD has the option to proceed to the next segment for either or both AVI-6002 and AVI-7288. If DoD exercises its options for all four
segments for both AVI-6002 and AVI-7288, contract activities would include all clinical and licensure activities necessary to obtain FDA regulatory approval for each therapeutic candidate and would provide for a total funding award to us of up to
$288.0 million over a period of six years, of which $161.5 million remains to be funded. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>June&nbsp;2010 Agreement
(H1N1/Influenza) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;4, 2010, we entered into a contract with the Defense Threat Reduction Agency&nbsp;to
advance the development of AVI-7100 as a medical countermeasure against the pandemic H1N1 influenza virus in cooperation with the Transformational Medical Technologies program of DoD. The period of performance for this contract ended on June&nbsp;3,
2011 and, as of December&nbsp;31, 2011, we have recognized revenue of $12.3 million and do not expect to receive any additional revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the revenue for each of the contracts with the U.S. government for the three months ended March&nbsp;31, 2012 and 2011. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 2010 Agreement <I>(Ebola and Marburg)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;2010 Agreement <I>(H1N1)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other Agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key Financial Metrics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Government Research Contract and Grant Revenue</I>.
Substantially all of our revenue is generated from U.S. government research contracts and grants. See &#147;Note 6 &#151; U.S. Government Contracts&#148; of the financial statements included elsewhere in this report. We recognize revenue from U.S.
government research contracts and grants during the period in which the related expenses are incurred and present such revenues and related expenses gross in the consolidated financial statements. Government contract revenue is highly dependent on
the timing of various activities performed by us and our third party vendors. Changes in the timing of activities performed in support of this contract have, and may in the future, result in unexpected fluctuations in our revenue from period to
period. We expect that future revenue generated under our government contracts will continue to be variable as a result of these factors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>License Arrangements</I>. Our license arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive licensed rights to patented or
patent pending compounds, technology access fees, various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We defer recognition of non-refundable upfront fees if we have continuing performance obligations when the technology, right, product or
service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through
research and development services that are required because of our know-how or because the services can only be performed by us, then such upfront fees are deferred and recognized over the period of continuing involvement. As of March&nbsp;31, 2012,
we had deferred revenue of $3.3 million, which represents upfront fees which we will recognize as revenue as we satisfy the outstanding performance obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development</I>. Research and development expense consists of costs associated with research activities as well as costs
associated with our product development efforts, conducting preclinical studies, and clinical trial and manufacturing costs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Direct research and development expenses associated with our programs include clinical trial site costs, clinical manufacturing costs,
costs incurred for consultants and other outside services, such as data management and statistical analysis support, and materials and supplies used in support of the clinical programs. Indirect costs of our clinical program include salaries, stock
based compensation, and an allocation of our facility costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount and timing of future research and development expense
will depend on our ability to obtain U.S. government awards to fund the advanced development of our antiviral therapeutic candidates. Without such funding, we would likely drastically reduce our spending in these areas. Future research and
development expenses may also increase if our internal projects, such as DMD, enter later stage clinical development. Our research and development programs are at an early stage and may not result in any approved products. Product candidates that
appear promising at early stages of development may not reach the market for a variety of reasons. Similarly, any of our product candidates may be found to be ineffective during clinical trials, may take longer to complete clinical trials than we
have anticipated, may fail to receive necessary regulatory approvals, or may prove impracticable to manufacture in commercial quantities at reasonable cost and with acceptable quality. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of these uncertainties and the other risks inherent in the drug development process, we cannot determine the duration and
completion costs of current or future clinical stages of any of our product candidates. Similarly, we cannot determine when, if, or to what extent we may generate revenue from the commercialization and sale of any product candidate. The timeframe
for development of any product candidate, associated development costs, and the probability of regulatory and commercial success vary widely. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>General and Administrative</I>. General and administrative expense consists principally of salaries, benefits, stock-based compensation expense, and related costs for personnel in our executive,
finance, legal, information technology, business development and human resource functions. Other general and administrative expenses include an allocation of our facility costs and professional fees for legal, consulting and accounting services.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Interest Income (Expense) and Other, Net</I>. Interest income (expense) and other, net, consists of interest on our cash
and cash equivalents, rental income and other income. Our cash equivalents consist of money market investments. Interest expense includes interest paid on our mortgage loan related to the Corvallis property. Other income includes rental income from
subleasing excess space in some of our facilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change in Fair Value of Warrants</I>. Warrants issued in connection
with our December 2007 and January&nbsp;and August 2009 financings are classified as liabilities, as opposed to equity, due to their settlement terms which require settlement in registered shares. The fair market value of these warrants was recorded
on the balance sheet at issuance and the warrants are marked to market each financial reporting period, with changes in the fair value recorded as a gain or loss in our statement of operations. The fair value of the warrants is determined using the
Black-Scholes option-pricing model, which requires the use of significant judgment and estimates related to the inputs used in the model and can result in significant swings in the fair market valuation primarily due to changes in our stock price.
For more information, see &#147;Note 5 &#151; Warrants&#148; of the financial statements included elsewhere in this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical
Accounting Policies and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discussion and analysis of our financial condition and results of operations are
based upon our financial statements included elsewhere in this report. The preparation of our financial statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Some of these judgments can be subjective and complex, and, consequently, actual
results may differ from these estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable. We believe that the estimates and judgments upon which we rely are reasonable
based upon historical experience and information available to us at the time that we make these estimates and judgments. To the extent there are material differences between these estimates and actual results, our financial statements will be
affected. Although we believe that our judgments and estimates are appropriate, actual results may differ from these estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The policies that we believe are the most critical to aid the understanding of our financial
results include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revenue recognition; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">stock-based compensation; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accounting for and valuation of warrants classified as liabilities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our critical accounting policies and significant estimates are detailed in our annual report on Form&nbsp;10-K filed with the Securities
and Exchange Commission, or SEC, on March&nbsp;13, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Three Months Ended March&nbsp;31,&nbsp;2012 and
2011 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth selected consolidated statements of operations data for each of the periods indicated:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March
31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Change</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>share amounts)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (loss):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain (loss) on change in warrant valuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic income (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted income (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue for the three months ended March&nbsp;31, 2012 decreased by $3.1 million, or 22%, compared to the three months ended March&nbsp;31, 2011. The decrease was due to a $2.4&nbsp;million decrease in
revenue associated with the H1N1 U.S. government research contract which was completed in June 2011 and a $0.7&nbsp;million decrease in revenue associated with the ongoing Ebola and Marburg U.S. government research contract. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense for the three months ended March&nbsp;31, 2012 was comparable to the three months ended March&nbsp;31, 2011. During the current quarter as compared to the prior year
quarter, spending on DMD increased by $1.8 million primarily due to the Phase IIb trial for eteplirsen and a $0.4 million increase in spending on other proprietary research. These increases were offset by a $1.2 million reduction in spending on the
H1N1 U.S. government contract which was completed in June 2011, a $0.6 million reduction in spending on the ongoing Ebola and Marburg U.S. government contract and a $0.4 million reduction in personnel related costs. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses for the three months ended March&nbsp;31, 2012 decreased by $1.7 million, or 35%, compared to the three months ended March&nbsp;31, 2011. The decrease is primarily due
to a $1.1 million decrease in personnel costs resulting from the December 2011 reorganization and an executive severance package recorded in the first quarter of 2011. Legal and professional service fees also decreased $0.5&nbsp;million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gain (Loss) on Change in Warrant Valuation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The $18.2 million change in fair value of our warrant liability for the three months ended March&nbsp;31, 2012 compared to the three months ended March&nbsp;31, 2011 was primarily attributable to
increases in our stock price. See &#147; &#151; Key Financial Metrics &#151; Change in Fair Value of Warrants,&#148; &#147; &#151; Critical Accounting Policies and Estimates &#151; Warrant Liability,&#148; and Note 5 to the unaudited condensed
consolidated financial statements included elsewhere in this report. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Income (Loss) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the three months ended March&nbsp;31, 2012 was $17.7 million, compared to net income of $1.8&nbsp;million for the three
months ended March&nbsp;31, 2011, a change of $19.5 million. The increase in the net loss for the three months ended March&nbsp;31, 2012 was due primarily to the $18.2 million incremental expense associated with the increase in warrant liability and
a $1.3 million increase in operating losses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidity and Capital Resources </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At March&nbsp;31, 2012, cash and cash equivalents were $30.6 million, compared to $39.9&nbsp;million at December&nbsp;31, 2011. Our
principal sources of liquidity are equity financings and revenue from our U.S. government research contracts. Our principal uses of cash are research and development expenses, general and administrative expenses and other working capital
requirements. Based on the factors described below, we believe that our currently available cash and cash equivalents, exclusive of the U.S. government exercising its options under the 2010 Ebola and Marburg agreement, are sufficient to finance our
operations for at least the next 12 months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sources of Funds </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our primary source of revenue is from development of product candidates pursuant to our contracts with the U.S. government. Government
funding is subject to the U.S. government&#146;s appropriations process and the U.S. government has the right under our contracts with them to terminate such contracts for convenience. If U.S. government funding is not received or is delayed, our
results of operations would be materially and adversely affected and we may need to seek additional sources of capital. We do not generate any revenue from non-government, commercial sale of our pharmaceutical product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require additional capital from time to time in order to fund our operations, continue the development of products and to expand
our product portfolio. We expect to seek additional financing primarily from, but not limited to, the sale and issuance of equity, or equity-linked or debt securities. We cannot assure you that financing will be available when and as needed or that,
if available, the financings will be on favorable or acceptable terms. If we are unable to obtain additional financing when and if we require, it would have a material adverse effect on our business and results of operations. To the extent we issue
additional equity securities, our existing shareholders could experience substantial dilution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never generated
revenue from the sale of commercial products and cannot offer any assurances that we will be able to do so in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Uses of Funds </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From inception in 1980 through the date of this report, our accumulated deficit is $327.7 million. Our principal uses of cash have been research and development expenses, general and administrative
expenses, costs associated with the acquisition of in-process research and development and other working capital requirements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Historical Trends </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash provided by (used in):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease in cash and equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Operating Activities</I>. We used $9.0&nbsp;million of cash in operating activities for the three
months ended March&nbsp;31, 2012, a decrease of $1.0 million, compared to $10.1 million of cash used in operating activities for the three months ended March&nbsp;31, 2011. The decrease in net cash used in operations during the comparative periods
was primarily attributable to a $2.6 million increase in cash provided from changes in working capital partially offset by a $1.3 million increase in net loss, excluding the noncash loss associated with the periodic revaluation of our warrants to
fair market value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing Activities</I>. We used $0.3&nbsp;million of cash in investing activities for
the three months ended March&nbsp;31, 2012, which is comparable to the $0.3&nbsp;million of cash used in investing activities for the three months ended March&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Financing Activities</I>. Financing activities for the three months ended March&nbsp;31, 2012 were due to repayment of debt compared to the three months ended March&nbsp;31, 2011 which included cash
provided by exercise of warrants partially offset by debt repayment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future expenditures and capital requirements depend
on numerous factors, most of which are difficult to project beyond the short term. These requirements include our ability to meet the requirements of our U.S. government research projects, the progress of our research and development programs and
our pre-clinical and clinical trials, the time and costs involved in obtaining regulatory approvals, the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, competing technological and
market developments, our ability to establish collaborative arrangements and the terms of any such arrangements, and the costs associated with commercialization of our products. Our cash requirements are expected to continue to increase as we
advance our research, development and commercialization programs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Contingencies </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our continuing operations, we have entered into long-term contractual arrangements from time to time for our facilities, the provision
of goods and services, and acquisition of technology access rights, among others. The following table presents noncancelable contractual obligations arising from these arrangements as of March&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;Than</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1 Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1-3&nbsp;Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3-5&nbsp;Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;Than</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to the Company and that specify all significant terms.
Purchase obligations relate primarily to our DMD development program. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off Balance Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the periods presented, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities
often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for another contractually narrow or limited purpose. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">See Note 10 to the unaudited condensed consolidated financial statements contained in Part&nbsp;I, Item&nbsp;1 of this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_8"></A>Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Interest Rate Sensitivity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had cash and cash equivalents of
$30.6&nbsp;million and $39.9&nbsp;million at March&nbsp;31, 2012 and December&nbsp;31, 2011, respectively. We do not enter into investments for trading or speculative purposes; our cash equivalents are invested in money market accounts. We believe
that we do not have any material exposure to changes in the fair value of these assets in the near term due to extremely low rates of investment interest and to the short term nature of our cash and cash equivalents. Future declines in interest
rates, however, would reduce investment income, but are not likely to be a material source of revenue to our company in the foreseeable future. A 0.1% decline in interest rates, occurring January&nbsp;1, 2012 and sustained throughout the period
ended March&nbsp;31, 2012, would be inconsequential. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_9"></A>Item&nbsp;4. Controls and Procedures. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Evaluation of Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We carried out an evaluation as of the end of the period covered by this report, under the supervision and with the participation of our management, including (1)&nbsp;our chief executive officer and
principal financial officer and (2)&nbsp;our principal accounting officer, of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. The purpose
of this evaluation was to determine whether as of the evaluation date our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in our filings with the Securities and
Exchange Commission, or SEC, under the Exchange Act (i)&nbsp;is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms and (ii)&nbsp;accumulated and communicated to our management, including
our chief executive officer and principal financial officer and our principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation, management has concluded that as of March&nbsp;31,
2012, our disclosure controls and procedures were effective. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Internal Control Over Financial Reporting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no changes in our internal control over financial reporting during the quarter ended March&nbsp;31, 2012 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_10">
</A>PART II &#151; OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_11"></A>Item&nbsp;1. Legal Proceedings. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of this report, we are not a party to any material legal proceedings with respect to us, our subsidiaries, or any of our
material properties. In the normal course of business, we may from time to time be named as a party to various legal claims, actions and complaints, including matters involving employment, intellectual property, effects from the use of drugs
utilizing our technology, or others. It is impossible to predict with certainty whether any resulting liability would have a material adverse effect on our financial position, results of operations or cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_12"></A>Item&nbsp;1A.&nbsp;Risk Factors. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Set forth below and elsewhere in this report and in other documents we file with the SEC are descriptions of risks and uncertainties that could cause actual results to differ materially from the
results contemplated by the forward-looking statements contained in this report. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered a reliable indicator
of future performance and investors should not use historical trends to anticipate results or trends in future periods. The risks and uncertainties described below are not the only ones facing us. Other events that we do not currently anticipate or
that we currently deem immaterial also affect our results of operations and financial condition. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Our Business
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our product candidates are at an early stage of development, and it is possible that none of our product candidates will ever become
commercial products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates are in relatively early stages of development. These product candidates
will require significant further development, financial resources and personnel to obtain regulatory approval and develop into commercially viable products, if at all. Currently, eteplirsen in DMD, AVI-6002 in Ebola and AVI-7288 in Marburg are in
active clinical development. The clinical development of AVI-7100 in influenza is currently paused and the rest of our product candidates are in preclinical development. We </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expect that much of our effort and many of our expenditures over the next several years will be devoted to development activities associated with eteplirsen and other exon-skipping candidates as
part of our larger pan-exon strategy in DMD and our antiviral candidates. With current resources, we may be restricted or delayed in our ability to develop other clinical and preclinical product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any of our product candidates, including eteplirsen, depends on first receiving required regulatory
approvals, and it is possible that we may never receive regulatory approval (including any accelerated approval by the U.S. Food and Drug Administration (the &#147;FDA&#148;) under Subpart H&#151;Accelerated Approval of New Drugs for Serious or
Life-Threatening Illnesses) for any of our product candidates based on an inability to adequately demonstrate the safety and effectiveness of our product candidates, lack of funding, changes in the regulatory landscape or other reasons. Even if a
product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Assuming that any of our product candidates receives the required
regulatory approvals, commercial success will depend on a number of factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment and demonstration of clinical efficacy and safety and acceptance of the same by the medical community; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effectiveness of the product; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of adequate reimbursement by third parties, including governmental payors such as the Medicare and Medicaid programs, managed care
organizations, and private health insurers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the product&#146;s potential advantage over alternative treatment methods; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the product can be produced in commercial quantities at acceptable costs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">marketing and distribution support for the product; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any exclusivities applicable to the product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although to date we have been granted orphan status for two of our product candidates in DMD and are seeking orphan status for AVI-6002 and AVI-7288, we are not guaranteed to receive orphan exclusivity
based on that status and would not enjoy such exclusivity in the event that another entity could get approval of the same product for the same indication before we receive market approval. Further, application of the orphan drug regulations in the
United States and Europe is uncertain and we cannot predict how the respective regulatory bodies will interpret and apply the regulations to our or our competitors&#146; product candidates. If another product receives orphan drug status for an
indication that we are targeting, and such product is approved for commercial sales before our product, regulators may interpret our product to be the same drug as the competing product and could prevent us from selling our product in the applicable
territories. Furthermore, pediatric exclusivity only applies if another product with exclusivity has not received regulatory approval, so if another regulatory exclusivity or patent protection exists for the product once it is approved, we would not
receive the benefit of any pediatric exclusivity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to develop and commercialize any of our product
candidates, if development is delayed or if sales revenue from any product candidate that receives marketing approval is insufficient, we may never reach sustained profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain or maintain required regulatory approvals, we will not be able to commercialize our product candidates, our ability to generate revenue will be materially impaired and our
business will not be successful. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The research, testing, manufacturing, labeling, approval, selling, marketing and
distribution of drug products are subject to extensive regulation by the FDA in the United States, and other regulatory authorities in other countries, with regulations differing from country to country. Marketing of our product candidates in the
United States or foreign countries is not permitted until we obtain marketing approval from the FDA or other foreign regulatory authorities, and we may never receive regulatory approval for the commercial sale of any of our product candidates.
Obtaining marketing approval is a lengthy, expensive and uncertain process and approval is never assured. As of the date of this report, we have not progressed to the point of preparing or filing the applications necessary to gain regulatory
approvals. Further, the FDA and other foreign regulatory agencies have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any product candidate we develop. In this regard, even if
we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other foreign regulatory authority. In addition, the FDA or their advisors may disagree
with our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may approve a product candidate for fewer indications than requested or may grant approval subject to the performance of post-approval studies for a
product candidate. Similarly, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, changes in regulatory requirements and guidance may occur and we may need to
amend clinical trial protocols or other approval strategies to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a
clinical trial. Changes in our approval strategies may require additional studies that were not originally planned. Other factors may also impact our ability to commercialize our product candidates, including, for example, the fact that a
therapeutic commercial product utilizing our RNA-based technologies has never been approved by any regulatory authority. Due to these factors, our current product candidates or any of our other future product candidates could take a significantly
longer time to gain regulatory approval than we expect or may never gain regulatory approval, which could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we receive regulatory approval for our product candidates, we will also be subject to ongoing FDA obligations and
oversight, including adverse event reporting requirements, marketing restrictions and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products. The FDA&#146;s
policies may also change and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. We cannot predict the likelihood,
nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States, or abroad. If we are not able to maintain regulatory compliance, we may be subject to civil and criminal
penalties, we may not be permitted to market our products and our business could suffer. Any delay in, or failure to, receive or maintain regulatory approval for any of our product candidates could harm our business and prevent us from ever
generating meaningful revenues or achieving profitability. We will need to obtain regulatory approval from authorities in foreign countries to market our product candidates in those countries. We have not filed for regulatory approval to market our
product candidates in any foreign jurisdiction. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approvals from foreign jurisdictions, the geographic market for our
product candidates would be limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our clinical trials may fail to demonstrate acceptable levels of safety and efficacy of our
product candidates, which could prevent or significantly delay their regulatory approval. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To obtain the requisite
regulatory approvals to market and sell any of our product candidates, we must demonstrate, through extensive preclinical and clinical studies, that the product candidate is safe and effective in humans. Ongoing and future clinical trials of our
product candidates may not show sufficient safety or efficacy to obtain regulatory approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase I clinical trials
generally are not designed to test the efficacy of a product candidate but rather are designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the product candidate&#146;s side effects at various doses and dosing
schedules in healthy volunteers. Delays in establishing the appropriate dosage levels can lead to delays in the overall clinical development of a product candidate. As of the date of this report, we do not believe that we have identified a
consistently effective dose of eteplirsen for individuals with DMD. We recently completed a U.S.-based Phase IIb clinical trial for eteplirsen at higher doses that was initiated in August 2011. Following completion of this study, we initiated an
open label extension study with the same participants from the original Phase IIb placebo controlled trial. These trials were initiated, in part, to further explore and identify a more consistently effective dose that may be more appropriate for
future clinical trials. We cannot assure you that these efforts will be successful. If a consistently effective dose is found in the U.S.-based clinical trial, we will expect to engage in discussions with regulatory authorities about the design and
subsequent execution of any further studies which may be required. Regulatory authorities might require more extensive clinical trials than anticipated and conforming to any guidance regulatory authorities provide does not guarantee receipt of
marketing approval, even if we believe our clinical trials are successful. Such clinical trials might include additional open label &#147;extension studies&#148; for all participants who have previously received eteplirsen, as well as other
participants (e.g., non-ambulatory participants) and any additional placebo-controlled &#147;pivotal&#148; study or studies. If we are not able to establish an optimal dosage in these trials we may need to conduct additional dose-ranging trials
before conducting our pivotal trials of the product. Any such additional clinical trials required by regulatory authorities would increase our costs and delay commercialization of eteplirsen. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, success in preclinical and early clinical trials does not ensure that later larger-scale trials will be successful nor does
it predict final results. Acceptable results in early trials may not be reproduced in later trials. For example, pivotal trials for eteplirsen will likely involve a larger number of participants to achieve statistical significance, will be expensive
and will take a substantial amount of time to complete. As a result, we may conduct lengthy and expensive clinical trials of our product candidates, only to learn that the product candidate is not an effective treatment or is not superior to
existing approved therapies, or has an unacceptable safety profile, which could prevent or significantly delay regulatory approval for such product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Animal Rule is a new and seldom-used approach to seeking approval of a new drug and our infectious disease program may not meet the requirements for this ill-defined path to regulatory approval.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials cannot be used to assess the efficacy of most biodefense countermeasures against rare and lethal
pathogens due to ethical considerations and the relative infrequency of naturally occurring cases. In the United States, we plan to develop the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
therapeutic product candidates to treat Ebola and Marburg viruses using the Animal Rule regulatory mechanism. Pursuant to the Animal Rule, the sponsor of a drug product must demonstrate efficacy
in animal models and safety in humans. There is no guarantee that the FDA will agree to this approach to the development of our infectious disease product candidates, considering that no validated animal model has been established as predicting
human outcomes in the prevention or treatment of any filovirus disease. Animal models represent, at best, a rough approximation of efficacy in humans, and, as such, countermeasures developed using animal models will be untested until their use in
humans during an emergency. We have yet to demonstrate the predictive value of our animal studies to the FDA&#146;s satisfaction. If we fail to do so, we will have to demonstrate efficacy of AVI-6002 and AVI-7288 through adequate well-controlled
trials in humans in order to obtain regulatory approval of these products in the United States, which, if possible, will greatly add to the time and expense required to commercialize these products. Furthermore, the Animal Rule mechanism has been
used only rarely and questions remain regarding the FDA&#146;s interpretation and implementation. No novel products have been approved using the Animal Rule. It has thus far been used to extend the indicated use of two previously licensed products
which had existing human efficacy data. We do not have any experience successfully navigating this approach to drug approval. Even if the Animal Rule represents a viable approach to seeking approval of AVI-6002 and AVI-7288, it may present
challenges for gaining final regulatory approval for these product candidates, including an extended timeline to approval and less predictable study requirements. In addition, the FDA would require post-marketing human efficacy studies if the
countermeasure is used in humans, which would most likely be in the aftermath of a bioterrorist attack. The ability to reliably perform efficacy clinical trials in the midst of a national crisis is uncertain. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The timing and conduct of animal studies may be further constrained given that filoviruses are classified for use only in BSL-4
laboratories. There are limited laboratories and staff world-wide that can work with these live viruses and companies will be competing for the limited availability of this critical infrastructure to test their countermeasures. Furthermore, we
anticipate limits in conforming to GLP requirements given the requirement for BSL-4 containment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on U.S. government contracts
to support several important research and development programs and substantially all of our revenue. If the U.S. government fails to fund such programs on a timely basis or at all, or such contracts are terminated, the results of our operations
would be materially and adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on U.S. government contracts and awards to fund several of our
development programs, including those for the Ebola and Marburg viruses and for substantially all of our current revenue. The funding of U.S. government programs is subject to Congressional appropriations. Congress generally appropriates funds on a
fiscal year basis even though a program may extend over several fiscal years, as is the case with our DoD contract for the development of our Ebola and Marburg product candidates. Consequently, programs are often only partially funded initially and
additional funds are committed only as Congress makes further appropriations. If appropriations for one of our programs become unavailable, or are reduced or delayed, our contracts may be terminated or adjusted by the government, which could have a
negative impact on our future revenue under such contract or subcontract. From time to time, when a formal appropriation bill has not been signed into law before the end of the U.S. government&#146;s fiscal year, Congress may pass a continuing
resolution that authorizes agencies of the U.S. government to continue to operate, generally at the same funding levels from the prior year, but does not authorize new spending initiatives, during a certain period. During such a period, or until the
regular appropriation bills are passed, delays can occur in government procurement due to lack of funding and such delays can affect our operations during the period of delay. Additionally, the DoD is planning on hundreds of billions of dollars in
cuts to defense spending over the next decade and faces a possible sequestration of an additional $600 billion over the same timeframe beginning in January 2013 unless Congress acts. These cuts would have widespread ramifications including on
DoD&#146;s procurement and research and development programs. The 2004 Project BioShield Act which created the Special Reserve Fund for use by DHHS to purchase countermeasures over 10 years avoids the uncertainty of the annual appropriations
process, but the $5.6 billion appropriation is rapidly depleting and will expire in 2013. Thus, the viability of DHHS as a potential customer hinges in part on Congress taking action to replenish the Special Reserve Fund. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, U.S. government contracts generally also permit the government to terminate the contract, in whole or in part, without prior
notice, at the government&#146;s convenience or for default based on performance. From time to time, we receive communications from the U.S. government regarding our performance, including requests for us to provide additional information and/or
take certain steps to remedy noted deficiencies. While we work closely with our contacts at the U.S. government and believe we can adequately address issues raised through such communications, there is no guarantee that we will be able to adequately
respond to all requests or remedy all deficiencies cited. If one of our contracts is terminated for convenience, we would generally be entitled to payments for our allowable costs and would receive some allowance for profit on the work performed. If
one of our contracts is terminated for default, we would generally be entitled to payments for our work that has been completed to that point. A termination arising out of our default could expose us to liability and have a negative impact on our
ability to obtain future contracts. Furthermore, if we fail to satisfy certain performance or deliverable requirements or to adhere to development timelines, revenues associated with the satisfaction of such requirements or timelines may be delayed
or may not be realized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The termination of one or more of these government contracts, whether due to lack of funding, for
convenience, for our failure to perform, or otherwise, or the occurrence of delays or product failures in connection with one or more of these contracts, could </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
negatively impact our financial condition. Furthermore, we can give no assurance that we would be able to procure new U.S. government contracts to offset the revenue lost as a result of
termination of any of our existing contracts. Even if our contracts are not terminated and are completed, there is no assurance that we will receive future government contracts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we successfully complete development of our Ebola and Marburg product candidates, the major, if not only, potential purchaser is
the U.S. government. The lack of a commercial market makes us reliant upon the U.S. government to determine and communicate the market for biodefense countermeasures and government purchasing is subject to evolving threat assessments and shifting
political priorities, which exacerbate market uncertainties. Within the DoD, the warfighter has evolving requirements specifically related to route of administration and time to treat. Until future studies are completed, it is unclear whether our
drug candidates will successfully meet these requirements. If they do not, DoD may choose to terminate the contract. With respect to the civilian sector, Ebola and Marburg viruses are among the top chemical, biological, radiological, and nuclear
threats to national security, yet DHHS has not defined the civilian requirement, making the broader demand for our drug candidates uncertain. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This expected dependence on government purchases presents additional challenges, since the government is incentivized to negotiate prices for countermeasures to just above their marginal cost of
production, which would severely limit our profit potential. If companies resist low prices, governments can, in extreme cases, threaten compulsory licensing or purchase patent-breaching generics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our U.S. government contracts may be terminated and we may be liable for penalties under a variety of procurement rules and regulations and changes
in government regulations or practices could adversely affect our profitability, cash balances or growth prospects. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must comply with laws and regulations relating to the formation, administration and performance of U.S. government contracts, which
affect how we do business with our customers. Such laws and regulations may potentially impose added costs on our business and our failure to comply with them may lead to penalties and the termination of our U.S. government contracts. Some
significant regulations that affect us include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Federal Acquisition Regulation and supplements, which regulate the formation, administration and performance of U.S. government contracts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Truth in Negotiations Act, which requires certification and disclosure of cost and pricing data in connection with contract negotiations; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Cost Accounting Standards, which impose accounting requirements that govern our right to reimbursement under certain cost-based government
contracts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our contracts with the U.S. government are subject to periodic review and investigation. If such
a review or investigation identifies improper or illegal activities, we may be subject to civil or criminal penalties or administrative sanctions, including the termination of contracts, forfeiture of profits, the triggering of price reduction
clauses, suspension of payments, fines and suspension or debarment from doing business with U.S. government agencies. We could also suffer harm to our reputation if allegations of impropriety were made against us, which would impair our ability to
win awards of contracts in the future or receive renewals of existing contracts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, U.S. government agencies
routinely audit and review their contractors&#146; performance on contracts, cost structure, pricing practices and compliance with applicable laws, regulations and standards. They also review the adequacy of, and a contractor&#146;s compliance with,
its internal control systems and policies, including the contractor&#146;s purchasing, property, estimating, compensation and management information systems. Such audits may result in adjustments to our contract costs, and any costs found to be
improperly allocated will not be reimbursed. We have recorded contract revenues for the periods presented in this report based upon costs we expect to realize upon final audit; however, we do not know the outcome of any future audits and adjustments
and, if future audit adjustments exceed our estimates, our results of operations could be adversely affected. Additionally, we may be required to enter into agreements and subcontracts with third parties, including suppliers, consultants and other
third party contractors in order to satisfy our contractual obligations pursuant to our agreements with the U.S. government. Negotiating and entering into such arrangements can be time-consuming and we may not be able to reach agreement with such
third parties. Any such agreement also has to be compliant with the terms of our government grants. Any delay or inability to enter into such arrangements or entering into such arrangements in a manner that is non-compliant with the terms of our
grants, may result in violations of our contracts with the U.S. government. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical trials for our product candidates are expensive and time consuming, may take longer than we
expect or may not be completed at all, and their outcomes are uncertain. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have completed a Phase Ib/II clinical
trial for eteplirsen in the UK and announced results in October 2010, which were published in <I>The Lancet</I> in July 2011. We have also completed a U.S.-based Phase IIb placebo controlled trial in eteplirsen and announced results in April 2012.
Following completion of this study, we initiated an open label extension study with the same participants from the original Phase IIb placebo controlled trial. We expect to commence additional trials of eteplirsen and other product candidates in the
future. Each of our clinical trials requires the investment of substantial planning, expense and time and the timing of the commencement, continuation and completion of these clinical trials may be subject to significant delays relating to various
causes, including scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling participants who meet trial eligibility criteria, failure of participants to complete the clinical trial, delay
or failure to obtain IRB or other regulatory approval to conduct a clinical trial at a prospective site, unexpected adverse events and shortages of available drug supply. Participant enrollment is a function of many factors, including the size of
the relevant population, the proximity of participants to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. We depend on medical institutions and
clinical research organizations, or CROs, to conduct our clinical trials in compliance with Good Clinical Practice, or GCP, and to the extent they fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are
delayed for a significant time in the execution of our trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, we have in the past conducted clinical
trials in foreign countries and may do so again in the future, which may subject us to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign CROs, as well as expose
us to risks associated with less experienced clinical investigators who are unknown to the FDA, and different standards of medical care. Foreign currency transactions insofar as changes in the relative value of the U.S. dollar to the foreign
currency where the trial is being conducted may impact our actual costs. In addition, for some programs (e.g., DMD and Ebola and Marburg infections) there are currently no approved drugs to compare against and an agreement about how to measure
efficacy has yet to be reached with the FDA and then demonstrated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials must be conducted in accordance with FDA
or other applicable foreign government guidelines and are subject to oversight by the FDA, other foreign governmental agencies and IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be
conducted with supplies of our product candidates produced under cGMP and other requirements in foreign countries, and may require large numbers of participants. The FDA or other foreign governmental agencies or we ourselves could delay, suspend or
halt our clinical trials of a product candidate for numerous reasons, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deficiencies in the trial design; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deficiencies in the conduct of the clinical trial including failure to conduct the clinical trial in accordance with regulatory requirements or
clinical protocols; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deficiencies in the clinical trial operations or trial sites resulting in the imposition of a clinical hold; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the product candidate may have unforeseen adverse side effects, including fatalities, or a determination may be made that a clinical trial presents
unacceptable health risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time required to determine whether the product candidate is effective may be longer than expected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fatalities or other adverse events arising during a clinical trial that may not be related to clinical trial treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the product candidate may appear to be no more effective than current therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the quality or stability of the product candidate may fail to conform to acceptable standards; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to produce or obtain sufficient quantities of the product candidate to complete the trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to reach agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation
and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to obtain IRB approval to conduct a clinical trial at a prospective site; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to obtain regulatory approval to conduct a clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of adequate funding to continue the clinical trial, including the occurrence of unforeseen costs due to enrollment delays, requirements to conduct
additional trials and studies and increased expenses associated with the services of our CROs and other third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to recruit and enroll individuals to participate in clinical trials for reasons including competition from other clinical trial programs
for the same or similar indications; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to retain participants who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of
efficacy or personal issues, or who are lost to further follow-up. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we may experience
significant setbacks in advanced clinical trials, even after promising results in earlier trials, such as unexpected adverse events that occur when our product candidates are combined with other therapies and drugs or given to larger populations,
which often occur in later-stage clinical trials. In addition, clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Also, patient advocacy groups and parents of trial
participants may demand additional clinical trials or continued access to drug even if our interpretation of clinical results received thus far leads us to determine that additional clinical trials or continued access are unwarranted. Any
disagreement with patient advocacy groups or parents of trial participants may require management&#146;s time and attention and may result in legal proceedings being instituted against us, which could be expensive, time-consuming and distracting,
and may result in delay of the program. Negative or inconclusive results or adverse medical events, including participant fatalities that may be attributable to our product candidates, during a clinical trial may necessitate that it be redesigned,
repeated or terminated. Further, some of our clinical trials may be overseen by an independent data safety monitoring board, or DSMB, and the DSMB may determine to delay or suspend one or more of these trials due to safety or futility findings based
on events occurring during a clinical trial. Any such delay, suspension, termination or request to repeat or redesign a trial could increase our costs and prevent or significantly delay our ability to commercialize our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have incurred operating losses since our inception and we may not achieve or sustain profitability. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had an operating loss of $6.9 million for the three months ended March&nbsp;31, 2012, and incurred an operating loss of
$35.9&nbsp;million for the year ended December&nbsp;31, 2011. As of March&nbsp;31, 2012, our accumulated deficit was $327.7 million. Our losses have resulted principally from expenses incurred in research and development of our technology and
products and from general and administrative expenses that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses in the future as we continue our research and development efforts and
seek to obtain regulatory approval of our products. Our ability to achieve profitability depends on our ability to raise additional capital, partner one or more programs, complete development of our products, obtain regulatory approvals and market
our products. It is uncertain when, if ever, we will become profitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will need additional funds to conduct our planned research
and development efforts. If we fail to continue to attract significant capital or fail to enter into strategic relationships, we may be unable to continue to develop our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require additional capital from time to time in the future in order to continue the development of product candidates in our
pipeline and to expand our product portfolio. The actual amount of funds that we will need will be determined by many factors, some of which are beyond our control. These factors include the success of our research and development efforts, the
status of our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
preclinical and clinical testing, costs relating to securing regulatory approvals and the costs and timing of obtaining new patent rights, regulatory changes and competitive and technological
developments in the market. An unforeseen change in these factors, or others, might increase our need for additional capital. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We would expect to seek additional financing from the sale and issuance of equity or equity-linked or debt securities, and we cannot
predict that financing will be available when and as we need financing or that, if available, the financing terms will be commercially reasonable. If we are unable to obtain additional financing, when and if we require or on commercially reasonable
terms, it would have a material adverse effect on our business and results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are able to consummate such
financings, the trading price of our common stock could be adversely affected and/or the terms of such financings may adversely affect the interests of our existing shareholders. To the extent we issue additional equity securities, our existing
shareholders could experience substantial dilution in their economic and voting rights. For example, we sold an aggregate of 72.2&nbsp;million shares of our common stock and issued warrants to purchase an additional 29.7&nbsp;million shares of our
common stock in connection with our December 2007,&nbsp;January 2009,&nbsp;August 2009 and April 2011 financings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, we
may also enter into relationships with pharmaceutical or biotechnology companies to perform research and development with respect to our RNA-based technologies, research programs or to conduct clinical trials and to market our product candidates.
Other than pre-clinical collaborations with academic/research institutions and a U.S. government entity for the development of additional exon-skipping drug candidates for the treatment of DMD, we currently do not have a strategic relationship with
a third party to perform research or development using our RNA-based technologies or assist us in funding the continued development and commercialization of any of our programs or drug candidates other than that with the U.S. government. If we are
unable to enter into partnerships or strategic relationships with respect to our technologies or any of our programs or drug candidates on favorable terms it may impede our ability to discover, develop and commercialize our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently rely on third-party manufacturers and other third parties for production of our drug products and our dependence on these
manufacturers may impair the advancement of our research and development programs and the development of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not currently have the internal ability to manufacture the product candidates that we need to conduct our clinical trials and we rely upon a limited number of manufacturers to supply our product
candidates and the components of our drug substance. We may also need to rely on manufacturers for the production of our product candidates to support our research and development programs. In addition, we rely on other third parties to perform
additional steps in the manufacturing process, including filling and labeling of vials and storage of our product candidates. For the foreseeable future, we expect to continue to rely on contract manufacturers and other third parties to produce,
fill vials and store sufficient quantities of our product candidates for use in our research and development programs and clinical trials. For example, for our Ebola and Marburg hemorrhagic fever virus development programs, we have entered into
agreements with two multinational manufacturing firms for the production of the API for Ebola and Marburg therapeutics. There is a limited number of companies that can produce PMO in the quantities and with the quality and purity that we require for
our development efforts. This might limit our ability to rapidly expand our programs or commercialize our products. If we are required to seek alternative supply arrangements, the resulting delays and potential inability to find suitable
replacements or bring on-line new suppliers could materially and adversely impact our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates
require precise, high-quality manufacturing. The failure to achieve and maintain high quality standards, including failure to detect or control anticipated or unanticipated manufacturing errors could result in patient injury or death or product
recalls. Contract drug manufacturers often encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified personnel. If our contract manufacturers or other third parties fail to deliver our
product candidates for our research and development programs and for clinical use on a timely basis, with sufficient quality, and at commercially reasonable prices, and we fail to find replacement manufacturers or to develop our own manufacturing
capabilities, we may be required to delay or suspend clinical trials, research and development programs or otherwise discontinue development and production of our product candidates. In addition, we depend on outside vendors for the supply of raw
materials used to produce our product candidates. If the third-party suppliers were to cease production or otherwise fail to supply us with quality raw materials and we are unable to contract on acceptable terms for these raw materials with
alternative suppliers, our ability to have our product candidates manufactured and to conduct preclinical testing and clinical trials of our product candidates would be adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not yet have all of the agreements necessary for the supply of our product candidates in quantities sufficient for commercial sale
and we may not be able to establish or maintain sufficient commercial manufacturing arrangements on commercially reasonable terms. Securing commercial quantities of our product candidates from contract manufacturers will require us to commit
significant capital and resources. We may also be required to enter into long-term manufacturing agreements that contain exclusivity provisions and/or substantial termination penalties. In addition, contract manufacturers have a limited number of
facilities in which our product candidates can be produced and any interruption of the operation of those facilities due to events such as equipment malfunction or failure or damage to the facility by natural disasters could result in the
cancellation of shipments, loss of product in the manufacturing process or a shortfall in available product candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our contract manufacturers are required to produce our clinical product candidates under
current Good Manufacturing Practice, or cGMP, conditions in order to meet acceptable standards for our clinical trials. If such standards change, the ability of contract manufacturers to produce our product candidates on the schedule we require for
our clinical trials may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with us or may discontinue their business before the time required by us to successfully produce and market our product
candidates. We and our contract manufacturers are subject to periodic unannounced inspection by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and
corresponding foreign standards. We do not have control over a third-party manufacturer&#146;s compliance with these regulations and standards. Any difficulties or delays in our contractors&#146; manufacturing and supply of product candidates or any
failure of our contractors to maintain compliance with the applicable regulations and standards could increase our costs, cause us to lose revenue, make us postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and
corresponding state and foreign authorities, prevent the import and/or export of our product candidates, or cause our products to be recalled or withdrawn. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and
commercializing resulting approved drug products, if any. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, our product candidates have been manufactured in
small quantities for preclinical studies and early stage clinical trials. In order to conduct larger or late-stage scale clinical trials for a product candidate and for commercialization of the resulting drug product if that product candidate is
approved for sale, we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for any of our product candidates, whether in collaboration with third-party manufacturers or on our own,
in a timely or cost-effective manner or at all. If a contract manufacturer makes improvements in the manufacturing process for our product candidates, we may not own, or may have to share, the intellectual property rights to those improvements.
Significant scale-up of manufacturing may require additional validation studies, which are costly and which the FDA must review and approve. In addition, quality issues may arise during those scale-up activities because of the inherent properties of
a product candidate itself or of a product candidate in combination with other components added during the manufacturing and packaging process, or during shipping and storage of the finished product or active pharmaceutical ingredients. If we are
unable to successfully scale-up manufacture of any of our product candidates in sufficient quality and quantity, the development of that product candidate and regulatory approval or commercial launch for any resulting drug products may be delayed or
there may be a shortage in supply, which could significantly harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on third parties to provide services in
connection with our preclinical and clinical development programs. The inadequate performance by or loss of any of these service providers could affect our product candidate development. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Several third parties provide services in connection with our preclinical and clinical development programs, including in vitro and in
vivo studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical assessments, data monitoring and management and statistical analysis and other outsourced activities. If these service providers do not
adequately perform the services for which we have contracted or cease to continue operations and we are not able to quickly find a replacement provider or we lose information or items associated with our product candidates, our development programs
may be delayed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our RNA-based, or antisense, technology has not been incorporated into a therapeutic commercial product and is still at
a relatively early stage of development. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our RNA-based platforms, utilizing proprietary PMO-based technology, have
not been incorporated into a therapeutic commercial product and are still at a relatively early stage of development. This technology is used in all of our therapeutic candidates, including eteplirsen. We are conducting toxicology, pharmacology,
pharmacokinetics and other preclinical studies and, although we have conducted Phase I clinical trials for AVI-6002, AVI-6003 (we will subsequently pursue development of AVI-7288, one of the two component oligomers in AVI-6003) and AVI-7100 and
conducted a Phase IIb clinical trial in eteplirsen, additional preclinical studies may be required for these product candidates and before other product candidates enter human clinical trials. In addition, preclinical models to study participant
toxicity and activity of compounds are not necessarily predictive of toxicity or efficacy of these compounds in the treatment of human disease and there may be substantially different results in clinical trials from the results obtained in
preclinical studies. Any failures or setbacks in utilizing our PMO-based technology, including adverse effects resulting from the use of this technology in humans, could have a detrimental impact on our internal product candidate pipeline and our
ability to maintain and/or enter into new corporate collaborations regarding these technologies, which would negatively affect our business and financial position. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to retain our key personnel or are unable to attract and retain additional qualified
personnel, our future growth, ability to perform our U.S. government contracts and our ability to compete would suffer. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are highly dependent on the efforts and abilities of the principal members of our senior management. Additionally, we have scientific
personnel with significant and unique expertise in RNA-based therapeutics and related technologies and personnel with experience overseeing compliance with and execution of the terms of our U.S. government contracts. The loss of the services of any
one of the principal members of our managerial, scientific or government contract compliance staff may prevent us from achieving our business objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The competition for qualified personnel in the biotechnology field and for qualified personnel with government contracting experience is intense, and our future success depends upon our ability to
attract, retain and motivate such personnel. In order to develop and commercialize our products successfully, we will be required to retain key managerial, scientific and government contract compliance staff. In certain instances, we may also need
to expand our workforce and our management ranks. We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, as well as academic and other research institutions. If we are unable to attract,
assimilate or retain such key personnel, our ability to advance our proprietary programs and perform our U.S. government contracts would be adversely affected. Any failure to perform under our U.S. government contracts could result in a termination
of the agreement, which would harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent changes in our executive leadership and any similar changes in the future may
serve as a significant distraction for our management and employees. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, Christopher Garabedian, a
member of our board of directors, was hired to serve as our president and chief executive officer. Since the beginning of 2011, there have been a number of changes to our executive leadership team. In February 2012, our former senior vice president
and general counsel, Ms.&nbsp;Effie Toshav, resigned from her employment with us to pursue other opportunities. Also, in April 2012, our senior vice president and chief scientific officer, Dr.&nbsp;Peter Linsley, notified us of his intent to resign
from his position with us effective June&nbsp;1, 2012. Such changes, or any other future changes in our executive leadership, may disrupt our operations as we adjust to the reallocation of responsibilities and assimilate new leadership and,
potentially, differing perspectives on our strategic direction. If the transition in executive leadership is not smooth, the resulting disruption could negatively affect our operations and impede our ability to execute our strategic plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may engage in future acquisitions that increase our capital requirements, dilute our shareholders, cause us to incur debt or assume
contingent liabilities and subject us to other risks. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We actively evaluate various strategic transactions on an
ongoing basis, including licensing or acquiring complementary products, technologies or businesses. Any potential acquisitions may entail numerous risks, including increased operating expenses and cash requirements, assimilation of operations and
products, retention of key employees, diversion of our management&#146;s attention and uncertainties in our ability to maintain key business relationships of the acquired entities. In addition, if we undertake acquisitions, we may issue dilutive
securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Asserting, defending and maintaining our intellectual property rights could be challenging and costly, and our failure to do so could harm our ability to compete and impair the outcome of our
operations. The pharmaceutical, biotechnology and academic environments are highly competitive and competing intellectual property could limit our ability to protect our products. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in significant part on our existing intellectually property rights and our ability to obtain additional patents
and licenses in the future. As of April&nbsp;30, 2012, we owned or controlled approximately 273 U.S. and corresponding foreign patents and 188 U.S. and corresponding foreign patent applications. We license patents from other parties for certain
complementary technologies. We cannot be certain that pending patent applications will result in patents being issued in the United States or foreign countries. We cannot be certain that we were the first to make the inventions covered by any of our
patents, if issued, or our pending patent applications. In addition, the patents that have been or will be issued may not afford meaningful protection for our technology and products. Competitors may develop products similar to ours that do not
conflict with our patents. To protect our rights to any of our patents, if issued, and proprietary information, we may need to litigate against infringing third parties, or avail ourselves of the courts or participate in hearings to determine the
scope and validity of those patents or other proprietary rights. These types of proceedings are often costly and could be very time-consuming to us, and we cannot assure you that the deciding authorities will rule in our favor. An unfavorable
decision could allow third parties to use our technology without being required to pay us licensing fees or may compel us to license needed technologies to avoid infringing third-party patent and proprietary rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical research and development is highly competitive; others may file patents first that cover our products or technology. For
example, our competitor Prosensa has rights to patent families corresponding to WO2002/024906 and WO2004/083432, including issued US 7,973,015, US 7,534,879, and granted European Patent No. EP 1619249. We opposed EP 1619249 in the Opposition
Division of the European Patent Office, or the Opposition Division, and in November 2011, we announced that, although we succeeded in invalidating some of the patent&#146;s claims, the Opposition Division maintained in amended form certain claims of
this patent relating to the treatment of DMD by skipping dystrophin exons 51 and 46. We and Prosensa both have the right to appeal this decision; however, pending final resolution of this matter and any appeal thereof, the patent at issue may
provide the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
basis for Prosensa or other parties that have rights to such patent to assert that our drug eteplirsen infringes on such patent. A final resolution of this opposition proceeding may take a number
of years and the outcome cannot be predicted or determined as of the date of this report. We are also aware of certain claims that have issued to Prosensa in Japan (JP Application No.&nbsp;2002-529499) that may provide the basis for Prosensa or
other parties that have rights to these claims to assert that our drug eteplirsen infringes on such claims. We believe we have a basis to invalidate some or all of these claims and are evaluating the potential initiation of invalidation proceedings
once these claims issue. Because we have not yet initiated an invalidation proceeding in Japan, the outcome and timing of such proceeding cannot be predicted or determined as of the date of this report. If we are unsuccessful in invalidating other
of Prosensa&#146;s claims or if previously invalidated claims are restored on appeal, our ability to commercialize both eteplirsen and other therapeutic candidates for our pan-exon strategy could be materially impaired. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will also depend partly on our ability to operate without infringing upon the proprietary rights of others as well as our
ability to prevent others from infringing on our proprietary rights. We may be required at times to take legal action to protect our proprietary rights and, despite our best efforts, we may be sued for infringing on the patent rights of others. We
have not received any communications or other indications from owners of related patents or others that such persons believe our products or technology may infringe on their patents. Patent litigation can involve complex factual and legal questions
and its outcome is uncertain. Patent litigation is costly and, even if we prevail, the cost of such litigation could adversely affect our financial condition. If we do not prevail, in addition to any damages we might have to pay, we could be
required to stop the infringing activity or obtain a license. If any patent related to our products or technology issues, and if our activities are determined to be covered by such a patent, we cannot assure you that we will be able to obtain or
maintain a license, which could have a material adverse effect on our business, financial condition, ability to sell our products, operating results and ability to obtain and/or maintain our strategic business relationships. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Others may challenge our patents and, as a result, our patents could be narrowed or invalidated. The patent position of pharmaceutical
and biotechnology firms, as well as academia, is generally highly uncertain, involves complex legal and factual questions, and has recently been the subject of much litigation. No consistent policy has emerged from the U.S. Patent and Trademark
Office, or USPTO, or the courts regarding the breadth of claims allowed or the degree of protection afforded under biotechnology patents. In addition, there is a substantial backlog of pharmaceutical and biotechnology patent applications at the
USPTO and the approval or rejection of patents may take several years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To help protect our proprietary rights in unpatented
proprietary information, trade secrets and know-how, we require our employees, consultants and advisors to execute confidentiality agreements and invention assignment agreements. However, such agreements may not provide us with adequate protection
if confidential information is used or disclosed improperly. In addition, in some situations these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisors have prior employment or
consulting relationships. Further, others may independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research collaborators may publish data and information to which we have rights. If we cannot maintain the confidentiality of our
technology and other confidential information in connection with our collaborations, then our ability to receive patent protection or protect our proprietary information may be impaired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid
technological change. We are aware of many pharmaceutical and biotechnology companies that are actively engaged in research and development in areas related to antisense technology and other RNA technologies or that are developing alternative
approaches to or therapeutics for the disease indications on which we are focused. Some of these competitors are developing or testing product candidates that now, or may in the future, compete directly with our product candidates. For example, we
believe that companies including Alnylam Pharmaceuticals, Isis Pharmaceuticals, and Santaris share a focus on RNA-based drug discovery and development. Competitors with respect to our exon-skipping DMD program, or eteplirsen, include Prosensa and
GlaxoSmithKline, or GSK, and other companies such as PTC Therapeutics and Summit plc have also been working on DMD programs. Tekmira Pharmaceuticals Corp. has a drug candidate (TKM-Ebola) for the treatment of Ebola virus infection. Similar to
AVI-6002, Tekmira&#146;s candidate has an open IND and is funded by the DoD. Tekmira initiated a Phase I clinical trial in February 2012. Tekmira&#146;s drug candidate may, or may not, prove to be safer or more efficacious or more responsive to
warfighter needs than our product candidate. While Tekmira&#146;s development efforts are presently behind our development of AVI-6002, it is possible that Tekmira could gain marketing approval before our product candidate. Furthermore, if DoD
funding is constrained, DoD may not be able to continue funding two competing products to treat the same disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical
trials evaluating the systemic administration of the Prosensa/GSK lead DMD drug candidate are currently ongoing, including a placebo-controlled global Phase III trial and two placebo-controlled Phase II trials, one based in the United States and one
based outside the United States. The Prosensa/GSK drug candidate may, or may not, prove to be safer or more efficacious than our product candidate and it could gain marketing approval before our product candidate. This might affect our ability to
successfully complete a clinical development program or market eteplirsen once approved. This competition may also extend to other exon-skipping drugs for DMD limiting our ability to gain market share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other potential competitors include large, fully integrated pharmaceutical companies and
more established biotechnology companies that have significantly greater resources and expertise in research and development, manufacturing, testing, obtaining regulatory approvals and marketing. Also, academic institutions, government agencies and
other public and private research organizations conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing. It is possible that these competitors will succeed in
developing technologies that are more effective than our product candidates or that would render our technology obsolete or noncompetitive. Our competitors may, among other things: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop safer or more effective products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">implement more effective approaches to sales and marketing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop less costly products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain quicker regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have access to more manufacturing capacity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop products that are more convenient and easier to administer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">form more advantageous strategic alliances; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish superior proprietary positions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to clinical trial claims and our insurance may not be adequate to cover damages. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently have no products that have been approved for commercial sale; however, the current and future use of our product candidates by us and our corporate collaborators in clinical trials, and the
sale of any approved products in the future, may expose us to liability claims. These claims might be made directly by consumers or healthcare providers or indirectly by pharmaceutical companies, our corporate collaborators or others selling such
products. We may experience financial losses in the future due to product liability claims. We have obtained limited general commercial liability insurance coverage for our clinical trials. We intend to expand our insurance coverage to include the
sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against all losses. If a successful
product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our operations involve the use of hazardous materials, and we must comply with environmental laws, which can be expensive, and may affect our
business and operating results. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development activities involve the use of hazardous materials,
including organic and inorganic solvents and reagents. Accordingly, we are subject to federal, state, and local laws and regulations governing the use, storage, handling, manufacturing, exposure to, and disposal of these hazardous materials. In
addition, we are subject to environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens, and the handling of biohazardous materials. Although we believe that our
activities conform in all material respects with such environmental laws, there can be no assurance that violations of these laws will not occur in the future as a result of human error, accident, equipment failure, or other causes. Liability under
environmental, health and safety laws can be joint and several and without regard to fault or negligence. The failure to comply with past, present, or future laws could result in the imposition of substantial fines and penalties, remediation costs,
property damage and personal injury claims, loss of permits or a cessation of operations, and any of these events could harm our business and financial conditions. We expect that our operations will be affected by other new environmental and health
and workplace safety laws on an ongoing basis, and although we cannot predict the ultimate impact of any such new laws, they may impose greater compliance costs or result in increased risks or penalties, which could harm our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our common stock may become ineligible for listing on The NASDAQ Stock Market, which would materially and adversely affect the liquidity and price of our common stock. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on The NASDAQ Global Market. The NASDAQ Global Market has several quantitative and qualitative requirements
with which companies must comply in order to maintain this listing, including a $1.00 minimum bid price per share and $50 million minimum value of listed securities. On December&nbsp;13, 2011, we received a letter from the listing qualifications
department staff of The NASDAQ Stock Market, notifying us that for the previous 30 consecutive business days the bid price of our common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing
requirements of NASDAQ set forth in Listing Rule 5450(a)(1). In order to regain compliance with this rule, by June&nbsp;11, 2012, the closing bid price of our common stock must be at least $1.00 per share for a minimum of ten consecutive business
days. On February&nbsp;21, 2012, we received a letter from the listing qualifications department staff of The NASDAQ Stock Market that our common stock&#146;s closing bid price had been at or above $1.00 per share for 10 consecutive business days
and, thus, we had regained compliance with Listing Rule 5450(a)(1). Although we have regained compliance with this listing rule, we could in the future be unable to meet The NASDAQ Global Market continued listing requirements. For example, the
closing price for our common stock on the NASDAQ has been less than $1.00 per share since April 17, 2012 and was $0.79 as recently as May&nbsp;9, 2012. If we fail to maintain compliance with The NASDAQ Stock Market&#146;s listing standards, and our
common stock becomes ineligible for listing on The NASDAQ Stock Market the liquidity and price of our common stock would be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If our common stock was delisted, the price of our stock and the ability of our shareholders to trade in our stock would be adversely affected. In addition, we would be subject to a number of restrictions
regarding the registration of our stock under U.S. federal securities laws, and we would not be able to allow our employees to exercise their outstanding options, which could adversely affect our business and results of operations. If we are
delisted in the future from The NASDAQ Stock Market, there may be other negative implications, including the potential loss of confidence by actual or potential collaboration partners, suppliers and employees and the loss of institutional investor
interest in our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our stock price is volatile and may fluctuate due to factors beyond our control. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market prices for, and trading volumes of, securities of biotechnology companies, including our securities, have been historically
volatile. The market has from time to time experienced significant price and volume fluctuations unrelated to the operating performance of particular companies. The market price of our common stock may fluctuate significantly due to a variety of
factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">positive or negative results of testing and clinical trials by ourselves, strategic partners, or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic
relationships on terms that are not deemed to be favorable to our company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">technological innovations or commercial product introductions by ourselves or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in government regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments concerning proprietary rights, including patents and litigation matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern relating to the commercial value or safety of any of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financing, through the issuance of equity or equity linked securities or incurrence of debt, or other corporate transactions;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">comments by securities analysts; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the perception that shares of our common stock may be delisted from The NASDAQ Stock Market; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions in our industry or in the economy as a whole. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the stock market has recently experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of individual companies. Broad market and industry factors may seriously affect the market price of companies&#146; stock, including ours, regardless of actual operating performance. In addition, in the
past, following periods of volatility in the overall market and the market price of a particular company&#146;s securities, securities class action litigation has often been instigated against these companies. Such litigation, if instigated against
us, could result in substantial costs and a diversion of our management&#146;s attention and resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions of our articles of
incorporation, bylaws and Oregon corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then current management and board of directors. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain provisions of our articles of incorporation and bylaws may make it more difficult for a third party to acquire control of us or
effect a change in our board of directors and management. These provisions include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">classification of our board of directors into two classes, with one class elected each year; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prohibition of cumulative voting of shares in the election of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prohibition of shareholder actions by less than unanimous written consent; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">express authorization of the board of directors to make, alter or repeal our bylaws; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by shareholders at shareholder
meetings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability of our board of directors to authorize the issuance of undesignated preferred stock, the terms and rights of which may be established and
shares of which may be issued without shareholder approval, including rights superior to the rights of the holders of common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, the Oregon Control Share Act and Business Combination Act may limit parties that acquire a significant amount of voting shares from exercising control over us for specific periods of time.
These provisions could discourage, delay or prevent a transaction involving a change of control, even if doing so would benefit our shareholders. These provisions also could discourage proxy contests and make it more difficult for shareholders to
elect directors of their choosing or cause us to take other corporate actions, such as replacing or removing management or members of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect our quarterly operating results to fluctuate in future periods, which may adversely affect our stock price. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our quarterly operating results have fluctuated in the past, and we believe they will continue to do so in the future. Some of these
fluctuations may be more pronounced than they were in the past as a result of the issuance of warrants to purchase 29.7&nbsp;million shares of our common stock by us in December 2007 and January and August 2009. Each of these warrants is classified
as a derivative liability. Accordingly, the fair value of the warrants is recorded on our consolidated balance sheet as a liability, and such fair value is adjusted at each financial reporting date with the adjustment to fair value reflected in our
consolidated statement of operations. The fair value of the warrants is determined using the Black-Scholes option valuation model. Fluctuations in the assumptions and factors </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
used in the Black-Scholes model can result in adjustments to the fair value of the warrants reflected on our balance sheet and, therefore, our statement of operations. Due to the classification
of such warrants and other factors, quarterly results of operations are difficult to forecast, and period-to-period comparisons of our operating results may not be predictive of future performance. Additionally, our quarterly operating results may
fluctuate due to the variable nature of our revenue and research and development expenses. Specifically, a change in the timing of activities performed in support of our U.S. government research contracts could either accelerate or defer anticipated
revenue from period to period. Likewise, our research and development expenses may experience fluctuations as a result of the timing of activities performed in support of our U.S. government research contracts and the timing and magnitude of
expenditures incurred in support of our DMD and other proprietary development programs. In one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price
of our common stock could decline. In addition, the market price of our common stock may fluctuate or decline regardless of our operating performance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>A significant number of shares of our common stock are issuable pursuant to outstanding options and warrants, and we expect to issue additional shares of common stock in the future. Sales of these
shares will dilute the interests of other security holders and may depress the price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of
March&nbsp;31, 2012, there were 135,743,787 shares of common stock outstanding, outstanding options to purchase 13,749,052 shares of common stock and outstanding warrants to purchase 29,204,857 shares of common stock. Additionally, as of
March&nbsp;31, 2012, there were 13,040,676 shares of common stock available for future issuance under our 2011 Equity Incentive Plan. In addition, we may issue additional common stock and warrants from time to time to finance our operations. We may
also issue additional shares to fund potential acquisitions or in connection with additional stock options or other equity awards granted to our employees, officers, directors and consultants under our 2011 Equity Incentive Plan. The issuance of
additional shares of common stock or warrants to purchase common stock, perception that such issuances may occur, or exercise of outstanding warrants or options will have a dilutive impact on other shareholders and could have a material negative
effect on the market price of our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_13"></A>Item&nbsp;2.&nbsp;Unregistered Sales of Equity Securities and
Use of Proceeds. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_14">
</A>Item&nbsp;3.&nbsp;Defaults Upon Senior Securities. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_15"></A>Item&nbsp;4.&nbsp;Mine Saftey Disclosures. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_16"></A>Item&nbsp;5.&nbsp;Other Information. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_17"></A>Item&nbsp;6.&nbsp;Exhibits. </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated&nbsp;by&nbsp;Reference&nbsp;to&nbsp;Filings&nbsp;Indicated</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:31pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Herewith</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s President and Chief Executive Officer, Christopher Garabedian, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s Vice President, Finance, Michael Jacobsen, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s President and Chief Executive Officer, Christopher Garabedian, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s Vice President, Finance, Michael Jacobsen, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated&nbsp;by&nbsp;Reference&nbsp;to&nbsp;Filings&nbsp;Indicated</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:31pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Herewith</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with Rule&nbsp;406T of Regulation&nbsp;S-T, the information in these exhibits is furnished and deemed not filed or a part of a registration statement or
prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section&nbsp;18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections and shall not be
incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_18"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AVI BIOPHARMA, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ CHRISTOPHER GARABEDIAN</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Garabedian</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc326013_19"></A>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated&nbsp;by&nbsp;Reference&nbsp;to&nbsp;Filings&nbsp;Indicated</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:31pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Herewith</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s President and Chief Executive Officer, Christopher Garabedian, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s Vice President, Finance, Michael Jacobsen, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s President and Chief Executive Officer, Christopher Garabedian, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Company&#146;s Vice President, Finance, Michael Jacobsen, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with Rule&nbsp;406T of Regulation&nbsp;S-T, the information in these exhibits is furnished and deemed not filed or a part of a registration statement or
prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section&nbsp;18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections and shall not be
incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d326013dex311.htm
<DESCRIPTION>SECTION 302 CEO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>SECTION 302 CEO CERTIFICATION</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Christopher Garabedian, certify that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Quarterly Report on Form 10-Q of AVI BioPharma, Inc., (the &#147;Registrant&#148;); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the Registrant as of, and for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The Registrant&#146;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the Registrant and have: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Evaluated the effectiveness of the Registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Disclosed in this report any change in the Registrant&#146;s internal control over financial reporting that occurred during the
Registrant&#146;s most recent fiscal quarter (the Registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#146;s internal control over
financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. The Registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the Registrant&#146;s auditors and the audit committee of the Registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the Registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#146;s internal control over financial reporting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher Garabedian</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Garabedian</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive and Financial Officer)</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d326013dex312.htm
<DESCRIPTION>SECTION 302 CFO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>SECTION 302 CFO CERTIFICATION</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Michael Jacobsen, certify that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Quarterly Report on Form 10-Q of AVI BioPharma, Inc., (the &#147;Registrant&#148;); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the Registrant as of, and for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The Registrant&#146;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the Registrant and have: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Evaluated the effectiveness of the Registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Disclosed in this report any change in the Registrant&#146;s internal control over financial reporting that occurred during the
Registrant&#146;s most recent fiscal quarter (the Registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#146;s internal control over
financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. The Registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the Registrant&#146;s auditors and the audit committee of the Registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the Registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#146;s internal control over financial reporting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael Jacobsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Jacobsen,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Accounting Officer)</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d326013dex321.htm
<DESCRIPTION>SECTION 906 CEO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>SECTION 906 CEO CERTIFICATION</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18 U.S.C. SECTION 1350) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">I, Christopher Garabedian, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report of AVI BioPharma, Inc. on
Form 10-Q for the quarterly period ended March&nbsp;31, 2012, fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly
presents, in all material respects, the financial condition and results of operations of AVI BioPharma, Inc. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher Garabedian</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Garabedian,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>President and Chief Executive Officer</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Executive and Financial Officer)</I></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley Act of
2002 has been provided to AVI BioPharma, Inc. and will be retained by AVI BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
by AVI BioPharma, Inc. for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except to the extent that AVI BioPharma, Inc. specifically incorporates it by reference. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d326013dex322.htm
<DESCRIPTION>SECTION 906 CFO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>SECTION 906 CFO CERTIFICATION</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18 U.S.C. SECTION 1350) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">I, Michael Jacobsen, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report of AVI BioPharma, Inc. on Form
10-Q for the quarterly period ended March&nbsp;31, 2012, fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents,
in all material respects, the financial condition and results of operations of AVI BioPharma, Inc. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael Jacobsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Jacobsen,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Vice President, Finance</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Accounting Officer)</I></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley Act of
2002 has been provided to AVI BioPharma, Inc. and will be retained by AVI BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
by AVI BioPharma, Inc. for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except to the extent that AVI BioPharma, Inc. specifically incorporates it by reference. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>avii-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 5.1.148.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2012 12:01:10 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:avii="http://www.avibio.com/20120331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="avii-20120331.xsd" />
  <!--Context Section-->
  <context id="As_Of_3_31_2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="As_Of_5_1_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2012-05-01</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2011_To_3_31_2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_22_1980_To_3_31_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>1980-07-22</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2012_To_3_31_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit13">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit12">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <avii:AccountsReceivableTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;4. ACCOUNTS RECEIVABLE &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Accounts receivable are stated at invoiced amount and do not bear interest. Because all accounts receivable are from the U.S. government and historically no amounts have been written off, an allowance for doubtful accounts receivable is not considered necessary. The accounts receivable balance included $2,623,000 and $2,093,000 of U.S. government receivables that were unbilled at March 31, 2012 and December 31, 2011, respectively.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</avii:AccountsReceivableTextBlock>
  <avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">2124000</avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets>
  <avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets>
  <avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:AssumptionOfLiabilitiesForAcquiredCompanyAssets>
  <avii:AssumptionOfLongTermDebtForBuildingPurchase contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">2200000</avii:AssumptionOfLongTermDebtForBuildingPurchase>
  <avii:AssumptionOfLongTermDebtForBuildingPurchase contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:AssumptionOfLongTermDebtForBuildingPurchase>
  <avii:AssumptionOfLongTermDebtForBuildingPurchase contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:AssumptionOfLongTermDebtForBuildingPurchase>
  <avii:ConversionOfInterestAccruedToCommonStock contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">8000</avii:ConversionOfInterestAccruedToCommonStock>
  <avii:ConversionOfInterestAccruedToCommonStock contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:ConversionOfInterestAccruedToCommonStock>
  <avii:ConversionOfInterestAccruedToCommonStock contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:ConversionOfInterestAccruedToCommonStock>
  <avii:GainLossOnDisposalOfAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-2336000</avii:GainLossOnDisposalOfAssets>
  <avii:GainLossOnDisposalOfAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">-26000</avii:GainLossOnDisposalOfAssets>
  <avii:GainLossOnDisposalOfAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-65000</avii:GainLossOnDisposalOfAssets>
  <avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">7004000</avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets>
  <avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">11226000</avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets>
  <avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">1830000</avii:IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets>
  <avii:IncreaseDecreaseOnWarrantValuation contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">14044000</avii:IncreaseDecreaseOnWarrantValuation>
  <avii:IncreaseDecreaseOnWarrantValuation contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">7274000</avii:IncreaseDecreaseOnWarrantValuation>
  <avii:IncreaseDecreaseOnWarrantValuation contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-10926000</avii:IncreaseDecreaseOnWarrantValuation>
  <avii:InterestExpenseIncomeAndOtherNet contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">9265000</avii:InterestExpenseIncomeAndOtherNet>
  <avii:InterestExpenseIncomeAndOtherNet contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">90000</avii:InterestExpenseIncomeAndOtherNet>
  <avii:InterestExpenseIncomeAndOtherNet contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">96000</avii:InterestExpenseIncomeAndOtherNet>
  <avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">1188000</avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">644000</avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <avii:IssuanceOfCommonStockForAcquiredCompanyAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">8075000</avii:IssuanceOfCommonStockForAcquiredCompanyAssets>
  <avii:IssuanceOfCommonStockForAcquiredCompanyAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:IssuanceOfCommonStockForAcquiredCompanyAssets>
  <avii:IssuanceOfCommonStockForAcquiredCompanyAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:IssuanceOfCommonStockForAcquiredCompanyAssets>
  <avii:IssuanceOfCommonStockForBuildingPurchase contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">750000</avii:IssuanceOfCommonStockForBuildingPurchase>
  <avii:IssuanceOfCommonStockForBuildingPurchase contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:IssuanceOfCommonStockForBuildingPurchase>
  <avii:IssuanceOfCommonStockForBuildingPurchase contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:IssuanceOfCommonStockForBuildingPurchase>
  <avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">12564000</avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities>
  <avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">5191000</avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities>
  <avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-1567000</avii:NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities>
  <avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-3863000</avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale>
  <avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale>
  <avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale>
  <avii:RecentAccountingPronouncementsTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;10. RECENT ACCOUNTING PRONOUNCEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;In April 2011, the Financial Accounting Standards Board ("FASB") issued guidance to achieve common fair value measurement and disclosure requirements between GAAP and International Financial Reporting Standards. This guidance amends current fair value measurement and disclosure guidance to include increased transparency around valuation inputs and investment categorization. The guidance is effective for fiscal years and interim periods beginning after December 15, 2011. The adoption of this new guidance did not have a material impact on the Company's financial statements. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;In June 2011, the FASB issued guidance regarding presentation of other comprehensive income in the financial statements. This guidance eliminated the option under GAAP to present other comprehensive income in the statement of changes in equity. Under the guidance, the Company had the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this new guidance did not have a material impact on the Company's financial statements.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</avii:RecentAccountingPronouncementsTextBlock>
  <avii:RevenueResearchContractsGrantsAndLicenseFees contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">147431000</avii:RevenueResearchContractsGrantsAndLicenseFees>
  <avii:RevenueResearchContractsGrantsAndLicenseFees contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">14296000</avii:RevenueResearchContractsGrantsAndLicenseFees>
  <avii:RevenueResearchContractsGrantsAndLicenseFees contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">11212000</avii:RevenueResearchContractsGrantsAndLicenseFees>
  <avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">17897000</avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering>
  <avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering>
  <avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering>
  <avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-13138000</avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale>
  <avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale>
  <avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:UnrealizedLossOnShortTermSecuritiesAvailableForSale>
  <avii:WarrantsValuation contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">5446000</avii:WarrantsValuation>
  <avii:WarrantsValuation contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">16372000</avii:WarrantsValuation>
  <avii:WithdrawalOfPartnershipNetAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">177000</avii:WithdrawalOfPartnershipNetAssets>
  <avii:WithdrawalOfPartnershipNetAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:WithdrawalOfPartnershipNetAssets>
  <avii:WithdrawalOfPartnershipNetAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:WithdrawalOfPartnershipNetAssets>
  <avii:WriteDownOfShortTermSecuritiesAvailableForSale contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">17001000</avii:WriteDownOfShortTermSecuritiesAvailableForSale>
  <avii:WriteDownOfShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</avii:WriteDownOfShortTermSecuritiesAvailableForSale>
  <avii:WriteDownOfShortTermSecuritiesAvailableForSale contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</avii:WriteDownOfShortTermSecuritiesAvailableForSale>
  <dei:AmendmentFlag contextRef="Duration_1_1_2012_To_3_31_2012">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2012_To_3_31_2012">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2012_To_3_31_2012">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2012_To_3_31_2012">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2012_To_3_31_2012">2012-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2012_To_3_31_2012">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2012_To_3_31_2012">0000873303</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_5_1_2012" unitRef="Unit12" decimals="INF">135743787</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2012_To_3_31_2012">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2012_To_3_31_2012">AVI BIOPHARMA INC</dei:EntityRegistrantName>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">9396000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">8195000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">3633000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">5135000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">15765000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">15982000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AcquisitionCosts contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-2389000</us-gaap:AcquisitionCosts>
  <us-gaap:AcquisitionCosts contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:AcquisitionCosts>
  <us-gaap:AcquisitionCosts contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:AcquisitionCosts>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">340968000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">341677000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">54368000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">46647000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">45184000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">37632000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">3863000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2010" unitRef="Unit1" decimals="-3">33589000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2011" unitRef="Unit1" decimals="-3">23283000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">39904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">30573000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">30573000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">-10306000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-9331000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2011" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_3_31_2012" unitRef="Unit1" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2011" unitRef="Unit13" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_3_31_2012" unitRef="Unit13" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">135743120</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">135743787</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">135743120</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">135743787</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">13000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">13000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-327668000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">1833000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-17704000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">3304000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">3304000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">20798000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">239000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">353000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativesAndFairValueTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;div&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;5. WARRANTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Warrants issued in connection with the Company's December 2007, January 2009 and August 2009 financings are classified as liabilities, as opposed to equity, due to their settlement terms which require settlement in registered shares. Additionally, the settlement terms may result in cash settlement upon the occurrence of certain specified transactions set forth in the warrant agreements. Warrants classified as liabilities are adjusted to fair value each reporting period with the fair value adjustment recorded in the statement of operations. All other warrants issued by the Company were recorded as additional paid-in capital and no further adjustments are made. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The fair value of the warrants classified as liabilities was recorded on the balance sheet at issuance and is adjusted to fair value at each financial reporting period, with changes in the fair value recorded as a gain or loss in the statement of operations. The fair value is determined using the Black-Scholes option-pricing model, which requires the use of significant judgment and estimates for the inputs used in the model. The following reflects the weighted-average assumptions for each of the periods indicated: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt; &lt;/p&gt;&lt;/div&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;&lt;td width="68%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="14%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="14%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three Months Ended March&amp;nbsp;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.2%-0.3 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.8%-1.3 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected lives&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.7-2.4&amp;nbsp;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.7-3.4&amp;nbsp;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;65.1%-82.4&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;71.4%-88.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Shares underlying warrants classified as liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;28,948,962&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;28,948,962&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Market value of stock at beginning of period&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.75&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.12&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Market value of stock at end of period&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.54&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.86&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;A reconciliation of the change in value of such warrants for the three months ended March 31, 2012 is as follows: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
&lt;tr&gt;&lt;td width="88%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom" nowrap="nowrap"&gt;

&lt;p style="border-bottom: #000000 1px solid; width: 48pt;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Balance at December&amp;nbsp;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,446&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Change in value of warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;10,926&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Reclassification to shareholders' equity upon exercise of warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Balance at March&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The following table summarizes information about warrants outstanding at March 31, 2012. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
&lt;tr&gt;&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Exercise&amp;nbsp;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Outstanding&amp;nbsp;Warrants&amp;nbsp;at&lt;br /&gt;March&amp;nbsp;31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Weighted&amp;nbsp;Average&amp;nbsp;Remaining&lt;br /&gt;Contractual Life (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Exercisable&lt;br /&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$0.0003&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,667&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;No&amp;nbsp;expiration&amp;nbsp;date&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,667&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.1679&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;238,228&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;238,228&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.14&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;No expiration date&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;14,124,202&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;14,124,202&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.45&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;66,142&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.8&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;66,142&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.78&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;9,410,310&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;9,410,310&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.45&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,348,308&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,348,308&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;29,204,857&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;29,204,857&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:DerivativesAndFairValueTextBlock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">309964000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">327668000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;7. STOCK COMPENSATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; margin-bottom: 0px; margin-left: 2%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock Options &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="padding-bottom: 0px; margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;In general, stock options granted prior to December 31, 2010 vest over a three year period, with one-third of the underlying shares vesting on each anniversary of grant, and have a ten year term. Beginning in January 2011, stock options granted generally vest over a four year period, with one-fourth of the underlying shares vesting on the first anniversary of the grant and 1/48&lt;/font&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;sup style="position: relative; bottom: 0.8ex; vertical-align: baseline;"&gt;th&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt; of the underlying shares vesting monthly thereafter, such that the underlying shares will be fully vested on the fourth anniversary of the grant. As of March 31, 2012, 13,040,676 shares of common stock remain available for future grant. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;A summary of the Company's stock option activity with respect to the three months ended March 31, 2012 follows: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;&lt;td width="62%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom" nowrap="nowrap"&gt;

&lt;p style="border-bottom: #000000 1px solid; width: 48pt;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Underlying&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Outstanding at December&amp;nbsp;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;14,505,857&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.86&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;653,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.40&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(667&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.92&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(1,409,138&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.42&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Outstanding at March&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;13,749,052&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.89&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;7.39&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2,626,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td height="8"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Vested at March&amp;nbsp;31, 2012 and expected to vest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;13,202,433&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.91&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;7.31&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2,477,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td height="8"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Exercisable at March&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,149,551&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.54&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;4.33&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;609,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The weighted-average fair value per share of stock-based awards granted to employees during the three months ended March 31, 2012 and 2011 was $0.91 and $1.54, respectively. During the three months ended March 31, 2012 and 2011, the total intrinsic value of stock options exercised was $280 and $0 respectively, and the total grant date fair value of stock options that vested was $1,942,000 and $1,089,000, respectively. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 2%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Valuation Assumptions &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Stock-based compensation costs are based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options. The fair value of stock grants is amortized as compensation expense on a straight-line basis over the vesting period of the grants. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The fair values of stock options granted during the periods presented were measured on the date of grant using the Black-Scholes option-pricing model, with the following assumptions: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;&lt;td width="78%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td height="8"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;
&lt;td height="8" colspan="4"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected lives&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5.3&amp;nbsp;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5.4&amp;nbsp;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;79.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;81.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;%&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 2%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation Expense &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;A summary of the stock-based compensation expense recognized in the statements of operations is as follows: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;&lt;td width="76%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;253&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;373&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;455&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;772&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;708&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1,145&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;As of March 31, 2012, there was $7,526,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted, including stock options and restricted stock. These costs are expected to be recognized over a weighted-average period of 3.1 years.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit13" decimals="2">0.02</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit13" decimals="2">-0.13</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit13" decimals="2">0.02</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit13" decimals="2">-0.13</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;2. NET INCOME (LOSS) PER SHARE &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares and dilutive common stock equivalent shares outstanding. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;&lt;td width="75%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in&amp;nbsp;thousands,&amp;nbsp;except&amp;nbsp;per&amp;nbsp;share&amp;nbsp;data)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Net income (loss)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(17,704&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;1,833&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Weighted-average number of shares of common stock and common stock equivalents&amp;nbsp;outstanding:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Weighted-average number of common shares outstanding for computing basic earnings per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;135,743&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;112,482&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Dilutive effect of warrants and stock options after application of the treasury stock method*&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;8,803&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Weighted-average number of common shares outstanding for computing diluted earnings per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;135,743&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;121,282&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Net income (loss) per share - basic&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(0.13 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Net income (loss) per share - dilutive&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(0.13 &lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Warrants and stock options to purchase 42,953,909 and 12,572,964 shares of common stock as of March&amp;nbsp;31, 2012 and 2011, respectively, were excluded from the net income (loss) per share calculation as their effect would have been anti-dilutive.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">2244000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">1852000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;3. FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The Company measures at fair value certain financial assets and liabilities in accordance with a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. There are three levels of inputs that may be used to measure fair-value: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;&lt;td width="5%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;

&lt;p align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Level 1 &amp;#8212; quoted prices for identical instruments in active markets; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;&lt;td width="5%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;

&lt;p align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Level 2 &amp;#8212; quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;&lt;td width="5%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;

&lt;p align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Level 3 &amp;#8212; valuations derived from valuation techniques in which one or more significant value drivers are unobservable. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The Company's assets and liabilities measured at fair value on a recurring basis consisted of the following as of the date indicated: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr style="line-height: 0pt; visibility: hidden; color: white;"&gt;&lt;td width="78%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Fair Value Measurement as of March&amp;nbsp;31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;30,573&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;30,573&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;30,573&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;30,573&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr style="line-height: 0pt; visibility: hidden; color: white;"&gt;&lt;td width="78%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Fair&amp;nbsp;Value&amp;nbsp;Measurement&amp;nbsp;as&amp;nbsp;of&amp;nbsp;March&amp;nbsp;31,&amp;nbsp;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Warrants*&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;16,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr style="line-height: 0pt; visibility: hidden; color: white;"&gt;&lt;td width="78%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Fair&amp;nbsp;Value&amp;nbsp;Measurement&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;39,904&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;39,904&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;39,904&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;39,904&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr style="line-height: 0pt; visibility: hidden; color: white;"&gt;&lt;td width="80%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font class="_mt" size="1"&gt;&lt;b&gt;00000000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Fair&amp;nbsp;Value&amp;nbsp;Measurement&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Level&amp;nbsp;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Warrants*&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,446&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,446&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,446&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;5,446&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;See "Note 5 &amp;#8212; Warrants" for additional information related to the determination of fair value of the warrants and a reconciliation of changes in fair value. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The carrying amounts reported in the balance sheets for accounts receivable, accounts payable, and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">2199000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">2298000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">4764000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">4704000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">107738000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">5026000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">3281000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOfInvestments contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">17001000</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ImpairmentOfInvestments contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ImpairmentOfInvestments contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ImpairmentOfRealEstate contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">1445000</us-gaap:ImpairmentOfRealEstate>
  <us-gaap:ImpairmentOfRealEstate contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:ImpairmentOfRealEstate>
  <us-gaap:ImpairmentOfRealEstate contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:ImpairmentOfRealEstate>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;8. INCOME TAXES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;At December 31, 2011, the Company had net deferred tax assets of approximately $116.8 million. The net deferred tax assets are primarily composed of U.S. federal and state tax net operating loss carryforwards, U.S. federal and state research and development credit carryforwards and share-based compensation expense. Due to uncertainties surrounding the Company's ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset its net deferred tax asset. Additionally, the Internal Revenue Code rules could limit the future use of its net operating loss and research and development credit carryforwards to offset future taxable income based on ownership changes and the value of the Company's stock.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">511000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">23000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">22000</us-gaap:InterestPaid>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">54368000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">46647000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">20601000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">29923000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">993000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">967000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;6. U.S. GOVERNMENT CONTRACTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The Company recognizes revenues from U.S. government research contracts during the period in which the related expenditures are incurred and presents these revenues and related expenses gross in the consolidated financial statements. In the periods presented, all of the revenue generated by the Company was derived from research contracts with and grants from the U.S. government. As of March 31, 2012, the Company had completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics against Ebola and Marburg. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;July 2010 Agreement (Ebola and Marburg) &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;On July 14, 2010, the Company was awarded a contract with the U.S. Department of Defense, or DoD, Chemical and Biological Defense Program through the U.S. Army Space and Missile Defense Command for the advanced development of the Company's hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, against the Ebola and Marburg viruses, respectively. In February 2012, the Company announced that it received approval from the FDA to proceed with a single oligomer from AVI-6003, AVI-7288, as the lead product candidate against Marburg virus infection. The contract is structured into four segments for each therapeutic candidate and has an aggregate period of performance spanning approximately six years if DoD exercises its options for all segments. Activities under the first segment began in July 2010 and include Phase I studies in healthy volunteers as well as preclinical studies which are scheduled to be completed in the second quarter of 2013. The aggregate available funding for the current segments is approximately $126.5 million of which $63.9 million has been recognized to date. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;After completion of the first segment, and each successive segment, DoD has the option to proceed to the next segment for either or both AVI-6002 and AVI-7288. If DoD exercises its options for all four segments for both AVI-6002 and AVI-7288 , contract activities would include all clinical and licensure activities necessary to obtain FDA regulatory approval for each therapeutic candidate and would provide for a total funding award to the Company of up to $288.0 million over a period of six years, of which $161.5 million remains to be funded. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;June 2010 Agreement (H1N1/Influenza) &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;On June 4, 2010, the Company entered into a contract with the Defense Threat Reduction Agency to advance the development of AVI-7100 as a medical countermeasure against the pandemic H1N1 influenza virus in cooperation with the Transformational Medical Technologies program of DoD. The period of performance for this contract ended on June 3, 2011 and, as of December 31, 2011, the Company has recognized revenue of $12.3 million and does not expect to receive any additional revenue. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The following table sets forth the revenue for each of the contracts with the U.S. government for the three months ended March 31, 2012 and 2011. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;&lt;td width="80%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;July 2010 Agreement &lt;i&gt;(Ebola and Marburg)&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;11,163&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;11,905&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;June&amp;nbsp;2010 Agreement &lt;i&gt;(H1N1)&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;2,324&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Other Agreements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;49&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;67&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;11,212&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;14,296&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">85000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">86000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">1757000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">1735000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">297127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">96000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-20000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-27291000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">-336000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-262000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-239263000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">-10066000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-9049000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-327668000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">1833000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-17704000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">10171000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">7364000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-10830000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">-337839000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">-5531000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">-6874000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 12px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;1. ORGANIZATION AND BASIS OF PRESENTATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;AVI BioPharma, Inc. (the "Company") is a biopharmaceutical company incorporated in the State of Oregon on July 22, 1980. The Company is focused on the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. Applying the Company's proprietary platform technologies, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. The Company is focused on rapidly advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen. In April 2012, the Company announced results from its Phase IIb placebo controlled trial in eteplirsen. Following completion of this study, the Company initiated an open label extension study with the same participants from the original Phase IIb placebo controlled trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses for which the Company has historically received and expects to continue to receive significant financial support from U.S. government research contracts. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company and its consolidated subsidiaries. The accompanying unaudited condensed consolidated balance sheet data as of December 31, 2011 was derived from audited financial statements not included in this report. The accompanying unaudited condensed consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") pertaining to interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The accompanying unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2011. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Since its inception in 1980, the Company has incurred losses of approximately $327.7 million, substantially all of which resulted from expenditures related to research and development, general and administrative charges and acquired in-process research and development resulting from two acquisitions. The Company has not generated any material revenue from product sales to date, and there can be no assurance that revenues from product sales will be achieved. Moreover, even if the Company does achieve revenue from product sales, the Company expects to incur operating losses over the next several years. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;In the periods presented, nearly all of the revenue generated by the Company was derived from research contracts and grants with the U.S. government. As of March 31, 2012, the Company had had substantially completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics against Ebola and Marburg. Pursuant to this agreement, as of March 31, 2012, the Company is currently entitled to receive up to an aggregate of $126.5 million for development of its product candidates, of which $63.9 million has been recognized as revenue and $62.6 million relates to development that has not yet been completed and has not been billed or recognized as revenue. In addition, if the U.S. government elects to exercise all its options under the agreement, an additional $161.5 million in funding is available. See "Note 6 &amp;#8212; U.S. Government Contracts" for additional information. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;At March 31, 2012, cash and cash equivalents were $30.6 million. The Company's principal sources of liquidity have been equity financings and revenue from its U.S. government research contracts. The Company's principal uses of cash have been research and development expenses, general and administrative expenses and other working capital requirements. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The Company believes it has sufficient cash to fund operations at least through the following 12 months. The Company anticipates receiving continued funding from the U.S. government to pursue the development of its therapeutics against Ebola and Marburg, and has assumed certain revenues from these awards in providing this guidance. Should the Company's funding from the U.S. government cease or be delayed, it would have a significant negative impact on the Company's financial condition and on this guidance and the Company would likely be forced to significantly curtail its research and development efforts unless additional funding was obtained. The Company is also likely to pursue additional funding through public or private financings and cash generated from establishing collaborations or licensing its technology to other companies. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Estimates and Uncertainties &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of liability classified warrants and stock-based awards, long lived asset impairment, and revenue recognition. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Commitments and Contingencies &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;As of the date of this report, the Company is not a party to any material legal proceedings with respect to itself, its subsidiaries, or any of its material properties. In the normal course of business, the Company may from time to time be named as a party to various legal claims, actions and complaints, including matters involving employment, intellectual property, effects from the use of therapeutics utilizing its technology, professional services or others. It is impossible to predict with certainty whether any resulting liability would have a material adverse effect on the Company's financial position, results of operations or cash flows. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;&lt;i&gt;Reclassifications &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Certain inception to date amounts have been reclassified to conform to current year presentation. These changes did not have a significant impact on the Company's net loss, assets, liabilities, shareholders' equity or cash flows.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">1647000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">1924000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">155000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">206000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease xsi:nil="true" contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" />
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease xsi:nil="true" contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" />
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease xsi:nil="true" contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" />
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">126000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">114000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">289000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">9745000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">109000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">253000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">112993000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">19888000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">227000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2011" unitRef="Unit13" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_3_31_2012" unitRef="Unit13" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2011" unitRef="Unit12" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_3_31_2012" unitRef="Unit12" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">80000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">297879000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">116000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">1000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">117724000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">4265000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">4105000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">366000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">20000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">21000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">348071000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">14801000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">14805000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">29461000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="Duration_1_1_2012_To_3_31_2012">&lt;div&gt; &lt;p style="margin-top: 18px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&lt;b&gt;9. RESTRUCTURING &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;In December 2011, the Company restructured its operations by reducing its workforce by 28%. Restructuring charges totaling $1,145,000 were recorded in 2011 and included severance and related costs. The charge included $548,000 to research and development expense and $597,000 to general and administrative expense. The restructuring was completed by January 31, 2012 and all severance costs are expected to be paid by July 31, 2012. &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Changes in the accrued employee compensation liability and the balance related to the December 2011 restructuring plan are as follows: &lt;/font&gt;&lt;/p&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
&lt;tr&gt;&lt;td width="77%"&gt; &lt;/td&gt;
&lt;td valign="bottom" width="20%"&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;
&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;Three&amp;nbsp;months&amp;nbsp;ending&lt;br /&gt;March 31,&amp;nbsp;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="1"&gt;&lt;b&gt;(in&amp;nbsp;thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Balance at January&amp;nbsp;1, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;828&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Restructuring charge for severance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;#8212;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Severance payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;(86&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 1px solid;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;

&lt;p style="text-indent: -1em; margin-left: 1em;"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;Balance at March&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font class="_mt" size="1"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;742&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family: Times New Roman;" class="_mt" size="2"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;&lt;td valign="bottom"&gt; &lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;

&lt;p style="border-top: #000000 3px double;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_7_22_1980_To_3_31_2012" unitRef="Unit1" decimals="-3">29703000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit1" decimals="-3">1145000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit1" decimals="-3">708000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2011" unitRef="Unit1" decimals="-3">31017000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2012" unitRef="Unit1" decimals="-3">14022000</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit12" decimals="-3">121285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit12" decimals="-3">135743000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_1_1_2011_To_3_31_2011" unitRef="Unit12" decimals="-3">112482000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_1_1_2012_To_3_31_2012" unitRef="Unit12" decimals="-3">135743000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avii-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 5.1.148.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2012 12:01:17 PM-->
<!--Modified on: 5/9/2012 12:01:17 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://www.avibio.com/20120331" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:avii="http://www.avibio.com/20120331" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>00200 - Statement - Statements Of Operations And Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00300 - Statement - Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureOrganizationAndBasisOfPresentation" id="DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Organization And Basis Of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureNetIncomeLossPerShare" id="DisclosureNetIncomeLossPerShare">
        <link:definition>10201 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureAccountsReceivable" id="DisclosureAccountsReceivable">
        <link:definition>10401 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>10501 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureUSGovernmentContracts" id="DisclosureUSGovernmentContracts">
        <link:definition>10601 - Disclosure - U.S. Government Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureStockCompensation" id="DisclosureStockCompensation">
        <link:definition>10701 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>10901 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avibio.com/2010-09-30/role/DisclosureRecentAccountingPronouncements" id="DisclosureRecentAccountingPronouncements">
        <link:definition>11001 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="avii-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="avii-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="avii-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <element id="avii_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="avii_WarrantsValuation" name="WarrantsValuation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="avii_IncreaseDecreaseOnWarrantValuation" name="IncreaseDecreaseOnWarrantValuation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_ConversionOfInterestAccruedToCommonStock" name="ConversionOfInterestAccruedToCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" name="IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_WithdrawalOfPartnershipNetAssets" name="WithdrawalOfPartnershipNetAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets" name="AssumptionOfLiabilitiesForAcquiredCompanyAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" name="IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_IssuanceOfCommonStockForBuildingPurchase" name="IssuanceOfCommonStockForBuildingPurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_IssuanceOfCommonStockForAcquiredCompanyAssets" name="IssuanceOfCommonStockForAcquiredCompanyAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_AssumptionOfLongTermDebtForBuildingPurchase" name="AssumptionOfLongTermDebtForBuildingPurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_USGovernmentContractsAbstract" name="USGovernmentContractsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="avii_InterestExpenseIncomeAndOtherNet" name="InterestExpenseIncomeAndOtherNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" name="ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" name="NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="avii_RevenueResearchContractsGrantsAndLicenseFees" name="RevenueResearchContractsGrantsAndLicenseFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_GainLossOnDisposalOfAssets" name="GainLossOnDisposalOfAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" name="UnrealizedLossOnShortTermSecuritiesAvailableForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_AccountsReceivableTextBlock" name="AccountsReceivableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="avii_RecentAccountingPronouncementsTextBlock" name="RecentAccountingPronouncementsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="avii_WriteDownOfShortTermSecuritiesAvailableForSale" name="WriteDownOfShortTermSecuritiesAvailableForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" name="RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avii-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 5.1.148.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2012 12:01:17 PM-->
<!--Modified on: 5/9/2012 12:01:17 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementBalanceSheets" roleURI="http://www.avibio.com/2010-09-30/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementStatementsOfCashFlows" roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows" />
  <calculationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_634261878041068820" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634261878041068820" xlink:to="us-gaap_AssetsCurrent_634721616776631759" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634721616776631759" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776631759" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634721616776631759" xlink:to="us-gaap_AccountsReceivableNetCurrent_634721616776631759" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634721616776631759" xlink:to="us-gaap_OtherAssetsCurrent_634721616776631759" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634261878041068820" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_634721616776631759" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634261878041068820" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_634721616776631759" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634261878041068820" xlink:to="us-gaap_OtherAssetsNoncurrent_634721616776631759" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_634261878041769828" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634261878041769828" xlink:to="us-gaap_LiabilitiesCurrent_634721616776631759" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="us-gaap_AccountsPayableCurrent_634721616776631759" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_634721616776631759" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="us-gaap_LongTermDebtCurrent_634721616776631759" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WarrantsValuation" xlink:label="avii_WarrantsValuation_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="avii_WarrantsValuation_634721616776631759" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="us-gaap_DeferredRevenueCurrent_634721616776631759" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634721616776631759" xlink:to="us-gaap_OtherLiabilitiesCurrent_634721616776631759" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634261878041769828" xlink:to="us-gaap_LongTermDebtNoncurrent_634721616776631759" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634261878041769828" xlink:to="us-gaap_LiabilitiesNoncurrent_634721616776631759" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634261878041769828" xlink:to="us-gaap_StockholdersEquity_634721616776631759" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634721616776631759" xlink:to="us-gaap_PreferredStockValue_634721616776631759" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634721616776631759" xlink:to="us-gaap_CommonStockValue_634721616776631759" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634721616776631759" xlink:to="us-gaap_AdditionalPaidInCapital_634721616776631759" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634721616776631759" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_634721616776631759" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements Of Operations And Comprehensive Income (Loss)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_634689571797730025" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_634689571797730025" xlink:to="us-gaap_NetIncomeLoss_634721616776631759" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_634721616776631759" xlink:to="us-gaap_NonoperatingIncomeExpense_634721616776631759" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseOnWarrantValuation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634721616776631759" xlink:to="avii_IncreaseDecreaseOnWarrantValuation_634721616776631759" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_InterestExpenseIncomeAndOtherNet" xlink:label="avii_InterestExpenseIncomeAndOtherNet_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634721616776631759" xlink:to="avii_InterestExpenseIncomeAndOtherNet_634721616776631759" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634721616776631759" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776631759" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634721616776631759" xlink:to="us-gaap_ImpairmentOfInvestments_634721616776631759" order="4" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_634721616776631759" xlink:to="us-gaap_OperatingIncomeLoss_634721616776631759" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634721616776631759" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634721616776631759" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634721616776631759" xlink:to="us-gaap_GeneralAndAdministrativeExpense_634721616776631759" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634721616776631759" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_634721616776631759" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RevenueResearchContractsGrantsAndLicenseFees" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634721616776631759" xlink:to="avii_RevenueResearchContractsGrantsAndLicenseFees_634721616776631759" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_634689571797730025" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776631759" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776631759" xlink:to="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_634721616776631759" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WriteDownOfShortTermSecuritiesAvailableForSale" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776631759" xlink:to="avii_WriteDownOfShortTermSecuritiesAvailableForSale_634721616776631759" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776631759" xlink:to="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_634721616776631759" order="3" use="optional" weight="1" priority="5" />
  </calculationLink>
  <calculationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634262732525684247" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634262732525684247" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_NetIncomeLoss_634721616776631759" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_DepreciationDepletionAndAmortization_634721616776631759" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_GainLossOnDisposalOfAssets" xlink:label="avii_GainLossOnDisposalOfAssets_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="avii_GainLossOnDisposalOfAssets_634721616776631759" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfRealEstate" xlink:label="us-gaap_ImpairmentOfRealEstate_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_ImpairmentOfRealEstate_634721616776631759" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_ShareBasedCompensation_634721616776631759" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_ConversionOfInterestAccruedToCommonStock" xlink:label="avii_ConversionOfInterestAccruedToCommonStock_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="avii_ConversionOfInterestAccruedToCommonStock_634721616776631759" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_ImpairmentOfInvestments_634721616776631759" order="7" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776631759" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_634721616776631759" order="9" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseOnWarrantValuation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="avii_IncreaseDecreaseOnWarrantValuation_634721616776631759" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_634721616776631759" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776631759" xlink:to="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_634721616776631759" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634262732525684247" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634721616776631759" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_634721616776631759" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_634721616776631759" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634721616776631759" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776631759" xlink:to="us-gaap_AcquisitionCosts_634721616776631759" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634262732525684247" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" xlink:to="us-gaap_RepaymentsOfLongTermDebt_634721616776631759" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_634721616776631759" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WithdrawalOfPartnershipNetAssets" xlink:label="avii_WithdrawalOfPartnershipNetAssets_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" xlink:to="avii_WithdrawalOfPartnershipNetAssets_634721616776631759" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" xlink:to="us-gaap_ProceedsFromConvertibleDebt_634721616776631759" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_634721616776631759" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776631759" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_634721616776631759" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>avii-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 5.1.148.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2012 12:01:17 PM-->
<!--Modified on: 5/9/2012 12:01:17 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_DocumentAndEntityInformationAbstract" xlink:label="avii_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="avii_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information[Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">End of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net of accumulated depreciation and amortization of $0 and $0</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net of accumulated depreciation and amortization of $15,982 and $15,765</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent Costs, net of accumulated amortization of $0 and $0</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent Costs, net of accumulated amortization of $2,298 and $2,199</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued employee compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Long-term Debt, Current Maturities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Long-term debt, current portion</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WarrantsValuation" xlink:label="avii_WarrantsValuation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_WarrantsValuation" xlink:to="avii_WarrantsValuation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_WarrantsValuation_lbl" xml:lang="en-US">The Company's warrants are non-cash liabilities and the Company will not expend any cash to settle these liabilities. The fair value of the warrants is recorded on the balance sheet at issuance and are marked to market at each financial reporting period, with changes in fair value recorded as a gain or loss in the statement of operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_WarrantsValuation_lbl" xml:lang="en-US">Warrants Valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_WarrantsValuation_lbl" xml:lang="en-US">Warrant valuation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt, non-current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term Debt, Excluding Current Maturities, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' Equity (Deficit):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.0001 par value, 20,000,000 shares authorized; none issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.0001 par value, 200,000,000 shares authorized; 0 and 0 issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.0001 par value, 300,000,000 and 200,000,000 shares authorized; 135,743,787 and 135,743,120 issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and Equipment accumulated depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Patent Costs accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock,Par Or Stated Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par or stated value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock,Par Or Stated Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements Of Operations And Comprehensive Income (Loss) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RevenueResearchContractsGrantsAndLicenseFees" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_RevenueResearchContractsGrantsAndLicenseFees" xlink:to="avii_RevenueResearchContractsGrantsAndLicenseFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_lbl" xml:lang="en-US">The Company's revenue is generated largely from U.S. government research contracts. The contracts with the U. S. government are cost plus contracts providing for reimbursed costs and a target fee. Revenue is recognized from U.S. government research contracts during the period in which the related expenses are incurred and present such revenues and related expenses gross in the consolidated financial statements. In addition the Company also receives revenue from license fees which consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive licensed rights to patented or patent pending compounds, technology access fees, various performance or sales milestones and future product royalty payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_lbl" xml:lang="en-US">Revenue Research Contracts Grants And License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_lbl" xml:lang="en-US">Revenues from license fees, grants and research contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_lbl" xml:lang="en-US">Revenues from license fees, grants and research contracts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Acquired in-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Acquired in-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Acquired in-process research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other non-operating (loss) income:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (loss):</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_InterestExpenseIncomeAndOtherNet" xlink:label="avii_InterestExpenseIncomeAndOtherNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_InterestExpenseIncomeAndOtherNet" xlink:to="avii_InterestExpenseIncomeAndOtherNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_InterestExpenseIncomeAndOtherNet_lbl" xml:lang="en-US">Non-operating interest income or (expense) related to investments and other activities, net as reported in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_InterestExpenseIncomeAndOtherNet_lbl" xml:lang="en-US">Interest (expense) income and other, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_InterestExpenseIncomeAndOtherNet_lbl" xml:lang="en-US">Interest income and other, net</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseOnWarrantValuation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_IncreaseDecreaseOnWarrantValuation" xlink:to="avii_IncreaseDecreaseOnWarrantValuation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_lbl" xml:lang="en-US">The income statement impact of changes in the fair value of the Company's noncash liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_lbl" xml:lang="en-US">(Increase) decrease on warrant valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_lbl" xml:lang="en-US">Increase (decrease) on warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_lbl" xml:lang="en-US">(Gain) loss on warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_lbl" xml:lang="en-US">Gain (loss) on change in warrant valuation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xml:lang="en-US">Realized gain on sale of short-term securities-available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xml:lang="en-US">Realized gain on sale of short-term securities-available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xml:lang="en-US">Realized gain on sale of short-term securities- available-for-sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Impairment of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Write-down of short-term securities- available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Write-down of short-term securities-available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Write-down of short-term securities-available-for-sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other non Operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other non Operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other non operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other non Operating income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WriteDownOfShortTermSecuritiesAvailableForSale" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_WriteDownOfShortTermSecuritiesAvailableForSale" xlink:to="avii_WriteDownOfShortTermSecuritiesAvailableForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Write down of short term securities available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Write Down of Short Term Securities Available for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Write-down of short-term securities-available-for-sale</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" xlink:to="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Realized gain on sale of short term securities available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Realized Gain on Sale of Short Term Securities Available for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Realized gain on sale of short-term securities-available-for-sale</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" xlink:to="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Unrealized loss on short term securities available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Unrealized Loss on Short Term Securities Available for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_lbl" xml:lang="en-US">Unrealized loss on short-term securities-available-for-sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per share - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net income (loss) per share - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding for computing basic income (loss) per share (in thousands)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding for computing diluted income (loss) per share (in thousands)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flows used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_GainLossOnDisposalOfAssets" xlink:label="avii_GainLossOnDisposalOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_GainLossOnDisposalOfAssets" xlink:to="avii_GainLossOnDisposalOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_GainLossOnDisposalOfAssets_lbl" xml:lang="en-US">The gain or (loss) recognized by the Company as a result of the difference between the sale price or salvage price and the book value of an asset that was sold or retired during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_GainLossOnDisposalOfAssets_lbl" xml:lang="en-US">Gain (Loss) On Disposal Of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avii_GainLossOnDisposalOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_GainLossOnDisposalOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfRealEstate" xlink:label="us-gaap_ImpairmentOfRealEstate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfRealEstate" xlink:to="us-gaap_ImpairmentOfRealEstate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfRealEstate_lbl" xml:lang="en-US">Impairment charge on real estate owned</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation, Total</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_ConversionOfInterestAccruedToCommonStock" xlink:label="avii_ConversionOfInterestAccruedToCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_ConversionOfInterestAccruedToCommonStock" xlink:to="avii_ConversionOfInterestAccruedToCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_ConversionOfInterestAccruedToCommonStock_lbl" xml:lang="en-US">The SEC requires development stage companies to disclose information since inception of the Company for certain financial statements. This line item represents a legacy item from when the Company used to issue stock to vendors the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_ConversionOfInterestAccruedToCommonStock_lbl" xml:lang="en-US">Conversion of interest accrued to common stock</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" xlink:to="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services, including accounts receivable and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_lbl" xml:lang="en-US">Increase Decrease In Accounts Receivable And Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_lbl" xml:lang="en-US">(Increase) in accounts receivable, other current assets and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_lbl" xml:lang="en-US">Accounts receivable and other current assets</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" xlink:to="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_lbl" xml:lang="en-US">The net increase (decrease) during the reporting period in the amount due to customers for the credit sale of goods and services, including accounts payables, accrued employee compensation and other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_lbl" xml:lang="en-US">Net increase in accounts payable, accrued employee compensation, and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable, accrued employee compensation, and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sale of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCosts_lbl" xml:lang="en-US">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-term Debt, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Buyback of common stock pursuant to rescission offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Buyback of common stock pursuant to rescission offering</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WithdrawalOfPartnershipNetAssets" xlink:label="avii_WithdrawalOfPartnershipNetAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_WithdrawalOfPartnershipNetAssets" xlink:to="avii_WithdrawalOfPartnershipNetAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_WithdrawalOfPartnershipNetAssets_lbl" xml:lang="en-US">The SEC requires development stage companies to disclose information since inception of the Company for certain financial statements. This line item represents a legacy item from when the Company Incorporated most of the partners converted their interests in the Company to common stock, some partners decided not to completely convert to common stock during the incorporation process and as a result withdrew assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_WithdrawalOfPartnershipNetAssets_lbl" xml:lang="en-US">Withdrawal of Partnership Net Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avii_WithdrawalOfPartnershipNetAssets_lbl" xml:lang="en-US">Withdrawal of partnership net assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Issuance of convertible debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US">Cash and cash equivalents:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid during the year for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING ACTIVITIES AND FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" xlink:label="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" xlink:to="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_lbl" xml:lang="en-US">The value of non-cash short-term investments classified as available-for-sale that the Company received as part of a private offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_lbl" xml:lang="en-US">Short Term Securities Available for Sale Received in Connection with Private Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_lbl" xml:lang="en-US">Short-term securities-available-for-sale received in connection with the private offering</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" xlink:label="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" xlink:to="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities_lbl" xml:lang="en-US">The non-cash value of the Company's issuance of common stock and warrants to satisfy the Company's liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities_lbl" xml:lang="en-US">Issuance of common stock and warrants in satisfaction of liabilities</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockForBuildingPurchase" xlink:label="avii_IssuanceOfCommonStockForBuildingPurchase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_IssuanceOfCommonStockForBuildingPurchase" xlink:to="avii_IssuanceOfCommonStockForBuildingPurchase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_IssuanceOfCommonStockForBuildingPurchase_lbl" xml:lang="en-US">The value of a non-cash issuance of common stock to for the purpose of purchasing a building.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_IssuanceOfCommonStockForBuildingPurchase_lbl" xml:lang="en-US">Issuance of common stock for building purchase</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AssumptionOfLongTermDebtForBuildingPurchase" xlink:label="avii_AssumptionOfLongTermDebtForBuildingPurchase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_AssumptionOfLongTermDebtForBuildingPurchase" xlink:to="avii_AssumptionOfLongTermDebtForBuildingPurchase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_AssumptionOfLongTermDebtForBuildingPurchase_lbl" xml:lang="en-US">The value of a non-cash transaction where the Company assumed long-term debt to for the purpose of purchasing a building.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_AssumptionOfLongTermDebtForBuildingPurchase_lbl" xml:lang="en-US">Assumption of long-term debt for building purchase</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockForAcquiredCompanyAssets" xlink:label="avii_IssuanceOfCommonStockForAcquiredCompanyAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_IssuanceOfCommonStockForAcquiredCompanyAssets" xlink:to="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_lbl" xml:lang="en-US">The value of a non-cash issuance of common stock for an asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_lbl" xml:lang="en-US">Issuance of Common Stock for Acquired Company Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_lbl" xml:lang="en-US">Issuance of common stock for Ercole assets</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets" xlink:label="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets" xlink:to="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_lbl" xml:lang="en-US">The non-cash value of liabilities assumed as part of an asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_lbl" xml:lang="en-US">Assumption of Liabilities for Acquired Company Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_lbl" xml:lang="en-US">Assumption of liabilities for Ercole assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization And Basis Of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization And Basis Of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Income (Loss) Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs Disclosure Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Accounts Receivable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AccountsReceivableTextBlock" xlink:label="avii_AccountsReceivableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_AccountsReceivableTextBlock" xlink:to="avii_AccountsReceivableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_AccountsReceivableTextBlock_lbl" xml:lang="en-US">Accounts receivable [Text Block].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_AccountsReceivableTextBlock_lbl" xml:lang="en-US">Accounts Receivable [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avii_AccountsReceivableTextBlock_lbl" xml:lang="en-US">Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_AccountsReceivableTextBlock_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Warrants [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_USGovernmentContractsAbstract" xlink:label="avii_USGovernmentContractsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_USGovernmentContractsAbstract" xlink:to="avii_USGovernmentContractsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_USGovernmentContractsAbstract_lbl" xml:lang="en-US">U.S. Government Contracts[Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_USGovernmentContractsAbstract_lbl" xml:lang="en-US">U.S. Government Contracts [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:to="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_lbl" xml:lang="en-US">Long-term Contracts or Programs Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_lbl" xml:lang="en-US">U.S. Government Contracts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAbstract" xlink:to="us-gaap_RestructuringCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostsAbstract_lbl" xml:lang="en-US">Restructuring [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestructuringCostsAbstract_lbl" xml:lang="en-US">Restructuring Costs, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RecentAccountingPronouncementsTextBlock" xlink:label="avii_RecentAccountingPronouncementsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avii_RecentAccountingPronouncementsTextBlock" xlink:to="avii_RecentAccountingPronouncementsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avii_RecentAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements [Text block].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avii_RecentAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements [Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avii_RecentAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>avii-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 5.1.148.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2012 12:01:17 PM-->
<!--Modified on: 5/9/2012 12:01:17 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.avibio.com/2010-09-30/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementBalanceSheets" roleURI="http://www.avibio.com/2010-09-30/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.avibio.com/2010-09-30/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#StatementStatementsOfCashFlows" roleURI="http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureOrganizationAndBasisOfPresentation" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureOrganizationAndBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureNetIncomeLossPerShare" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureNetIncomeLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureAccountsReceivable" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureAccountsReceivable" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureWarrants" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureWarrants" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureUSGovernmentContracts" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureUSGovernmentContracts" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureStockCompensation" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureStockCompensation" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureIncomeTaxes" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureRestructuring" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureRestructuring" />
  <roleRef xlink:type="simple" xlink:href="avii-20120331.xsd#DisclosureRecentAccountingPronouncements" roleURI="http://www.avibio.com/2010-09-30/role/DisclosureRecentAccountingPronouncements" />
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_DocumentAndEntityInformationAbstract" xlink:label="avii_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_634721616776731758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_634721616776731758" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_634721616776731758" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_634721616776731758" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_634721616776731758" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_634721616776731758" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_634721616776731758" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_634721616776731758" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_634721616776731758" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_634721616776731758" order="10" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_634261878029351972" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634261878029351972" xlink:to="us-gaap_AssetsAbstract_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_AccountsReceivableNetCurrent_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_OtherAssetsCurrent_634721616776731758" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_AssetsCurrent_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_OtherAssetsNoncurrent_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634721616776731758" xlink:to="us-gaap_Assets_634721616776731758" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634261878029351972" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_AccountsPayableCurrent_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_LongTermDebtCurrent_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WarrantsValuation" xlink:label="avii_WarrantsValuation_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="avii_WarrantsValuation_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_DeferredRevenueCurrent_634721616776731758" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_OtherLiabilitiesCurrent_634721616776731758" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_LiabilitiesCurrent_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_CommitmentsAndContingencies_634721616776731758" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_LongTermDebtNoncurrent_634721616776731758" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_LiabilitiesNoncurrent_634721616776731758" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_StockholdersEquityAbstract_634721616776731758" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_PreferredStockValue_634721616776731758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_CommonStockValue_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_AdditionalPaidInCapital_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_StockholdersEquity_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634721616776731758" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_634721616776731758" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_634721616776731758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_634721616776731758" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_634721616776731758" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_634721616776731758" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements Of Operations And Comprehensive Income (Loss)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_634689571797119964" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RevenueResearchContractsGrantsAndLicenseFees" xlink:label="avii_RevenueResearchContractsGrantsAndLicenseFees_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634689571797119964" xlink:to="avii_RevenueResearchContractsGrantsAndLicenseFees_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634689571797119964" xlink:to="us-gaap_OperatingExpensesAbstract_634721616776731758" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_634721616776731758" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_634721616776731758" xlink:to="us-gaap_GeneralAndAdministrativeExpense_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_634721616776731758" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_634721616776731758" xlink:to="us-gaap_OperatingIncomeLoss_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_634721616776731758" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_InterestExpenseIncomeAndOtherNet" xlink:label="avii_InterestExpenseIncomeAndOtherNet_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="avii_InterestExpenseIncomeAndOtherNet_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseOnWarrantValuation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="avii_IncreaseDecreaseOnWarrantValuation_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_ImpairmentOfInvestments_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_NonoperatingIncomeExpense_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_NetIncomeLoss_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WriteDownOfShortTermSecuritiesAvailableForSale" xlink:label="avii_WriteDownOfShortTermSecuritiesAvailableForSale_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" xlink:to="avii_WriteDownOfShortTermSecuritiesAvailableForSale_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale" xlink:label="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" xlink:to="avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale" xlink:label="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" xlink:to="avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_634721616776731758" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_634721616776731758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_EarningsPerShareBasic_634721616776731758" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_EarningsPerShareDiluted_634721616776731758" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_634721616776731758" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634721616776731758" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634721616776731758" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_634262732509761351" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634262732509761351" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_NetIncomeLoss_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_DepreciationDepletionAndAmortization_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_GainLossOnDisposalOfAssets" xlink:label="avii_GainLossOnDisposalOfAssets_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="avii_GainLossOnDisposalOfAssets_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ImpairmentOfInvestments_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfRealEstate" xlink:label="us-gaap_ImpairmentOfRealEstate_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ImpairmentOfRealEstate_634721616776731758" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ShareBasedCompensation_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_ConversionOfInterestAccruedToCommonStock" xlink:label="avii_ConversionOfInterestAccruedToCommonStock_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="avii_ConversionOfInterestAccruedToCommonStock_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_634721616776731758" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseOnWarrantValuation" xlink:label="avii_IncreaseDecreaseOnWarrantValuation_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="avii_IncreaseDecreaseOnWarrantValuation_634721616776731758" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets" xlink:label="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets_634721616776731758" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities" xlink:label="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities_634721616776731758" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_634721616776731758" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634262732509761351" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_AcquisitionCosts_634721616776731758" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634262732509761351" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_RepaymentsOfLongTermDebt_634721616776731758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_634721616776731758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_WithdrawalOfPartnershipNetAssets" xlink:label="avii_WithdrawalOfPartnershipNetAssets_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="avii_WithdrawalOfPartnershipNetAssets_634721616776731758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_ProceedsFromConvertibleDebt_634721616776731758" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_634721616776731758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634721616776731758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634721616776731758" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_634721616776731758" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776731758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_634721616776731758" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634721616776731758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6347216167767317581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_634721616776731758" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6347216167767317581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_634721616776731758" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_634721616776831757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_634721616776831757" xlink:to="us-gaap_InterestPaid_634721616776831757" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_634721616776831757" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering" xlink:label="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities" xlink:label="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities_634721616776831757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockForBuildingPurchase" xlink:label="avii_IssuanceOfCommonStockForBuildingPurchase_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_IssuanceOfCommonStockForBuildingPurchase_634721616776831757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AssumptionOfLongTermDebtForBuildingPurchase" xlink:label="avii_AssumptionOfLongTermDebtForBuildingPurchase_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_AssumptionOfLongTermDebtForBuildingPurchase_634721616776831757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_IssuanceOfCommonStockForAcquiredCompanyAssets" xlink:label="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_IssuanceOfCommonStockForAcquiredCompanyAssets_634721616776831757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets" xlink:label="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_634721616776831757" xlink:to="avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets_634721616776831757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureOrganizationAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Organization And Basis Of Presentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureNetIncomeLossPerShare" xlink:type="extended" xlink:title="10201 - Disclosure - Net Income (Loss) Per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureAccountsReceivable" xlink:type="extended" xlink:title="10401 - Disclosure - Accounts Receivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_AccountsReceivableTextBlock" xlink:label="avii_AccountsReceivableTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="avii_AccountsReceivableTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureWarrants" xlink:type="extended" xlink:title="10501 - Disclosure - Warrants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureUSGovernmentContracts" xlink:type="extended" xlink:title="10601 - Disclosure - U.S. Government Contracts">
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_USGovernmentContractsAbstract" xlink:label="avii_USGovernmentContractsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avii_USGovernmentContractsAbstract" xlink:to="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureStockCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureRestructuring" xlink:type="extended" xlink:title="10901 - Disclosure - Restructuring">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.avibio.com/2010-09-30/role/DisclosureRecentAccountingPronouncements" xlink:type="extended" xlink:title="11001 - Disclosure - Recent Accounting Pronouncements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <loc xlink:type="locator" xlink:href="avii-20120331.xsd#avii_RecentAccountingPronouncementsTextBlock" xlink:label="avii_RecentAccountingPronouncementsTextBlock_634721616776831757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="avii_RecentAccountingPronouncementsTextBlock_634721616776831757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_AccountsReceivableTextBlock', window );">Accounts Receivable</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>4. ACCOUNTS RECEIVABLE </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Accounts receivable are stated at invoiced amount and do not bear interest. Because all accounts receivable are from the U.S. government and historically no amounts have been written off, an allowance for doubtful accounts receivable is not considered necessary. The accounts receivable balance included $2,623,000 and $2,093,000 of U.S. government receivables that were unbilled at March 31, 2012 and December 31, 2011, respectively.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_AccountsReceivableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accounts receivable [Text Block].</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_AccountsReceivableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%L86YC95]3:&5E
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"86QA
M;F-E7U-H965T<U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]/9E]/<&5R871I;VYS7T%N
M9%]#/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A
M=&5M96YT<U]/9E]#87-H7T9L;W=S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7T%N9%]"87-I<U]/9E]0<F5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F5T7TEN
M8V]M95],;W-S7U!E<E]3:&%R93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C;W5N='-?4F5C96EV
M86)L93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E=A
M<G)A;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M55-?1V]V97)N;65N=%]#;VYT<F%C=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=&]C:U]#;VUP96YS871I;VX\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y297-T<G5C='5R
M:6YG/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5C
M96YT7T%C8V]U;G1I;F=?4')O;F]U;F-E;65N/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R
M:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O
M<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H
M965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13
M=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E
M8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD
M:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H
M;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W
M97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?-#0V-U]A
M-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5104%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT($%N
M9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87D@,#$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@06YD($5N=&ET>2!);F9O
M<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D
M($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-87(@
M,S$L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C
M86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y1,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^059)($))3U!(05)-02!)3D,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,#`P,#@W,S,P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I
M;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!
M8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,S4L-S0S+#<X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?-#0V
M-U]A-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$510T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)A;&%N8V4@
M4VAE971S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=',\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PU
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,Y+#DP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PQ,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8S,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3(T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV
M-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S<L-C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#4L,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M
M96YT+"!N970@;V8@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N(&%N9"!A;6]R
M=&EZ871I;VX@;V8@)#$U+#DX,B!A;F0@)#$U+#<V-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PQ,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(V-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT($-O<W1S+"!N
M970@;V8@86-C=6UU;&%T960@86UO<G1I>F%T:6]N(&]F("0R+#(Y."!A;F0@
M)#(L,3DY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<P-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#8L-C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-30L,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S
M(&%N9"!3:&%R96AO;&1E<G,G($5Q=6ET>3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,SDV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&5M<&QO>65E(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PX-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#(T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&1E8G0L(&-U<G)E;G0@
M<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N="!V86QU871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V+#,W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L-#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#,P-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@0W5R<F5N="!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CDL.3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`L-C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@0V]N
M=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B="P@;F]N+6-U
M<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F5H;VQD97)S)R!%<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)"XP,#`Q('!A<B!V
M86QU92P@,C`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9#L@;F]N92!I<W-U
M960@86YD(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D+C`P,#$@<&%R('9A;'5E+"`S,#`L
M,#`P+#`P,"!A;F0@,C`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[(#$S
M-2PW-#,L-S@W(&%N9"`Q,S4L-S0S+#$R,"!I<W-U960@86YD(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S0Q+#8W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,T,"PY-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9FEC:70@86-C=6UU;&%T960@
M9'5R:6YG('1H92!D979E;&]P;65N="!S=&%G93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,S(W+#8V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#DL.38T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-H87)E
M:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-"PP,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,2PP,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<R!A;F0@4VAA<F5H
M;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#8L-C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U-"PS-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V9E,S5E-C@Y7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F
M9C@Q8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F93,U938X.5]B
M.#<S7S0T-C=?83=C-E]D9#-E-S$R9F8X,6,O5V]R:W-H965T<R]3:&5E=#`S
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%5$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY"
M86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY"86QA;F-E(%-H965T<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,34L.3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-2PW-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A=&5N="!#;W-T<R!A8V-U;75L871E
M9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BPR.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A<B!O<B!S=&%T
M960@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O
M8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R(&]R('-T871E9"!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,S4L-S0S+#<X-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S-2PW-#,L,3(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,U+#<T,RPW.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S4L-S0S+#$R,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F4S-64V.#E?8C@W
M,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F9C@Q
M8R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S2T%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T871E;65N=',@3V8@3W!E<F%T:6]N<R!!
M;F0@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS.#`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N=',@3V8@
M3W!E<F%T:6]N<R!!;F0@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5V96YU97,@9G)O;2!L:6-E;G-E(&9E97,L(&=R86YT<R!A;F0@
M<F5S96%R8V@@8V]N=')A8W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$Q+#(Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,30L,CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#<L-#,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A
M=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PX,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PX,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#@L,#<Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-RPW,S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<F5D(&EN+7!R
M;V-E<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Y+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#@W-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#4S,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,S<L
M.#,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@*&QO<W,I.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O
M;64@86YD(&]T:&5R+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#(V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V%I;B`H;&]S<RD@;VX@8VAA;F=E(&EN('=A<G)A
M;G0@=F%L=6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M,"PY,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPR-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PP-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E86QI>F5D(&=A:6X@;VX@<V%L92!O9B!S
M:&]R="UT97)M('-E8W5R:71I97,M(&%V86EL86)L92UF;W(M<V%L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5W)I=&4M9&]W
M;B!O9B!S:&]R="UT97)M('-E8W5R:71I97,M(&%V86EL86)L92UF;W(M<V%L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPP,#$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;W1H97(@;F]N(&]P97)A=&EN9R!I;F-O;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$P+#@S,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,V-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#$W,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I
M;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-RPW,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PX,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S,C<L-C8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!C;VUP<F5H96YS
M:79E(&EN8V]M92`H;&]S<RDZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=R:71E+61O=VX@;V8@<VAO<G0M=&5R;2!S96-U
M<FET:65S+6%V86EL86)L92UF;W(M<V%L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E86QI>F5D(&=A:6X@;VX@<V%L92!O
M9B!S:&]R="UT97)M('-E8W5R:71I97,M879A:6QA8FQE+69O<BUS86QE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#8S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L
M:7IE9"!L;W-S(&]N('-H;W)T+71E<FT@<V5C=7)I=&EE<RUA=F%I;&%B;&4M
M9F]R+7-A;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,L
M,3,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!I;F-O;64@*&QO
M<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$W+#<P-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L.#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@S,C<L-C8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E
M("T@8F%S:6,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I('!E<B!S:&%R92`M(&1I;'5T
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<@9F]R(&-O;7!U=&EN9R!B87-I8R!I;F-O;64@*&QO<W,I
M('!E<B!S:&%R92`H:6X@=&AO=7-A;F1S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,U+#<T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q,BPT.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@
M;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@9F]R(&-O;7!U
M=&EN9R!D:6QU=&5D(&EN8V]M92`H;&]S<RD@<&5R('-H87)E("AI;B!T:&]U
M<V%N9',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S4L-S0S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(Q+#(X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?-#0V-U]A
M-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5.5T)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T871E;65N=',@
M3V8@0V%S:"!&;&]W<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,X,"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W
M<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-RPW,#0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#@S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,S(W+#8V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE
M(&YE="!I;F-O;64@*&QO<W,I('1O(&YE="!C87-H(&9L;W=S('5S960@:6X@
M;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PW
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,@;VX@9&ES<&]S86P@;V8@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E86QI>F5D(&=A:6X@;VX@
M<V%L92!O9B!S:&]R="UT97)M('-E8W5R:71I97,M879A:6QA8FQE+69O<BUS
M86QE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#8S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5W)I=&4M9&]W;B!O9B!S:&]R="UT97)M('-E8W5R:71I97,M879A:6QA8FQE
M+69O<BUS86QE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26UP86ER;65N="!C:&%R9V4@;VX@<F5A;"!E<W1A=&4@;W=N960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.2PW,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@:6YT97)E<W0@
M86-C<G5E9"!T;R!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-Q=6ER960@:6XM<')O8V5S<R!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CDL-#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&]N('=A<G)A;G0@;&EA
M8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M+#(W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-"PP-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XH26YC<F5A<V4I(&EN(&%C8V]U;G1S(')E8V5I=F%B
M;&4L(&]T:&5R(&-U<G)E;G0@87-S971S(&%N9"!O=&AE<B!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#,P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#(R-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#`P
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@86-C;W5N=',@<&%Y86)L92P@
M86-C<G5E9"!E;7!L;WEE92!C;VUP96YS871I;VXL(&%N9"!O=&AE<B!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-C<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPU-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#`T.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M,"PP-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C,Y+#(V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S
M=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PX
M.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0871E;G0@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH.2PW-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!M87)K971A8FQE('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$R
M+#DY,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-A;&4@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-RPW,C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,S@Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,S8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L,CDQ*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O8VLL('=A<G)A;G1S+"!A
M;F0@<&%R=&YE<G-H:7`@=6YI=',L(&YE="!O9B!O9F9E<FEN9R!C;W-T<RP@
M86YD(&5X97)C:7-E(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDW+#@W.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT
M<R!O9B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S8V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0G5Y8F%C:R!O9B!C;VUM;VX@<W1O8VL@<'5R
M<W5A;G0@=&\@<F5S8VES<VEO;B!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7:71H9')A=V%L(&]F('!A<G1N97)S
M:&EP(&YE="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@9&5B=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I
M9&5D(&)Y("AU<V5D(&EN*2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3<L,3(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A
M<V4@*&1E8W)E87-E*2!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#,S,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PS,#8I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L
M-3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN
M9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M+#DP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,S+#4X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`L-3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,L,C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L-3<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-54%!,
M14U%3E1!3"!$25-#3$]355)%($]&($-!4T@@1DQ/5R!)3D9/4DU!5$E/3CH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!P86ED(&1U<FEN9R!T:&4@>65A<B!F;W(@:6YT97)E<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%
M345.5$%,(%-#2$5$54Q%($]&($Y/3D-!4T@@24Y615-424Y'($%#5$E6251)
M15,@04Y$($9)3D%.0TE.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&]R="UT97)M('-E8W5R:71I
M97,M879A:6QA8FQE+69O<BUS86QE(')E8V5I=F5D(&EN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@<')I=F%T92!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPX.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!A;F0@=V%R<F%N=',@:6X@<V%T:7-F86-T:6]N(&]F(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@8G5I;&1I;F<@<'5R8VAA<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-U;7!T
M:6]N(&]F(&QO;F<M=&5R;2!D96)T(&9O<B!B=6EL9&EN9R!P=7)C:&%S93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!%<F-O;&4@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#<U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-U;7!T:6]N(&]F
M(&QI86)I;&ET:65S(&9O<B!%<F-O;&4@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,3(T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!!;F0@0F%S:7,@3V8@4')E<V5N=&%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3W)G86YI>F%T:6]N($%N9"!"87-I<R!/9B!0<F5S96YT871I;VX@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<F=A;FEZ871I;VX@06YD($)A<VES($]F(%!R97-E;G1A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@,3)P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG
M(&-L87-S/3-$7VUT('-I>F4],T0R/CQB/C$N($]21T%.25I!5$E/3B!!3D0@
M0D%325,@3T8@4%)%4T5.5$%424].(#PO8CX\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^059)
M($)I;U!H87)M82P@26YC+B`H=&AE(")#;VUP86YY(BD@:7,@82!B:6]P:&%R
M;6%C975T:6-A;"!C;VUP86YY(&EN8V]R<&]R871E9"!I;B!T:&4@4W1A=&4@
M;V8@3W)E9V]N(&]N($IU;'D@,C(L(#$Y.#`N(%1H92!#;VUP86YY(&ES(&9O
M8W5S960@;VX@=&AE(&1I<V-O=F5R>2!A;F0@9&5V96QO<&UE;G0@;V8@=6YI
M<75E(%).02UB87-E9"!T:&5R87!E=71I8W,@9F]R('1H92!T<F5A=&UE;G0@
M;V8@<F%R92!A;F0@:6YF96-T:6]U<R!D:7-E87-E<RX@07!P;'EI;F<@=&AE
M($-O;7!A;GDG<R!P<F]P<FEE=&%R>2!P;&%T9F]R;2!T96-H;F]L;V=I97,L
M('1H92!#;VUP86YY(&ES(&%B;&4@=&\@=&%R9V5T(&$@8G)O860@<F%N9V4@
M;V8@9&ES96%S97,@86YD(&1I<V]R9&5R<R!T:')O=6=H(&1I<W1I;F-T(%).
M02UB87-E9"!M96-H86YI<VUS(&]F(&%C=&EO;BX@5&AE($-O;7!A;GD@:7,@
M9F]C=7-E9"!O;B!R87!I9&QY(&%D=F%N8VEN9R!T:&4@9&5V96QO<&UE;G0@
M;V8@:71S($1U8VAE;FYE(&UU<V-U;&%R(&1Y<W1R;W!H>2!D<G5G(&-A;F1I
M9&%T97,L(&EN8VQU9&EN9R!I=',@;&5A9"!P<F]D=6-T(&-A;F1I9&%T92P@
M971E<&QI<G-E;BX@26X@07!R:6P@,C`Q,BP@=&AE($-O;7!A;GD@86YN;W5N
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M=',N(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R
M<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\
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M="!D871A(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q('=A<R!D97)I=F5D(&9R
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M<RX@/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,3)P
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M+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q,G!X
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M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+B!4:&4@<F5S=6QT<R!O9B!O<&5R
M871I;VYS(&9O<B!T:&4@:6YT97)I;2!P97)I;V1S('!R97-E;G1E9"!A<F4@
M;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&\@
M8F4@97AP96-T960@9F]R('1H92!F=6QL('EE87(N(#PO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT.B`S
M,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^4VEN8V4@:71S(&EN8V5P=&EO;B!I;B`Q.3@P+"!T:&4@0V]M<&%N>2!H
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M<B!T:&4@;F5X="!S979E<F%L('EE87)S+B`\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.B`Q,G!X.R!T97AT+6EN9&5N=#H@,S)P>#L@
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M(&=O=F5R;FUE;G0N($%S(&]F($UA<F-H(#,Q+"`R,#$R+"!T:&4@0V]M<&%N
M>2!H860@:&%D('-U8G-T86YT:6%L;'D@8V]M<&QE=&5D(&%L;"!O9B!I=',@
M8V]N=')A8W1S('=I=&@@=&AE(%4N4RX@9V]V97)N;65N="!E>&-E<'0@9F]R
M('1H92!*=6QY(#(P,3`@86=R965M96YT(&9O<B!T:&4@9&5V96QO<&UE;G0@
M;V8@=&AE<F%P975T:6-S(&%G86EN<W0@16)O;&$@86YD($UA<F)U<F<N(%!U
M<G-U86YT('1O('1H:7,@86=R965M96YT+"!A<R!O9B!-87)C:"`S,2P@,C`Q
M,BP@=&AE($-O;7!A;GD@:7,@8W5R<F5N=&QY(&5N=&ET;&5D('1O(')E8V5I
M=F4@=7`@=&\@86X@86=G<F5G871E(&]F("0Q,C8N-2!M:6QL:6]N(&9O<B!D
M979E;&]P;65N="!O9B!I=',@<')O9'5C="!C86YD:61A=&5S+"!O9B!W:&EC
M:"`D-C,N.2!M:6QL:6]N(&AA<R!B965N(')E8V]G;FEZ960@87,@<F5V96YU
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M(%-E92`B3F]T92`V("8C.#(Q,CL@52Y3+B!';W9E<FYM96YT($-O;G1R86-T
M<R(@9F]R(&%D9&ET:6]N86P@:6YF;W)M871I;VXN(#PO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT.B`S
M,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^070@36%R8V@@,S$L(#(P,3(L(&-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',@=V5R92`D,S`N-B!M:6QL:6]N+B!4:&4@0V]M<&%N>2=S('!R:6YC:7!A
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M(&%N9"!O=&AE<B!W;W)K:6YG(&-A<&ET86P@<F5Q=6ER96UE;G1S+B`\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q,G!X.R!T97AT
M+6EN9&5N=#H@,S)P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$
M7VUT('-I>F4],T0R/E1H92!#;VUP86YY(&)E;&EE=F5S(&ET(&AA<R!S=69F
M:6-I96YT(&-A<V@@=&\@9G5N9"!O<&5R871I;VYS(&%T(&QE87-T('1H<F]U
M9V@@=&AE(&9O;&QO=VEN9R`Q,B!M;VYT:',N(%1H92!#;VUP86YY(&%N=&EC
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M<RX@/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,3AP
M>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!M87)G:6XM;&5F=#H@-"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA
M<W,],T1?;70@<VEZ93TS1#(^/&(^/&D^17-T:6UA=&5S(&%N9"!5;F-E<G1A
M:6YT:65S(#PO:3X\+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R
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M=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$X<'@[(&UA<F=I
M;BUB;W1T;VTZ(#!P>#L@;6%R9VEN+6QE9G0Z(#0E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0R/CQB/CQI/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S
M(#PO:3X\+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$X<'@[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#L@;6%R9VEN+6QE9G0Z(#0E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S
M/3-$7VUT('-I>F4],T0R/CQB/CQI/E)E8VQA<W-I9FEC871I;VYS(#PO:3X\
M+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@-G!X
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M)R!E<75I='D@;W(@8V%S:"!F;&]W<RX\+V9O;G0^/"]P/B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V9E,S5E-C@Y
M7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F9C@Q8PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]F93,U938X.5]B.#<S7S0T-C=?83=C-E]D9#-E-S$R
M9F8X,6,O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H
M87)E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H87)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($EN8V]M92`H3&]S<RD@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/B`\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q.'!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M/&(^,BX@3D54($E.0T]-12`H3$]34RD@4$52(%-(05)%(#PO8CX\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD
M96YT.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^0F%S:6,@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&ES
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M(&]U='-T86YD:6YG+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G
M:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#L@9F]N="US:7IE.B`Q
M,G!X.R<^)FYB<W`[/"]P/@T*#0H\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93LG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
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M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^5&AR964F
M;F)S<#M-;VYT:',F;F)S<#M%;F1E9"9N8G-P.TUA<F-H)FYB<W`[,S$L/"]B
M/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S
M<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!X
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M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
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M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CXH:6XF;F)S<#MT:&]U<V%N
M9',L)FYB<W`[97AC97!T)FYB<W`[<&5R)FYB<W`[<VAA<F4F;F)S<#MD871A
M*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$=&]P/@T*#0H\
M<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE9G0Z(#%E
M;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY.970@:6YC;VUE("AL;W-S*3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
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M="!S:7IE/3-$,CXI)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L
M87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?
M;70@<VEZ93TS1#(^5V5I9VAT960M879E<F%G92!N=6UB97(@;V8@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!A;F0@8V]M;6]N('-T;V-K(&5Q=6EV86QE;G1S
M)FYB<W`[;W5T<W1A;F1I;F<Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF
M;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,]
M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-
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M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S
M/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT
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M9"!V86QI9VX],T1T;W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M
M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R
M/D1I;'5T:79E(&5F9F5C="!O9B!W87)R86YT<R!A;F0@<W1O8VL@;W!T:6]N
M<R!A9G1E<B!A<'!L:6-A=&EO;B!O9B!T:&4@=')E87-U<GD@<W1O8VL@;65T
M:&]D*CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)B,X,C$R.R9N8G-P
M.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I
M>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
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M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT
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M,T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F
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M,CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@[)SX\
M=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S
M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG
M;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA
M<F=I;BUL969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^3F5T(&EN
M8V]M92`H;&]S<RD@<&5R('-H87)E("T@8F%S:6,\+V9O;G0^/"]P/CPO=&0^
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M:7IE/3-$,CXH,"XQ,R`\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXI)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L
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M<STS1%]M="!S:7IE/3-$,CXP+C`R/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#%P>#LG/CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.SPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
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M;W-S*2!P97(@<VAA<F4@+2!D:6QU=&EV93PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^
M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/BDF;F)S<#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,]
M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$
M7VUT('-I>F4],T0R/C`N,#(\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF
M;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,7!X.R<^/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X\+W1R
M/CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R
M9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$R<'@[)SXF;F)S<#L\+W`^
M#0H-"CQT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"CQT<CX\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
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M8V]M;6]N('-T;V-K(&%S(&]F($UA<F-H)FYB<W`[,S$L(#(P,3(@86YD(#(P
M,3$L(')E<W!E8W1I=F5L>2P@=V5R92!E>&-L=61E9"!F<F]M('1H92!N970@
M:6YC;VUE("AL;W-S*2!P97(@<VAA<F4@8V%L8W5L871I;VX@87,@=&AE:7(@
M969F96-T('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E+CPO9F]N=#X\
M+W1D/CPO='(^/"]T86)L93X@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!-96%S
M=7)E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,]
M,T1?;70@<VEZ93TS1#(^/&(^,RX@1D%)4B!604Q512!-14%355)%345.5%,@
M/"]B/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#9P
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M8F4@=7-E9"!T;R!M96%S=7)E(&9A:7(M=F%L=64Z(#PO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@
M,'!X.R!F;VYT+7-I>F4Z(#9P>#LG/B9N8G-P.SPO<#X-"@T*/'1A8FQE('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[)R!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*/'1R/CQT9"!W:61T:#TS1#4E/CQF;VYT(&-L87-S/3-$7VUT('-I>F4]
M,T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#(E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)B,Q
M-#D[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X-"@T*/'`@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY,979E;"`Q("8C.#(Q,CL@
M<75O=&5D('!R:6-E<R!F;W(@:61E;G1I8V%L(&EN<W1R=6UE;G1S(&EN(&%C
M=&EV92!M87)K971S.R`\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*
M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ
M(#!P>#L@9F]N="US:7IE.B`V<'@[)SXF;F)S<#L\+W`^#0H-"CQT86)L92!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R<@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X-"CQT<CX\=&0@=VED=&@],T0U)3X\9F]N="!C;&%S<STS1%]M="!S:7IE
M/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0R)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B8C
M,30Y.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^#0H-"CQP(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^3&5V96P@,B`F(S@R,3([
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M/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&9O;G0M<VEZ
M93H@-G!X.R<^)FYB<W`[/"]P/@T*#0H\=&%B;&4@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93LG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(^/'1D('=I
M9'1H/3-$-24^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF(S$T.3L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!C;&%S<STS
M1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@86QI9VX],T1L969T/@T*#0H\<"!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S
M/3-$7VUT('-I>F4],T0R/DQE=F5L(#,@)B,X,C$R.R!V86QU871I;VYS(&1E
M<FEV960@9G)O;2!V86QU871I;VX@=&5C:&YI<75E<R!I;B!W:&EC:"!O;F4@
M;W(@;6]R92!S:6=N:69I8V%N="!V86QU92!D<FEV97)S(&%R92!U;F]B<V5R
M=F%B;&4N(#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H-"CQP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^5&AE
M($-O;7!A;GDG<R!A<W-E=',@86YD(&QI86)I;&ET:65S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@8V]N<VES=&5D(&]F
M('1H92!F;VQL;W=I;F<@87,@;V8@=&AE(&1A=&4@:6YD:6-A=&5D.B`\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA<F=I
M;BUB;W1T;VTZ(#!P>#L@9F]N="US:7IE.B`Q,G!X.R<^)FYB<W`[/"]P/@T*
M#0H\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93LG
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<CX-"CQT<B!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,'!T.R!V:7-I8FEL:71Y.B!H:61D96X[(&-O;&]R.B!W:&ET
M93LG/CQT9"!W:61T:#TS1#<X)3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^,#`P,#`P
M,#`\+V(^/"]F;VYT/CPO=&0^#0H\=&0^(#PO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/C`P
M,#`P,#`P/"]B/CPO9F]N=#X\+W1D/@T*/'1D/B`\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3X\
M8CXP,#`P,#`P,#PO8CX\+V9O;G0^/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X@/"]T9#X-"CQT9#X@/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^/&(^,#`P,#`P,#`\+V(^/"]F;VYT/CPO=&0^#0H\=&0^(#PO=&0^/"]T
M<CX-"CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT
M('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/D9A:7(@
M5F%L=64@365A<W5R96UE;G0@87,@;V8@36%R8V@F;F)S<#LS,2P@,C`Q,CPO
M8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4]
M,T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
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M<#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
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M93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0Q/CQB/DQE=F5L)FYB<W`[,CPO8CX\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^
M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!X('-O
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M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT(&-L
M87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S
M<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CXH:6X@=&AO=7-A;F1S*3PO8CX\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,]
M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N
M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@
M<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!B9V-O;&]R
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M<W,],T1?;70@<VEZ93TS1#(^,S`L-3<S/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C
M,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@
M(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO
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M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C,P+#4W,SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N
M8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q<'@[)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D
M/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[(&9O;G0M<VEZ93H@,3)P>#LG/B9N8G-P
M.SPO<#X-"@T*/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^#0H\='(@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#!P=#L@=FES:6)I;&ET>3H@:&ED9&5N.R!C;VQO
M<CH@=VAI=&4[)SX\=&0@=VED=&@],T0W."4^(#PO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB
M/C`P,#`P,#`P/"]B/CPO9F]N=#X\+W1D/@T*/'1D/B`\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B`\+W1D/@T*/'1D/B`\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$
M,3X\8CXP,#`P,#`P,#PO8CX\+V9O;G0^/"]T9#X-"CQT9#X@/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X@/"]T9#X-"CQT9#X@/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^/&(^,#`P,#`P,#`\+V(^/"]F;VYT/CPO=&0^#0H\=&0^(#PO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^(#PO=&0^#0H\=&0^
M(#PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT(&-L87-S/3-$7VUT
M('-I>F4],T0Q/CQB/C`P,#`P,#`P/"]B/CPO9F]N=#X\+W1D/@T*/'1D/B`\
M+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S
M<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[
M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\
M8CY&86ER)FYB<W`[5F%L=64F;F)S<#M-96%S=7)E;65N="9N8G-P.V%S)FYB
M<W`[;V8F;F)S<#M-87)C:"9N8G-P.S,Q+"9N8G-P.S(P,3(\+V(^/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT
M('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(^/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S
M<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[
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M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/DQE=F5L)FYB<W`[
M,3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N
M8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O
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M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A
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M9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S
M/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!C;&%S<STS1%]M
M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT
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M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q
M/B9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F
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M;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT
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M1%]M="!S:7IE/3-$,CXF(S@R,3([)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,]
M,T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
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M,CXF(S@R,3([)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N
M8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S
M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF
M;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX-"CQT<CX\=&0@=F%L:6=N
M/3-$=&]P/@T*#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R
M9VEN+6QE9G0Z(#%E;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY4;W1A;"!L
M:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F
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M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N
M8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^,38L,S<R/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA
M<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>#LG/CQT9"!V86QI9VX]
M,T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N
M8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P
M.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N
M8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S
M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\
M<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX\+W1A8FQE/@T*#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P
M>#L@9F]N="US:7IE.B`Q,G!X.R<^)FYB<W`[/"]P/@T*#0H\=&%B;&4@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93LG(&)O<F1E<CTS1#`@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A
M;&EG;CTS1&-E;G1E<CX-"CQT<B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,'!T
M.R!V:7-I8FEL:71Y.B!H:61D96X[(&-O;&]R.B!W:&ET93LG/CQT9"!W:61T
M:#TS1#<X)3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O
M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^,#`P,#`P,#`\+V(^/"]F;VYT
M/CPO=&0^#0H\=&0^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/C`P,#`P,#`P/"]B/CPO
M9F]N=#X\+W1D/@T*/'1D/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CXP,#`P,#`P,#PO
M8CX\+V9O;G0^/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^,#`P,#`P
M,#`\+V(^/"]F;VYT/CPO=&0^#0H\=&0^(#PO=&0^/"]T<CX-"CQT<CX\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N
M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C
M;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI
M9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/D9A:7(F;F)S<#M686QU929N
M8G-P.TUE87-U<F5M96YT)FYB<W`[87,F;F)S<#MO9B9N8G-P.T1E8V5M8F5R
M)FYB<W`[,S$L)FYB<W`[,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$
M,3XF;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O
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M93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG
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M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/DQE=F5L)FYB<W`[
M,CPO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N
M8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S
M<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[
M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\
M8CXH:6X@=&AO=7-A;F1S*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$
M7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!C;&%S<STS1%]M="!S
M:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO
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M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^,SDL.3`T
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT
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M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F
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M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
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M<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N
M8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S
M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF
M;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L:60[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
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M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$
M7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N/3-$8F]T
M=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S
M<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D
M97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF
M;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B
M;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S
M<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9#XF;F)S<#L\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&9O
M;G0M<VEZ93H@,3)P>#LG/B9N8G-P.SPO<#X-"@T*/'1A8FQE('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX]
M,T1C96YT97(^#0H\='(@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#!P=#L@=FES
M:6)I;&ET>3H@:&ED9&5N.R!C;VQO<CH@=VAI=&4[)SX\=&0@=VED=&@],T0X
M,"4^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^(#PO
M=&0^#0H\=&0^(#PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT(&-L
M87-S/3-$7VUT('-I>F4],T0Q/CQB/C`P,#`P,#`P/"]B/CPO9F]N=#X\+W1D
M/@T*/'1D/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CXP,#`P,#`P,#PO8CX\+V9O;G0^
M/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^,#`P,#`P,#`\+V(^/"]F
M;VYT/CPO=&0^#0H\=&0^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/C`P,#`P,#`P/"]B
M/CPO9F]N=#X\+W1D/@T*/'1D/B`\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,]
M,T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C
M;&%S<STS1%]M="!S:7IE/3-$,3X\8CY&86ER)FYB<W`[5F%L=64F;F)S<#M-
M96%S=7)E;65N="9N8G-P.V%S)FYB<W`[;V8F;F)S<#M$96-E;6)E<B9N8G-P
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M<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L
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M93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0Q/CQB/DQE=F5L)FYB<W`[,3PO8CX\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^
M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!X('-O
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M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
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M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P
M.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?
M;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D('9A;&EG;CTS1'1O<#X-
M"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T
M.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[
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M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^
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M<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#%P>#LG/CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q
M<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P
M,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C
M,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D
M/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N="!S
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
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M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L
M87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$
M,3XF;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^-2PT-#8\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#LF
M;F)S<#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,7!X.R<^/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X
M(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T
M9#X\+W1R/CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P
M>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$R<'@[)SXF;F)S
M<#L\+W`^#0H-"CQT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<CX\=&0@=F%L:6=N/3-$=&]P('=I
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M=64N(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G
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M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D%C8V]U;G1S(%)E8V5I=F%B;&4\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!296-E
M:79A8FQE(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C;W5N=',@4F5C96EV86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#H@,3AP>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0R/CQB/C0N($%#0T]53E13(%)%0T5)5D%"3$4@/"]B/CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#9P>#L@=&5X="UI
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M)#(L-C(S+#`P,"!A;F0@)#(L,#DS+#`P,"!O9B!5+E,N(&=O=F5R;FUE;G0@
M<F5C96EV86)L97,@=&AA="!W97)E('5N8FEL;&5D(&%T($UA<F-H(#,Q+"`R
M,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@<F5S<&5C=&EV96QY+CPO9F]N
M=#X\+W`^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?
M-#0V-U]A-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H965T,3`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY787)R86YT
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E=A<G)A;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78^#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z(#$X<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS
M1%]M="!S:7IE/3-$,CX\8CXU+B!705)204Y44R`\+V(^/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@-G!X.R!T97AT+6EN9&5N=#H@
M,S)P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4]
M,T0R/E=A<G)A;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($-O
M;7!A;GDG<R!$96-E;6)E<B`R,#`W+"!*86YU87)Y(#(P,#D@86YD($%U9W5S
M="`R,#`Y(&9I;F%N8VEN9W,@87)E(&-L87-S:69I960@87,@;&EA8FEL:71I
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M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!T97AT
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M;G,@9F]R(&5A8V@@;V8@=&AE('!E<FEO9',@:6YD:6-A=&5D.B`\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB
M;W1T;VTZ(#!P>#L@9F]N="US:7IE.B`Q,G!X.R<^(#PO<#X\+V1I=CX-"@T*
M/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H\='(^/'1D('=I9'1H/3-$-C@E
M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X@/"]T
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M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA
M<W,],T1?;70@<VEZ93TS1#$^/&(^5&AR964@36]N=&AS($5N9&5D($UA<F-H
M)FYB<W`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,]
M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N
M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
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M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
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M"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T
M.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C`N,B4M,"XS
M(#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B4F;F)S<#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL
M969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^17AP96-T960@9&EV
M:61E;F0@>6EE;&0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C`@/"]F
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M;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA
M<F=I;BUL969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^17AP96-T
M960@;&EV97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG
M(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^,"XW+3(N-"9N8G-P.WEE87)S/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I
M>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^,2XW
M+3,N-"9N8G-P.WEE87)S/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB
M<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX\=&0@=F%L:6=N/3-$
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M)R!C;&%S<STS1%]M="!S:7IE/3-$,CXE)FYB<W`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q
M/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^-S$N-"4M.#@N
M-3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B4F;F)S<#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1T
M;W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM
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M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[
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M)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P
M.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1'1O
M<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL
M969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
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M<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$=&]P/@T*#0H\<"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE9G0Z(#%E;3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C
M;&%S<STS1%]M="!S:7IE/3-$,CY-87)K970@=F%L=64@;V8@<W1O8VL@870@
M96YD(&]F('!E<FEO9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M
M="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C$N-30\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#LF;F)S<#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M87)G:6XM8F]T
M=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^02!R96-O;F-I;&EA
M=&EO;B!O9B!T:&4@8VAA;F=E(&EN('9A;'5E(&]F('-U8V@@=V%R<F%N=',@
M9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3(@:7,@
M87,@9F]L;&]W<SH@/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&9O;G0M<VEZ93H@,3)P
M>#LG/B9N8G-P.SPO<#X-"@T*/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(^#0H\
M='(^/'1D('=I9'1H/3-$.#@E/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D/B`\+W1D/@T*
M/'1D/B`\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!W:61T:#H@-#AP=#LG/CQF;VYT('-T>6QE/3-$
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M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$=&]P/@T*#0H\
M<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE9G0Z(#%E
M;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY"86QA;F-E(&%T($1E8V5M8F5R
M)FYB<W`[,S$L(#(P,3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N
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M/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1T;W`^#0H-
M"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@
M,65M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/E)E8VQA<W-I9FEC871I;VX@
M=&\@<VAA<F5H;VQD97)S)R!E<75I='D@=7!O;B!E>&5R8VES92!O9B!W87)R
M86YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)B,X,C$R.R9N8G-P
M.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M<'@[)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L
M:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-
M"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X\+W1R/@T*/'1R/CQT
M9"!V86QI9VX],T1T;W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M
M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R
M/D)A;&%N8V4@870@36%R8V@F;F)S<#LS,2P@,C`Q,CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N
M8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/CPO
M='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,3)P>#L@
M=&5X="UI;F1E;G0Z(#,R<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S
M<STS1%]M="!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ
M97,@:6YF;W)M871I;VX@86)O=70@=V%R<F%N=',@;W5T<W1A;F1I;F<@870@
M36%R8V@@,S$L(#(P,3(N(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4Z
M(#$R<'@[)SXF;F)S<#L\+W`^#0H-"CQT86)L92!S='EL93TS1"=B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R
M/@T*/'1R/CQT9#X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R,24^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0^(#PO=&0^#0H\=&0^(#PO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C$E/B`\+W1D/@T*
M/'1D/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)3X@
M/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X\+W1R
M/@T*/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/D5X97)C:7-E
M)FYB<W`[4')I8V4\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!X
M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CY/=71S=&%N9&EN9R9N
M8G-P.U=A<G)A;G1S)FYB<W`[870\8G(@+SY-87)C:"9N8G-P.S,Q+"`R,#$R
M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C
M;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/E=E:6=H=&5D)FYB<W`[
M079E<F%G929N8G-P.U)E;6%I;FEN9SQB<B`O/D-O;G1R86-T=6%L($QI9F4@
M*%EE87)S*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L
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M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)#`N
M,#`P,SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C
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M9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[
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M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C$V+#8V-SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXP+C8\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
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M="!S:7IE/3-$,CXQ+#`P,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M/3-$,CXQ+#`P,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
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M<STS1%]M="!S:7IE/3-$,CXQ-"PQ,C0L,C`R/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M,T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT
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M.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
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M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S
M/3-$7VUT('-I>F4],T0R/C8V+#$T,CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
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M4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXY+#0Q,"PS,3`\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C
M;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXR+C0\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@
M<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?
M;70@<VEZ93TS1#(^.2PT,3`L,S$P/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!B9V-O;&]R
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M,T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R
M/C4L,S0X+#,P.#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
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M>F4],T0R/C`N-SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\
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M;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)FYB<W`[
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.SPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/B`\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^,CDL,C`T+#@U-SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M;VT^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L
M93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX\+W1A
M8FQE/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V9E,S5E-C@Y7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F9C@Q8PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F93,U938X.5]B.#<S7S0T
M-C=?83=C-E]D9#-E-S$R9F8X,6,O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^52Y3+B!';W9E
M<FYM96YT($-O;G1R86-T<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E4N4RX@1V]V97)N;65N="!#;VYT<F%C=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5+E,N($=O=F5R;FUE;G0@0V]N=')A8W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.B`Q.'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^/&(^-BX@52Y3+B!'3U9%4DY-14Y4($-/3E1204-44R`\+V(^
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@-G!X.R!T
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M87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@:&%D(&-O;7!L971E9"!A;&P@
M;V8@:71S(&-O;G1R86-T<R!W:71H('1H92!5+E,N(&=O=F5R;FUE;G0@97AC
M97!T(&9O<B!T:&4@2G5L>2`R,#$P(&%G<F5E;65N="!F;W(@=&AE(&1E=F5L
M;W!M96YT(&]F('1H97)A<&5U=&EC<R!A9V%I;G-T($5B;VQA(&%N9"!-87)B
M=7)G+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q
M.'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&UA<F=I;BUL969T.B`T)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C
M;&%S<STS1%]M="!S:7IE/3-$,CX\8CX\:3Y*=6QY(#(P,3`@06=R965M96YT
M("A%8F]L82!A;F0@36%R8G5R9RD@/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD96YT.B`S,G!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M3VX@2G5L>2`Q-"P@,C`Q,"P@=&AE($-O;7!A;GD@=V%S(&%W87)D960@82!C
M;VYT<F%C="!W:71H('1H92!5+E,N($1E<&%R=&UE;G0@;V8@1&5F96YS92P@
M;W(@1&]$+"!#:&5M:6-A;"!A;F0@0FEO;&]G:6-A;"!$969E;G-E(%!R;V=R
M86T@=&AR;W5G:"!T:&4@52Y3+B!!<FUY(%-P86-E(&%N9"!-:7-S:6QE($1E
M9F5N<V4@0V]M;6%N9"!F;W(@=&AE(&%D=F%N8V5D(&1E=F5L;W!M96YT(&]F
M('1H92!#;VUP86YY)W,@:&5M;W)R:&%G:6,@9F5V97(@=FER=7,@=&AE<F%P
M975T:6,@8V%N9&ED871E<RP@059)+38P,#(@86YD($%622TV,#`S+"!A9V%I
M;G-T('1H92!%8F]L82!A;F0@36%R8G5R9R!V:7)U<V5S+"!R97-P96-T:79E
M;'DN($EN($9E8G)U87)Y(#(P,3(L('1H92!#;VUP86YY(&%N;F]U;F-E9"!T
M:&%T(&ET(')E8V5I=F5D(&%P<')O=F%L(&9R;VT@=&AE($9$02!T;R!P<F]C
M965D('=I=&@@82!S:6YG;&4@;VQI9V]M97(@9G)O;2!!5DDM-C`P,RP@059)
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M=6QY(#(P,3`@86YD(&EN8VQU9&4@4&AA<V4@22!S='5D:65S(&EN(&AE86QT
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M87,@8F5E;B!R96-O9VYI>F5D('1O(&1A=&4N(#PO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT.B`S,G!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M069T97(@8V]M<&QE=&EO;B!O9B!T:&4@9FER<W0@<V5G;65N="P@86YD(&5A
M8V@@<W5C8V5S<VEV92!S96=M96YT+"!$;T0@:&%S('1H92!O<'1I;VX@=&\@
M<')O8V5E9"!T;R!T:&4@;F5X="!S96=M96YT(&9O<B!E:71H97(@;W(@8F]T
M:"!!5DDM-C`P,B!A;F0@059)+3<R.#@N($EF($1O1"!E>&5R8VES97,@:71S
M(&]P=&EO;G,@9F]R(&%L;"!F;W5R('-E9VUE;G1S(&9O<B!B;W1H($%622TV
M,#`R(&%N9"!!5DDM-S(X."`L(&-O;G1R86-T(&%C=&EV:71I97,@=V]U;&0@
M:6YC;'5D92!A;&P@8VQI;FEC86P@86YD(&QI8V5N<W5R92!A8W1I=FET:65S
M(&YE8V5S<V%R>2!T;R!O8G1A:6X@1D1!(')E9W5L871O<GD@87!P<F]V86P@
M9F]R(&5A8V@@=&AE<F%P975T:6,@8V%N9&ED871E(&%N9"!W;W5L9"!P<F]V
M:61E(&9O<B!A('1O=&%L(&9U;F1I;F<@87=A<F0@=&\@=&AE($-O;7!A;GD@
M;V8@=7`@=&\@)#(X."XP(&UI;&QI;VX@;W9E<B!A('!E<FEO9"!O9B!S:7@@
M>65A<G,L(&]F('=H:6-H("0Q-C$N-2!M:6QL:6]N(')E;6%I;G,@=&\@8F4@
M9G5N9&5D+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.B`Q.'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&UA<F=I;BUL969T.B`T)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M)R!C;&%S<STS1%]M="!S:7IE/3-$,CX\8CX\:3Y*=6YE(#(P,3`@06=R965M
M96YT("A(,4XQ+TEN9FQU96YZ82D@/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD96YT.B`S,G!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M3VX@2G5N92`T+"`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C
M;VYT<F%C="!W:71H('1H92!$969E;G-E(%1H<F5A="!2961U8W1I;VX@06=E
M;F-Y('1O(&%D=F%N8V4@=&AE(&1E=F5L;W!M96YT(&]F($%622TW,3`P(&%S
M(&$@;65D:6-A;"!C;W5N=&5R;65A<W5R92!A9V%I;G-T('1H92!P86YD96UI
M8R!(,4XQ(&EN9FQU96YZ82!V:7)U<R!I;B!C;V]P97)A=&EO;B!W:71H('1H
M92!4<F%N<V9O<FUA=&EO;F%L($UE9&EC86P@5&5C:&YO;&]G:65S('!R;V=R
M86T@;V8@1&]$+B!4:&4@<&5R:6]D(&]F('!E<F9O<FUA;F-E(&9O<B!T:&ES
M(&-O;G1R86-T(&5N9&5D(&]N($IU;F4@,RP@,C`Q,2!A;F0L(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!H87,@<F5C;V=N:7IE9"!R
M979E;G5E(&]F("0Q,BXS(&UI;&QI;VX@86YD(&1O97,@;F]T(&5X<&5C="!T
M;R!R96-E:79E(&%N>2!A9&1I=&EO;F%L(')E=F5N=64N(#PO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT
M.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H('1H92!R979E
M;G5E(&9O<B!E86-H(&]F('1H92!C;VYT<F%C=',@=VET:"!T:&4@52Y3+B!G
M;W9E<FYM96YT(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q
M+"`R,#$R(&%N9"`R,#$Q+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#L@9F]N="US:7IE
M.B`Q,G!X.R<^)FYB<W`[/"]P/@T*#0H\=&%B;&4@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93LG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
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M<#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^5&AR
M964F;F)S<#M-;VYT:',F;F)S<#M%;F1E9"9N8G-P.TUA<F-H)FYB<W`[,S$L
M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C
M;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X\+W1R/@T*
M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ
M93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
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M,T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
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M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,3X\8CXH:6X@=&AO
M=7-A;F1S*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$=&]P
M/@T*#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE
M9G0Z(#%E;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY*=6QY(#(P,3`@06=R
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M+W1R/@T*/'1R/CQT9"!V86QI9VX],T1T;W`^#0H-"CQP('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$
M7VUT('-I>F4],T0R/DIU;F4F;F)S<#LR,#$P($%G<F5E;65N="`\:3XH2#%.
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M<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L
M87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C(L,S(T/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,]
M,T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M,CXV-SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO
M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@[
M)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-
M"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q<'@@<V]L:60[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\
M<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX-"CQT<CX\=&0@
M=F%L:6=N/3-$=&]P/@T*#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E
M;3L@;6%R9VEN+6QE9G0Z(#%E;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY4
M;W1A;#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C$Q+#(Q,CPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S
M/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF
M;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG
M(&-L87-S/3-$7VUT('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS
M1#(^,30L,CDV/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#%P>#LG/CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L
M93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O
M=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX\
M+W1A8FQE/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@
M0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W1O8VL@0V]M<&5N<V%T:6]N(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/B`\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q.'!X.R!M87)G:6XM
M8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^/&(^-RX@4U1/
M0TL@0T]-4$5.4T%424].(#PO8CX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=M87)G:6XM=&]P.B`V<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#L@;6%R9VEN
M+6QE9G0Z(#(E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/CQB/CQI/E-T;V-K
M($]P=&EO;G,@/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,'!X.R!M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD
M96YT.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^26X@9V5N97)A;"P@<W1O8VL@;W!T:6]N<R!G<F%N=&5D('!R
M:6]R('1O($1E8V5M8F5R(#,Q+"`R,#$P('9E<W0@;W9E<B!A('1H<F5E('EE
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M7VUT('-I>F4],T0Q/CQS=7`@<W1Y;&4],T0G<&]S:71I;VXZ(')E;&%T:79E
M.R!B;W1T;VTZ(#`N.&5X.R!V97)T:6-A;"UA;&EG;CH@8F%S96QI;F4[)SYT
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M="X@07,@;V8@36%R8V@@,S$L(#(P,3(L(#$S+#`T,"PV-S8@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!R96UA:6X@879A:6QA8FQE(&9O<B!F=71U<F4@9W)A
M;G0N(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R
M<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@
M8VQA<W,],T1?;70@<VEZ93TS1#(^02!S=6UM87)Y(&]F('1H92!#;VUP86YY
M)W,@<W1O8VL@;W!T:6]N(&%C=&EV:71Y('=I=&@@<F5S<&5C="!T;R!T:&4@
M=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&9O;&QO=W,Z(#PO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R
M9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$R<'@[)SXF;F)S<#L\+W`^
M#0H-"CQT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/@T*/'1R/CQT9"!W:61T:#TS
M1#8R)3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X@
M/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X@/"]T9#X-"CQT9#X@/"]T
M9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-
M"CQT9#X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X@
M/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X\+W1R
M/@T*/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*
M#0H\<"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI
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M,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
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M,T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX]
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M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^5V5I9VAT
M960\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
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M93TS1#$^/&(^0V]N=')A8W1U86P\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS
M1%]M="!S:7IE/3-$,3X\8CY497)M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S
M<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[
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M(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1T;W`^#0H-"CQP('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG
M(&-L87-S/3-$7VUT('-I>F4],T0R/D]U='-T86YD:6YG(&%T($1E8V5M8F5R
M)FYB<W`[,S$L(#(P,3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?
M;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I
M>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG
M;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA
M<F=I;BUL969T.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^1W)A;G1E
M9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF
M;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^-C4S+#`P,#PO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
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M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L
M87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S
M<#LF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X@/"]T9#X\+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/CQT
M9"!V86QI9VX],T1T;W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M
M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R
M/D5X97)C:7-E9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F
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M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/BDF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N
M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C
M;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB
M<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\
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M97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L
M87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S
M<#LF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X@/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,7!X.R<^/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O
M;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N
M8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
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M8G-P.S,Q+"`R,#$R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0R/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXQ,RPW
M-#DL,#4R/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT
M('-I>F4],T0R/C(L-C(V+#`P,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R
M/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#L\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-
M"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\
M<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/B`\+W1D/CPO='(^#0H\='(^/'1D/B`\+W1D/@T*/'1D
M(&-O;'-P86X],T0T/B`\+W1D/@T*/'1D(&-O;'-P86X],T0T/B`\+W1D/@T*
M/'1D(&-O;'-P86X],T0T/B`\+W1D/@T*/'1D(&-O;'-P86X],T0T/B`\+W1D
M/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,]
M,T1?;70@<VEZ93TS1#(^5F5S=&5D(&%T($UA<F-H)FYB<W`[,S$L(#(P,3(@
M86YD(&5X<&5C=&5D('1O('9E<W0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P
M.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA
M<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\
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M,T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS
M1%]M="!S:7IE/3-$,CXF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M-RXS,3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
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M<W,],T1?;70@<VEZ93TS1#(^,BPT-S<L,#`P/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#%P>#LG/CQT9"!V86QI9VX],T1B;W1T;VT^
M(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(",P,#`P,#`@,W!X(&1O=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N
M8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.SPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O
M=6)L93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-
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M8VES86)L92!A="!-87)C:"9N8G-P.S,Q+"`R,#$R/"]F;VYT/CPO<#X\+W1D
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M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^-C`Y+#`P,#PO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S
M/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N/3-$
M8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S
M<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D
M97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#L\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B`\+W1D/CPO='(^/"]T86)L
M93X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!T97AT+6EN9&5N
M=#H@,S)P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I
M>F4],T0R/E1H92!W96EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@<&5R('-H
M87)E(&]F('-T;V-K+6)A<V5D(&%W87)D<R!G<F%N=&5D('1O(&5M<&QO>65E
M<R!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
M,B!A;F0@,C`Q,2!W87,@)#`N.3$@86YD("0Q+C4T+"!R97-P96-T:79E;'DN
M($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R
M(&%N9"`R,#$Q+"!T:&4@=&]T86P@:6YT<FEN<VEC('9A;'5E(&]F('-T;V-K
M(&]P=&EO;G,@97AE<F-I<V5D('=A<R`D,C@P(&%N9"`D,"!R97-P96-T:79E
M;'DL(&%N9"!T:&4@=&]T86P@9W)A;G0@9&%T92!F86ER('9A;'5E(&]F('-T
M;V-K(&]P=&EO;G,@=&AA="!V97-T960@=V%S("0Q+#DT,BPP,#`@86YD("0Q
M+#`X.2PP,#`L(')E<W!E8W1I=F5L>2X@/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@,3AP>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!M
M87)G:6XM;&5F=#H@,B4[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^/&(^/&D^
M5F%L=6%T:6]N($%S<W5M<'1I;VYS(#PO:3X\+V(^/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@-G!X.R!T97AT+6EN9&5N=#H@,S)P
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M9"!O9B!T:&4@9W)A;G1S+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.B`Q,G!X.R!T97AT+6EN9&5N=#H@,S)P>#L@;6%R9VEN+6)O
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M+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O
M='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$R<'@[)SXF;F)S<#L\+W`^#0H-"CQT
M86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$-S8E(&%L:6=N/3-$8V5N=&5R/@T*/'1R/CQT9"!W:61T:#TS1#<X)3X@
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X@/"]T9#X-
M"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)3X@/"]T9#X-"CQT9#X@/"]T9#X-"CQT
M9#X@/"]T9#X-"CQT9#X@/"]T9#X\+W1R/@T*/'1R/CQT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT
M('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS
M1%]M="!S:7IE/3-$,3X\8CY4:')E929N8G-P.TUO;G1H<R9N8G-P.T5N9&5D
M)FYB<W`[36%R8V@F;F)S<#LS,2P\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I
M>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M
M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P>"!S;VQI9#LG('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@
M<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F
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M9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
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M)R!C;&%S<STS1%]M="!S:7IE/3-$,CXE)FYB<W`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<CX\=&0@=F%L:6=N/3-$=&]P/@T*#0H\<"!S='EL93TS1"=T97AT
M+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE9G0Z(#%E;3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M
M="!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@
M<VEZ93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXF;F)S<#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA
M<W,],T1?;70@<VEZ93TS1#(^,"`\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$
M,CXE)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB
M<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C`@/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?
M;70@<VEZ93TS1#(^)29N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^/'1D('9A;&EG;CTS1'1O<#X-"@T*/'`@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T.B`Q96T[)SX\9F]N
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M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO
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M;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?
M;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/C4N
M-"9N8G-P.WEE87)S/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[
M)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX\=&0@=F%L:6=N/3-$=&]P
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M=#X\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#H@,3AP>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!M87)G:6XM;&5F=#H@,B4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^/&(^/&D^4W1O8VLM8F%S960@0V]M
M<&5N<V%T:6]N($5X<&5N<V4@/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.B`V<'@[('1E>'0M:6YD96YT.B`S,G!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^02!S
M=6UM87)Y(&]F('1H92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS
M92!R96-O9VYI>F5D(&EN('1H92!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@
M:7,@87,@9F]L;&]W<SH@/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[(&9O;G0M<VEZ93H@
M,3)P>#LG/B9N8G-P.SPO<#X-"@T*/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^
M#0H\='(^/'1D('=I9'1H/3-$-S8E/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@E/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D/B`\+W1D
M/@T*/'1D/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D/B`\+W1D/@T*/'1D/B`\+W1D/CPO
M='(^#0H\='(^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S<STS1%]M
M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[)FYB<W`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`Q<'@@<V]L:60[)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0Q/CQB/E1H<F5E
M)FYB<W`[36]N=&AS)FYB<W`[16YD960F;F)S<#M-87)C:"9N8G-P.S,Q+#PO
M8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA
M<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4]
M,T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!C;&%S<STS1%]M="!S:7IE/3-$,3XF;F)S<#LF;F)S<#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?
M;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!X('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
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M93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^*&EN('1H;W5S
M86YD<RD\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D('9A;&EG;CTS1'1O<#X-
M"@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ96T[(&UA<F=I;BUL969T
M.B`Q96T[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\
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M<#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/CQT9"!V86QI9VX],T1T;W`^#0H-
M"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@
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M93TS1#$^)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#%P>#LG/CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P
M,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`Q
M<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P
M,#`P,"`Q<'@@<V]L:60[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,7!X('-O;&ED.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1T;W`^
M#0H-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F
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M,T1?;70@<VEZ93TS1#(^-S`X/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^
M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CXQ+#$T-3PO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L
M87-S/3-$7VUT('-I>F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@[)SX\=&0@=F%L:6=N
M/3-$8F]T=&]M/B`\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S<#LF
M;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B
M;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF;F)S
M<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#-P>"!D;W5B;&4[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9#XF;F)S<#L\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@,3)P>#L@=&5X="UI;F1E;G0Z(#,R<'@[(&UA
M<F=I;BUB;W1T;VTZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY!<R!O
M9B!-87)C:"`S,2P@,C`Q,BP@=&AE<F4@=V%S("0W+#4R-BPP,#`@;V8@=6YR
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M87)S+CPO9F]N=#X\+W`^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S
M93<Q,F9F.#%C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E
M-C@Y7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H
M965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY);F-O;64@5&%X97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@
M5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$X<'@[(&UA<F=I;BUB;W1T;VTZ(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CX\8CXX+B!)3D-/344@5$%815,@
M/"]B/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#9P
M>#L@=&5X="UI;F1E;G0Z(#,R<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[)R!C
M;&%S<STS1%]M="!S:7IE/3-$,CY!="!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE
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M($-O;7!A;GDG<R!S=&]C:RX\+V9O;G0^/"]P/B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4F5S=')U8W1U<FEN9SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<W1R=6-T=7)I;F<@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<G5C='5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/B`\<"!S='EL93TS1"=M87)G:6XM=&]P.B`Q.'!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^/&(^
M.2X@4D535%)50U154DE.1R`\+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
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M8W1U<FEN9R!C:&%R9V5S('1O=&%L:6YG("0Q+#$T-2PP,#`@=V5R92!R96-O
M<F1E9"!I;B`R,#$Q(&%N9"!I;F-L=61E9"!S979E<F%N8V4@86YD(')E;&%T
M960@8V]S=',N(%1H92!C:&%R9V4@:6YC;'5D960@)#4T."PP,#`@=&\@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V4@86YD("0U.3<L,#`P('1O
M(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4N(%1H92!R97-T
M<G5C='5R:6YG('=A<R!C;VUP;&5T960@8GD@2F%N=6%R>2`S,2P@,C`Q,B!A
M;F0@86QL('-E=F5R86YC92!C;W-T<R!A<F4@97AP96-T960@=&\@8F4@<&%I
M9"!B>2!*=6QY(#,Q+"`R,#$R+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=M87)G:6XM=&]P.B`Q,G!X.R!T97AT+6EN9&5N=#H@,S)P>#L@;6%R9VEN
M+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/D-H86YG97,@
M:6X@=&AE(&%C8W)U960@96UP;&]Y964@8V]M<&5N<V%T:6]N(&QI86)I;&ET
M>2!A;F0@=&AE(&)A;&%N8V4@<F5L871E9"!T;R!T:&4@1&5C96UB97(@,C`Q
M,2!R97-T<G5C='5R:6YG('!L86X@87)E(&%S(&9O;&QO=W,Z(#PO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O
M='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$R<'@[)SXF;F)S<#L\+W`^#0H-"CQT
M86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
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M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M>"!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^5&AR964F;F)S<#MM
M;VYT:',F;F)S<#ME;F1I;F<\8G(@+SY-87)C:"`S,2PF;F)S<#LR,#$R/"]B
M/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S
M<STS1%]M="!S:7IE/3-$,3XF;F)S<#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS
M1#$^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT(&-L87-S/3-$7VUT('-I>F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#$^/&(^*&EN)FYB<W`[=&AO
M=7-A;F1S*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@8VQA<W,],T1?;70@<VEZ93TS1#$^)FYB<W`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$=&]P
M/@T*#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R9VEN+6QE
M9G0Z(#%E;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY"86QA;F-E(&%T($IA
M;G5A<GDF;F)S<#LQ+"`R,#$R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG
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M;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[)FYB<W`[/"]F;VYT
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M)FYB<W`[)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[
M)FYB<W`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F
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M8VQA<W,],T1?;70@<VEZ93TS1#(^)FYB<W`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I
M>F4],T0R/B@X-CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/BD\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X.R<^/'1D
M('9A;&EG;CTS1&)O='1O;3X@/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H-"CQP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,7!X('-O;&ED.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^/"]T<CX-"CQT<CX\=&0@=F%L:6=N
M/3-$=&]P/@T*#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3%E;3L@;6%R
M9VEN+6QE9G0Z(#%E;3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[)R!C;&%S<STS1%]M="!S:7IE/3-$,CY"86QA;F-E
M(&%T($UA<F-H)FYB<W`[,S$L(#(P,3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
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M;W1T;VT^)FYB<W`[)FYB<W`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M#0H-"CQP('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,W!X(&1O=6)L
M93LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`S<'@@9&]U8FQE.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0^)FYB<W`[/"]T9#X\+W1R/CPO=&%B;&4^
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W8S9?9&0S93<Q,F9F.#%C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9E,S5E-C@Y7V(X-S-?-#0V-U]A
M-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE971S+U-H965T,34N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296-E;G0@06-C;W5N
M=&EN9R!0<F]N;W5N8V5M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO
M=6YC96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/CQB/C$P+B!214-%3E0@04-#3U5.
M5$E.1R!04D].3U5.0T5-14Y44R`\+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@-G!X.R!T97AT+6EN9&5N=#H@,S)P>#L@;6%R
M9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CLG(&-L87-S/3-$7VUT('-I>F4],T0R/DEN($%P
M<FEL(#(P,3$L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@
M0F]A<F0@*")&05-"(BD@:7-S=65D(&=U:61A;F-E('1O(&%C:&EE=F4@8V]M
M;6]N(&9A:7(@=F%L=64@;65A<W5R96UE;G0@86YD(&1I<V-L;W-U<F4@<F5Q
M=6ER96UE;G1S(&)E='=E96X@1T%!4"!A;F0@26YT97)N871I;VYA;"!&:6YA
M;F-I86P@4F5P;W)T:6YG(%-T86YD87)D<RX@5&AI<R!G=6ED86YC92!A;65N
M9',@8W5R<F5N="!F86ER('9A;'5E(&UE87-U<F5M96YT(&%N9"!D:7-C;&]S
M=7)E(&=U:61A;F-E('1O(&EN8VQU9&4@:6YC<F5A<V5D('1R86YS<&%R96YC
M>2!A<F]U;F0@=F%L=6%T:6]N(&EN<'5T<R!A;F0@:6YV97-T;65N="!C871E
M9V]R:7IA=&EO;BX@5&AE(&=U:61A;F-E(&ES(&5F9F5C=&EV92!F;W(@9FES
M8V%L('EE87)S(&%N9"!I;G1E<FEM('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R
M($1E8V5M8F5R(#$U+"`R,#$Q+B!4:&4@861O<'1I;VX@;V8@=&AI<R!N97<@
M9W5I9&%N8V4@9&ED(&YO="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H
M92!#;VUP86YY)W,@9FEN86YC:6%L('-T871E;65N=',N(#PO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$R<'@[('1E>'0M:6YD96YT
M.B`S,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<@8VQA<W,],T1?;70@<VEZ
M93TS1#(^26X@2G5N92`R,#$Q+"!T:&4@1D%30B!I<W-U960@9W5I9&%N8V4@
M<F5G87)D:6YG('!R97-E;G1A=&EO;B!O9B!O=&AE<B!C;VUP<F5H96YS:79E
M(&EN8V]M92!I;B!T:&4@9FEN86YC:6%L('-T871E;65N=',N(%1H:7,@9W5I
M9&%N8V4@96QI;6EN871E9"!T:&4@;W!T:6]N('5N9&5R($=!05`@=&\@<')E
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M>65A<G,L(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,2X@5&AE
M(&%D;W!T:6]N(&]F('1H:7,@;F5W(&=U:61A;F-E(&1I9"!N;W0@:&%V92!A
M(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!S
M=&%T96UE;G1S+CPO9F]N=#X\+W`^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F4S-64V.#E?8C@W,U\T-#8W7V$W
M8S9?9&0S93<Q,F9F.#%C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V9E,S5E-C@Y7V(X-S-?-#0V-U]A-V,V7V1D,V4W,3)F9C@Q8R]7;W)K<VAE
M971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M
M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL
M92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-
M"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]F93,U938X.5]B.#<S7S0T-C=?
583=C-E]D9#-E-S$R9F8X,6,M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div> <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>3. FAIR VALUE MEASUREMENTS </b></font></p>

<p style="margin-top: 6px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The Company measures at fair value certain financial assets and liabilities in accordance with a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. There are three levels of inputs that may be used to measure fair-value: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr><td width="5%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" width="2%" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">&#149;</font></td>
<td valign="top" width="1%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" align="left">

<p align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">Level 1 &#8212; quoted prices for identical instruments in active markets; </font></p></td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr><td width="5%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" width="2%" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">&#149;</font></td>
<td valign="top" width="1%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" align="left">

<p align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">Level 2 &#8212; quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and </font></p></td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 6px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr><td width="5%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" width="2%" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">&#149;</font></td>
<td valign="top" width="1%"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="top" align="left">

<p align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">Level 3 &#8212; valuations derived from valuation techniques in which one or more significant value drivers are unobservable. </font></p></td></tr></table>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The Company's assets and liabilities measured at fair value on a recurring basis consisted of the following as of the date indicated: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr style="line-height: 0pt; visibility: hidden; color: white;"><td width="78%"> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Fair Value Measurement as of March&nbsp;31, 2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Total</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;1</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;2</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;3</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Cash and cash equivalents</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">30,573</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">30,573</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total assets</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">30,573</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">30,573</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr style="line-height: 0pt; visibility: hidden; color: white;"><td width="78%"> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;March&nbsp;31,&nbsp;2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Total</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;1</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;2</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;3</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Warrants*</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,372</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,372</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total liabilities</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,372</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,372</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr style="line-height: 0pt; visibility: hidden; color: white;"><td width="78%"> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Total</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;1</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;2</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;3</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Cash and cash equivalents</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">39,904</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">39,904</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total assets</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">39,904</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">39,904</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr style="line-height: 0pt; visibility: hidden; color: white;"><td width="80%"> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td>
<td valign="bottom" width="3%"> </td>
<td> </td>
<td nowrap="nowrap"><font class="_mt" size="1"><b>00000000</b></font></td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="14" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Total</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;1</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;2</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Level&nbsp;3</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Warrants*</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,446</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,446</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total liabilities</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,446</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,446</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr><td valign="top" width="2%" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">*</font></td>
<td valign="top" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">See "Note 5 &#8212; Warrants" for additional information related to the determination of fair value of the warrants and a reconciliation of changes in fair value. </font></td></tr></table>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The carrying amounts reported in the balance sheets for accounts receivable, accounts payable, and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example,  transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techniques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example,  impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods.  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementInputsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 30,573<span></span></td>
        <td class="nump">$ 39,904<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">5,135<span></span></td>
        <td class="nump">3,633<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">1,924<span></span></td>
        <td class="nump">1,647<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">37,632<span></span></td>
        <td class="nump">45,184<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net of accumulated depreciation and amortization of $15,982 and $15,765</a></td>
        <td class="nump">4,105<span></span></td>
        <td class="nump">4,265<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent Costs, net of accumulated amortization of $2,298 and $2,199</a></td>
        <td class="nump">4,704<span></span></td>
        <td class="nump">4,764<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">206<span></span></td>
        <td class="nump">155<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">46,647<span></span></td>
        <td class="nump">54,368<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Shareholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">8,195<span></span></td>
        <td class="nump">9,396<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation</a></td>
        <td class="nump">1,852<span></span></td>
        <td class="nump">2,244<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
        <td class="nump">86<span></span></td>
        <td class="nump">85<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_WarrantsValuation', window );">Warrant valuation</a></td>
        <td class="nump">16,372<span></span></td>
        <td class="nump">5,446<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">3,304<span></span></td>
        <td class="nump">3,304<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
        <td class="nump">114<span></span></td>
        <td class="nump">126<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">29,923<span></span></td>
        <td class="nump">20,601<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, non-current portion</a></td>
        <td class="nump">1,735<span></span></td>
        <td class="nump">1,757<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">967<span></span></td>
        <td class="nump">993<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value, 20,000,000 shares authorized; none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.0001 par value, 300,000,000 and 200,000,000 shares authorized; 135,743,787 and 135,743,120 issued and outstanding</a></td>
        <td class="nump">13<span></span></td>
        <td class="nump">13<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">341,677<span></span></td>
        <td class="nump">340,968<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(327,668)<span></span></td>
        <td class="num">(309,964)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
        <td class="nump">14,022<span></span></td>
        <td class="nump">31,017<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
        <td class="nump">$ 46,647<span></span></td>
        <td class="nump">$ 54,368<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_WarrantsValuation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's warrants are non-cash liabilities and the Company will not expend any cash to settle these liabilities. The fair value of the warrants is recorded on the balance sheet at issuance and are marked to market at each financial reporting period, with changes in fair value recorded as a gain or loss in the statement of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_WarrantsValuation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 7<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization And Basis Of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization And Basis Of Presentation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization And Basis Of Presentation</a></td>
        <td class="text"><div> <p style="margin-top: 12px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>1. ORGANIZATION AND BASIS OF PRESENTATION </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">AVI BioPharma, Inc. (the "Company") is a biopharmaceutical company incorporated in the State of Oregon on July 22, 1980. The Company is focused on the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. Applying the Company's proprietary platform technologies, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. The Company is focused on rapidly advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen. In April 2012, the Company announced results from its Phase IIb placebo controlled trial in eteplirsen. Following completion of this study, the Company initiated an open label extension study with the same participants from the original Phase IIb placebo controlled trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses for which the Company has historically received and expects to continue to receive significant financial support from U.S. government research contracts. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company and its consolidated subsidiaries. The accompanying unaudited condensed consolidated balance sheet data as of December 31, 2011 was derived from audited financial statements not included in this report. The accompanying unaudited condensed consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") pertaining to interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The accompanying unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2011. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Since its inception in 1980, the Company has incurred losses of approximately $327.7 million, substantially all of which resulted from expenditures related to research and development, general and administrative charges and acquired in-process research and development resulting from two acquisitions. The Company has not generated any material revenue from product sales to date, and there can be no assurance that revenues from product sales will be achieved. Moreover, even if the Company does achieve revenue from product sales, the Company expects to incur operating losses over the next several years. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In the periods presented, nearly all of the revenue generated by the Company was derived from research contracts and grants with the U.S. government. As of March 31, 2012, the Company had had substantially completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics against Ebola and Marburg. Pursuant to this agreement, as of March 31, 2012, the Company is currently entitled to receive up to an aggregate of $126.5 million for development of its product candidates, of which $63.9 million has been recognized as revenue and $62.6 million relates to development that has not yet been completed and has not been billed or recognized as revenue. In addition, if the U.S. government elects to exercise all its options under the agreement, an additional $161.5 million in funding is available. See "Note 6 &#8212; U.S. Government Contracts" for additional information. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">At March 31, 2012, cash and cash equivalents were $30.6 million. The Company's principal sources of liquidity have been equity financings and revenue from its U.S. government research contracts. The Company's principal uses of cash have been research and development expenses, general and administrative expenses and other working capital requirements. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The Company believes it has sufficient cash to fund operations at least through the following 12 months. The Company anticipates receiving continued funding from the U.S. government to pursue the development of its therapeutics against Ebola and Marburg, and has assumed certain revenues from these awards in providing this guidance. Should the Company's funding from the U.S. government cease or be delayed, it would have a significant negative impact on the Company's financial condition and on this guidance and the Company would likely be forced to significantly curtail its research and development efforts unless additional funding was obtained. The Company is also likely to pursue additional funding through public or private financings and cash generated from establishing collaborations or licensing its technology to other companies. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Estimates and Uncertainties </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of liability classified warrants and stock-based awards, long lived asset impairment, and revenue recognition. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Commitments and Contingencies </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">As of the date of this report, the Company is not a party to any material legal proceedings with respect to itself, its subsidiaries, or any of its material properties. In the normal course of business, the Company may from time to time be named as a party to various legal claims, actions and complaints, including matters involving employment, intellectual property, effects from the use of therapeutics utilizing its technology, professional services or others. It is impossible to predict with certainty whether any resulting liability would have a material adverse effect on the Company's financial position, results of operations or cash flows. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Reclassifications </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Certain inception to date amounts have been reclassified to conform to current year presentation. These changes did not have a significant impact on the Company's net loss, assets, liabilities, shareholders' equity or cash flows.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Income (Loss) Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>2. NET INCOME (LOSS) PER SHARE </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares and dilutive common stock equivalent shares outstanding. </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr><td width="75%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Net income (loss)</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(17,704</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1,833</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Weighted-average number of shares of common stock and common stock equivalents&nbsp;outstanding:</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Weighted-average number of common shares outstanding for computing basic earnings per share</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">135,743</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">112,482</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Dilutive effect of warrants and stock options after application of the treasury stock method*</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">8,803</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Weighted-average number of common shares outstanding for computing diluted earnings per share</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">135,743</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">121,282</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Net income (loss) per share - basic</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(0.13 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.02</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Net income (loss) per share - dilutive</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(0.13 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.02</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr><td valign="top" width="2%" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">*</font></td>
<td valign="top" align="left"><font style="font-family: Times New Roman;" class="_mt" size="2">Warrants and stock options to purchase 42,953,909 and 12,572,964 shares of common stock as of March&nbsp;31, 2012 and 2011, respectively, were excluded from the net income (loss) per share calculation as their effect would have been anti-dilutive.</font></td></tr></table> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and Equipment accumulated depreciation and amortization</a></td>
        <td class="nump">$ 15,982<span></span></td>
        <td class="nump">$ 15,765<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patent Costs accumulated amortization</a></td>
        <td class="nump">$ 2,298<span></span></td>
        <td class="nump">$ 2,199<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">135,743,787<span></span></td>
        <td class="nump">135,743,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">135,743,787<span></span></td>
        <td class="nump">135,743,120<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 01, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">AVI BIOPHARMA INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000873303<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">135,743,787<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3KAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements Of Operations And Comprehensive Income (Loss) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">380 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations And Comprehensive Income (Loss) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_RevenueResearchContractsGrantsAndLicenseFees', window );">Revenues from license fees, grants and research contracts</a></td>
        <td class="nump">$ 11,212<span></span></td>
        <td class="nump">$ 14,296<span></span></td>
        <td class="nump">$ 147,431<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">14,805<span></span></td>
        <td class="nump">14,801<span></span></td>
        <td class="nump">348,071<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,281<span></span></td>
        <td class="nump">5,026<span></span></td>
        <td class="nump">107,738<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">29,461<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(6,874)<span></span></td>
        <td class="num">(5,531)<span></span></td>
        <td class="num">(337,839)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_InterestExpenseIncomeAndOtherNet', window );">Interest income and other, net</a></td>
        <td class="nump">96<span></span></td>
        <td class="nump">90<span></span></td>
        <td class="nump">9,265<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IncreaseDecreaseOnWarrantValuation', window );">Gain (loss) on change in warrant valuation</a></td>
        <td class="num">(10,926)<span></span></td>
        <td class="nump">7,274<span></span></td>
        <td class="nump">14,044<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gain on sale of short-term securities- available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,863<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Write-down of short-term securities- available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(17,001)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other non operating income</a></td>
        <td class="num">(10,830)<span></span></td>
        <td class="nump">7,364<span></span></td>
        <td class="nump">10,171<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">(17,704)<span></span></td>
        <td class="nump">1,833<span></span></td>
        <td class="num">(327,668)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_WriteDownOfShortTermSecuritiesAvailableForSale', window );">Write-down of short-term securities-available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">17,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale', window );">Realized gain on sale of short-term securities-available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(3,863)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale', window );">Unrealized loss on short-term securities-available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(13,138)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease', window );">Other comprehensive income (loss)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
        <td class="num">$ (17,704)<span></span></td>
        <td class="nump">$ 1,833<span></span></td>
        <td class="num">$ (327,668)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic</a></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted</a></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding for computing basic income (loss) per share (in thousands)</a></td>
        <td class="nump">135,743<span></span></td>
        <td class="nump">112,482<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding for computing diluted income (loss) per share (in thousands)</a></td>
        <td class="nump">135,743<span></span></td>
        <td class="nump">121,285<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IncreaseDecreaseOnWarrantValuation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The income statement impact of changes in the fair value of the Company's noncash liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IncreaseDecreaseOnWarrantValuation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_InterestExpenseIncomeAndOtherNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-operating interest income or (expense) related to investments and other activities, net as reported in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_InterestExpenseIncomeAndOtherNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Realized gain on sale of short term securities available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_RealizedGainOnSaleOfShortTermSecuritiesAvailableForSale</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_RevenueResearchContractsGrantsAndLicenseFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's revenue is generated largely from U.S. government research contracts. The contracts with the U. S. government are cost plus contracts providing for reimbursed costs and a target fee. Revenue is recognized from U.S. government research contracts during the period in which the related expenses are incurred and present such revenues and related expenses gross in the consolidated financial statements. In addition the Company also receives revenue from license fees which consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive licensed rights to patented or patent pending compounds, technology access fees, various performance or sales milestones and future product royalty payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_RevenueResearchContractsGrantsAndLicenseFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrealized loss on short term securities available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_UnrealizedLossOnShortTermSecuritiesAvailableForSale</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_WriteDownOfShortTermSecuritiesAvailableForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Write down of short term securities available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_WriteDownOfShortTermSecuritiesAvailableForSale</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 21<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 36, 37, 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 11, 12, 36<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15C<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 16B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6956420&amp;loc=d3e25351-111560<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-2/124-2<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents Other Comprehensive Income or Loss, Net of Tax, for the period.  Includes deferred gains or losses on qualifying hedges, unrealized holding gains or losses on available-for-sale securities, minimum pension liability, and cumulative translation adjustment. While for technical reasons this element has no balance attribute, the default assumption is a credit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 22, 23, 24, 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e599-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 4<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>7. STOCK COMPENSATION </b></font></p>

<p style="margin-top: 6px; margin-bottom: 0px; margin-left: 2%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Stock Options </i></b></font></p>

<p style="padding-bottom: 0px; margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In general, stock options granted prior to December 31, 2010 vest over a three year period, with one-third of the underlying shares vesting on each anniversary of grant, and have a ten year term. Beginning in January 2011, stock options granted generally vest over a four year period, with one-fourth of the underlying shares vesting on the first anniversary of the grant and 1/48</font><font style="font-family: Times New Roman;" class="_mt" size="1"><sup style="position: relative; bottom: 0.8ex; vertical-align: baseline;">th</sup></font><font style="font-family: Times New Roman;" class="_mt" size="2"> of the underlying shares vesting monthly thereafter, such that the underlying shares will be fully vested on the fourth anniversary of the grant. As of March 31, 2012, 13,040,676 shares of common stock remain available for future grant. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">A summary of the Company's stock option activity with respect to the three months ended March 31, 2012 follows: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr><td width="62%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom" nowrap="nowrap">

<p style="border-bottom: #000000 1px solid; width: 48pt;"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Stock Options</b></font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Underlying<br />Shares</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Weighted</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Average</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Exercise</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Price</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Weighted</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Average</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Remaining</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Contractual</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Term</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Aggregate</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Intrinsic</b></font><br /><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Value</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Outstanding at December&nbsp;31, 2011</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">14,505,857</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.86</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Granted</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">653,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.40</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Exercised</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(667</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.92</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Canceled or expired</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(1,409,138</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.42</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Outstanding at March&nbsp;31, 2012</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">13,749,052</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.89</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">7.39</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2,626,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr><td height="8"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Vested at March&nbsp;31, 2012 and expected to vest</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">13,202,433</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.91</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">7.31</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2,477,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr><td height="8"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Exercisable at March&nbsp;31, 2012</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,149,551</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2.54</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">4.33</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">609,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr></table>

<p style="margin-top: 0px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The weighted-average fair value per share of stock-based awards granted to employees during the three months ended March 31, 2012 and 2011 was $0.91 and $1.54, respectively. During the three months ended March 31, 2012 and 2011, the total intrinsic value of stock options exercised was $280 and $0 respectively, and the total grant date fair value of stock options that vested was $1,942,000 and $1,089,000, respectively. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 2%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Valuation Assumptions </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Stock-based compensation costs are based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options. The fair value of stock grants is amortized as compensation expense on a straight-line basis over the vesting period of the grants. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The fair values of stock options granted during the periods presented were measured on the date of grant using the Black-Scholes option-pricing model, with the following assumptions: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr><td width="78%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td height="8"> </td>
<td height="8" colspan="4"> </td>
<td height="8" colspan="4"> </td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Risk-free interest rate</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.1</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2.4</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected dividend yield</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected lives</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5.3&nbsp;years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5.4&nbsp;years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected volatility</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">79.7</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">81.6</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr></table>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 2%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Stock-based Compensation Expense </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">A summary of the stock-based compensation expense recognized in the statements of operations is as follows: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr><td width="76%"> </td>
<td valign="bottom" width="8%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="8%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Research and development</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">253</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">373</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">General and administrative</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">455</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">772</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">708</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1,145</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">As of March 31, 2012, there was $7,526,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted, including stock options and restricted stock. These costs are expected to be recognized over a weighted-average period of 3.1 years.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>U.S. Government Contracts<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_USGovernmentContractsAbstract', window );"><strong>U.S. Government Contracts [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">U.S. Government Contracts</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>6. U.S. GOVERNMENT CONTRACTS </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The Company recognizes revenues from U.S. government research contracts during the period in which the related expenditures are incurred and presents these revenues and related expenses gross in the consolidated financial statements. In the periods presented, all of the revenue generated by the Company was derived from research contracts with and grants from the U.S. government. As of March 31, 2012, the Company had completed all of its contracts with the U.S. government except for the July 2010 agreement for the development of therapeutics against Ebola and Marburg. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>July 2010 Agreement (Ebola and Marburg) </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">On July 14, 2010, the Company was awarded a contract with the U.S. Department of Defense, or DoD, Chemical and Biological Defense Program through the U.S. Army Space and Missile Defense Command for the advanced development of the Company's hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, against the Ebola and Marburg viruses, respectively. In February 2012, the Company announced that it received approval from the FDA to proceed with a single oligomer from AVI-6003, AVI-7288, as the lead product candidate against Marburg virus infection. The contract is structured into four segments for each therapeutic candidate and has an aggregate period of performance spanning approximately six years if DoD exercises its options for all segments. Activities under the first segment began in July 2010 and include Phase I studies in healthy volunteers as well as preclinical studies which are scheduled to be completed in the second quarter of 2013. The aggregate available funding for the current segments is approximately $126.5 million of which $63.9 million has been recognized to date. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">After completion of the first segment, and each successive segment, DoD has the option to proceed to the next segment for either or both AVI-6002 and AVI-7288. If DoD exercises its options for all four segments for both AVI-6002 and AVI-7288 , contract activities would include all clinical and licensure activities necessary to obtain FDA regulatory approval for each therapeutic candidate and would provide for a total funding award to the Company of up to $288.0 million over a period of six years, of which $161.5 million remains to be funded. </font></p>

<p style="margin-top: 18px; margin-bottom: 0px; margin-left: 4%;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>June 2010 Agreement (H1N1/Influenza) </i></b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">On June 4, 2010, the Company entered into a contract with the Defense Threat Reduction Agency to advance the development of AVI-7100 as a medical countermeasure against the pandemic H1N1 influenza virus in cooperation with the Transformational Medical Technologies program of DoD. The period of performance for this contract ended on June 3, 2011 and, as of December 31, 2011, the Company has recognized revenue of $12.3 million and does not expect to receive any additional revenue. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The following table sets forth the revenue for each of the contracts with the U.S. government for the three months ended March 31, 2012 and 2011. </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr><td width="80%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">July 2010 Agreement <i>(Ebola and Marburg)</i></font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">11,163</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">11,905</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">June&nbsp;2010 Agreement <i>(H1N1)</i></font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2,324</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Other Agreements</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">49</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">67</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Total</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">11,212</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">14,296</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_USGovernmentContractsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_USGovernmentContractsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term contracts or programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 405<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471944&amp;loc=d3e56414-109416<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 45<br><br> -Paragraph 12, 15, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 94<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 35<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6407836&amp;loc=d3e58033-111643<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 11<br><br> -Section A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 275<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471736&amp;loc=d3e54651-109401<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 11<br><br> -Section B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 6<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 11<br><br> -Section C<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_RecentAccountingPronouncementsTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div> <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>10. RECENT ACCOUNTING PRONOUNCEMENTS </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In April 2011, the Financial Accounting Standards Board ("FASB") issued guidance to achieve common fair value measurement and disclosure requirements between GAAP and International Financial Reporting Standards. This guidance amends current fair value measurement and disclosure guidance to include increased transparency around valuation inputs and investment categorization. The guidance is effective for fiscal years and interim periods beginning after December 15, 2011. The adoption of this new guidance did not have a material impact on the Company's financial statements. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In June 2011, the FASB issued guidance regarding presentation of other comprehensive income in the financial statements. This guidance eliminated the option under GAAP to present other comprehensive income in the statement of changes in equity. Under the guidance, the Company had the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this new guidance did not have a material impact on the Company's financial statements.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_RecentAccountingPronouncementsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recent accounting pronouncements [Text block].</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_RecentAccountingPronouncementsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001193125-12-223884-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-223884-xbrl.zip
M4$L#!!0````(`"](JD`)[WMZ'T$``%%=`P`1`!P`879I:2TR,#$R,#,S,2YX
M;6Q55`D``RF\JT\IO*M/=7@+``$$)0X```0Y`0``[%U9<^,VMGY/5?X#KF9Z
M)E.EA8M6Q]U3\M*Y3KIMC^U.YCZY(!*2,$V1&H"4K?SZ>P"0(K5+%+792E7:
M%`F>#1\.#I8#GO_SM>>@`6&<>N['G%[4<HBXEF=3M_,Q%_`"YA:EN7]^^O&'
M\_\I%/Y]\?`%V9X5](CK(XL1[!,;O5"_BRZ9QWF;,H):0_1`!\1'CU[;?\%P
M)Z2/*D6]J)?K10UU?;]_5BJ]O+P4F2C+PZ)%R^L5"B&W"\R!.KPGV1I%??3D
M,N3LN6>H4FJ4#$TWD&Z<:?J9KJ'[KZK@:XLY"/1S^<=<@J&X7?18!][2S!)U
MN8]=B^14R3.'NM\7%!>/6R!75/QUJOR+*4OKC4:C))]&1?&`TK&2<*-%/:&R
M5$`S33TJ2[E7-O3:(KE5B>@%F\2T94%.K&+'&Y3@@:"N%S2]$-,71>@:5@$D
M=##NC]YH8]Z2I<,'LUAP.LLN0%XO_?OKET>K2WJX,&($%8;0N;#7&9>/'D@;
M2?N=^<,^^9CCM-=WA$#R7I>1]L><,&DALEWQE=LY5%*$!$@\UR>O`$-B^8`^
MB0EX8H6WJ?TQU^3/=^UG\]G4GX4"2@@H`^BF_C#\!;^I+>ZT*6%("D?&-(M,
M?7GS6^Z3!O_5:Z:IF>>E^+6(<&F,\GF?,.K9"3[2&OXG94T3K'E>BNY%%!+O
MG)="9>9IIANA:MHAJ:85=&-CU2K/4C'CD!0S"EH%&L%FBD5H/#3-,D3C@36T
MC=!X%3`LW`O`4>GV_.0=D$<!E9A_!9WEI\A#"WS&=T<%B6LGBJG*CNZEM$CM
MV3">]49=2YID_[".E1>R%;1:P3"6F<3(R"0A2(Q#M8A2=160I+`(],G?7#K5
M(0?BGK"2>*B;(VO8=`":Q,Q%N5N(/,&4'AO=A@<]@GG`R*<P)#K[]GAU7HIN
MCEXOS7Y?DKTBKM>C[CS",EHZXUT(4/D\RM,DSDL)#52A60K'U;^<W7PJ4T3F
M&B-)`VKD*8"H:K)*X/ZU0V20/_%$1%QG3<OR`M?G#\0B=(!;#GF"2KYP/.L[
M"FO\081GRV#_-\?_&6STMX[_,Q+7?<3]H0,H[V'6H6[!]_IG2*_W7W]&X9V6
MY_M>[PQI<"\GWA.OM8%E]*:X+K1QCSK#,_1$>X2C6_*"'KP>=G_.(<O!'$8#
MSST_ASC]$UXP1F1:XJ)<1,W+R[MOMT^/Z.'Z\OKF]^;%EVLI7:D5E2P)+J,?
M?7'UXP\__C!7A:K00%@%PEW1-L^0:>Q`J:B:$!O5$Q+#,6C88O"$`3[NP*.6
MN.Z)D@B[-@SOD.OYJ$4P@^<^`1#Z171!+!QP>-]Q$)Y#M\V\'O*[!'TK/A81
MN";"7(DA0;9+.30-:@&!(3`(.7+4Q0,8,A+BHA=&?1_^>NUV'EX1K+P7,39`
M;8^!6$'+;P>SN5,N90;L<6AP#!1RX2'GF`V+Z`DDFO52"SN2.G4M)[#AG;\:
M^:IAYL&32HGAI]90/[WVE$XQ(0XZ@RU?@"\*W!9U'&7<KYA9763J>22'IX+D
M%;S4:X$[#^_"OV#>OFAB`^(,BW/`I>`7MI3STK(VF&RIG`>]OFB#=^TO%(-P
MU*>$?_98T_IO`*-U^]+K];$[A((P"I_=>N?TXTCX$5E2>2!D$XOVL`-0+(`7
M-W2C#+:+Q%U/D*Q5F!V<+='@L&0WUK)^QK)[;N>)L-X5:?GPZD5`'3%#=!\`
MPC%XA2QA8XA09J;XBX7(4O3LX+)SF3.`R<HR7WIN.+5WU[X)NPKP2RP@]I,'
MN.IY[J,_-RA(AX]Z#(Y5V6<F\4:PV)>TZ0"10MI?,'6_>)S?N5>4]SV.G;MV
M]MU*P3#-:HR!^4PWD"Q5/1>,'8FU7H46JI4UQ;IQQ<0^)Q"LR+\W[G2LT73M
M.XCTV&7`&$1#V5=S3=,2T4-JD;:G5BJ,Z+J11,GAJK4>QO2ZJ6U7JSOW#\P8
M=OW?L1-(2;,$FU[6R@O0-LT\`TE3X:=FU/8DYYI.1]<:BX"^1%+5W5R_]HDK
MX&-YO1%@;HF?9<V#E)6DF(LY;RQDJDIO:+N7<+WJ;E3320A!IQB!W[43`044
M#;'!;]Q'$(JWL34U?LFT]>OU1%"Y@5#;5"T5<JIC7NV@%4L7I6Y1IUU,D=2U
M6F5)!:TP4,]`_(T&-ON7.T/P;"#W-F=%)$Z6";Y@I+Z9S%N!Q[:ES184"Z2%
M3BV*;^)0]QX/99RKALS7O;[C#0D1D()>4<H9]8G;ZM6,2C7A_;,3<H>:I\)=
M16_H;T/O=6/N2K6V9<4?"';HG\06\PAWT+<ZT$X>NQ[SQ7SA([$")M]H#C!U
M!"-H.*)0IO,_9KUJQFJFE&A;.FWD*0]3EW1^-`M=+#$SH)`K/"_S7+BTY+(T
MW^*"L[;+]69=*\IUYMNG:-WYYO87=/]P=PO7E]=?K\5"]%&N/M^XJ-EGU`G7
M.<6Z\&?J0M]*L8/B:D6//G9MS&R.+CSX@W[*?6X^7N3^@2ATQ<1&G8#:<IW6
M]Q"VNI0,!%Y%WXS:F#(TP$Y`4+C#8;3<;%-N.9ZXA1B1\9R$#6H1_T4L-O_2
M;-[+@G*\ZDK4@%RQA`^D#V@=$U`L)5,>"X2!)(AMJ3FL%:5)JA.N/(N_TE';
MR(=A"^]CH&<-$69@(UN25!,TU.T'H(.@2-T!#++5-FSLDX['Z)^RD%KO'G$!
M>4F[K1:8Y3IZ&T0!]88$LX@2&(#VD-JW(RP$J'"%XK@-3^(U:[VBUJS#%77;
MD^M%8FW<%V9Q`1,CMC:UY8J\7-W'`#7!`]A2"*DM7^SI%G@((^R_<Y`JLKO<
MG"#KJHC2H%TW]@;W7P.7)-$.,)X",2,=@)*P;I\1#N+AR(B>Z'8%LN%!%[IC
M46%4SI[`'TEPMI'&,4D<*G<A"2S!*V$=`8R`ML0\P"[DO`+'$1\A(,2];@>L
M`<]$B_*'1?1-TO43@,LG*Q:J?TR,!&]Q5W#V7-DL@;Q+_(B[@.4\L0B54L-[
M"-#LOWARUP=T*`KA<TRT:HO(SVP2(L%!6L2#,4=8[G":R1J;1E;L4\=ZX0%Q
M`_(`M2:VLX@]]0Q$X[_(^16(%K]02\SS?289#U_*M;*I)^.\U>7(5/QTZSQE
M(SDGNF_AUUS-T0W=V%CX%8(]M1Q$[!L7B+IJG^$?T-3N&1T`NN^@E3+1P+*$
M5:W>2`R2LA-RAYIO-,8X9HW3C42VHO$WEX4#'+6<ONM!L&[J9F+1(H4XVU!F
M(V0>E@[IL+:9#M&JQ>P5V:D<FF7S8.5RH@N:HKTFW]4];-6L&2ORA29F,_PB
M=J'<8^:[A/$N[=^2+>PGT6L)M[^,\<8R;M00=B5=.HBO(QT@GEQY+^[.)PEU
MJ.Q$\+B>(!EKL!D6#D#RE#A)(;E-Z%E33*J(X<AG!Z\5#GQJ@PSDO#1%)*8=
M[C;Z+`=\_P?A[+7*75J+32'*%UQ$,>9Y%6;+JR+W<D3Y&>ZMU38__2OD-Y?:
M/(9"IO79B7]G,1Q1FV:G9$ECT&0RV5R*TPR?AOWU^.A:X5_C'`2)F/"US)&[
M)&)\X]RX-GG]C0S7XI!,PIM+<8IAO,[X*%.^[@)?)*+:D^'P1-[S1#LTD@WQ
MYO8SZ&M68`Q=J]?&A%G`;5*RS]0A[%+-+JYGB*9E$4<DVA$;22I)$<;(3O)\
M(!W*Q2RH?XM[Z]5O\_<;='%S=_^_S8>O371S>YED.DXWS*!39Q><3:R.A6UZ
MH^"K88;C_\4\4LJQ^@83O5%)+4:\6Q,Z]RR,8E9-<Z8TLSAM)-/*!JI`(TDO
M4M`+'('Q*])G0%:B$ZX=$JZD-GMB"4'-R]\SKT^8/[QW`(/P[/J_`>WW-C6I
M7JE5IQ3(1*R=*;MZ4%=IU(V=Z`KW.15O7'H\\^R%>F-"AW%N:61)&V)N08:U
M@\459;!MJI;H[C$5\S2X3WWL;.:.REJC6A^OC-ELTLJRLAW,LEX-!ZCKB3(]
MREM_FL"<-$)B'+>4T<HJEJO5<FU%/EET-N6*7B_/X#?;ER]ANWI%UJJFL3+7
MB4%0/#SZ11RFE=Q"D:D3&NV@22-(UBIL[+OV+WMZGY=:]DO,N]"#B3^B%QO`
MRV(QQK_$C`TAE/]=;D-8T'ZTI2`Q*Q,]U4H\LQ%S92`8IE$W]R7E&EU-HZ&5
M]VW,Y7Y!J]2V9$PUEI],`\K4J:TH_&Q)LM8A70:IKIE:]=!T6',7:L,,E^TS
M4,'K]:C<XR26F<7",T".N);8-_O*Z9E+G8\YGP4DMV;C+&7(9X%E9K`)IU[N
M,;MCC_(8%MF$P!IR-F8M/<RI&1^M");7$Z9?SC$+$>>:8+L2JOFK9N!WQ>8W
M8J]EO.GI,G7NQ#ATYS/;1*JY]IH6RLQ2J!NU%VTS,ZE91=U8))%BE%::-<R3
MF.+<3)C%<ZY9VV=JSC6E7!E;:A6Q-H^%=',>G&=%$\LYKSY_M";C>/NA2F*]
M)?Y=^PF_9IO-8-2J$^/O!:PWE#'=7K:Z.66X[<JW;MY+K3897*\JX15I$QB8
MV^$>MTPFN<T)86;S2"G'ZN%P.C&63Z)F>M:35FO4)Z1<+D%6,J=J#8;9V+?`
MZS4/LV)N++#<!@=-283'GS%ETE]FDX$37B_>TK_3$R`K1?1'\^&A>;2)-]&6
MJRCW@$HXA=L:U6']X[O*1UO7(02NY=&OV`TP&XI?#;D=OAET`NZKW^$.=+?#
MY9&/4@9QU*R-,$=.G#28%[^]?M^362U>F#&01W8@,U]``,H0)[X?'C/J$];C
MZ*5+K6Z4L)-\##HPN8(K#W=41Z,643Q'[@Q5XL$4Q1X>BB,6`T?2L&`0FBP3
M],,M]IZELG@L(C,="/,Q%!<G,RKE9%Z..D6`"P(B<0#L&*9)O"B+(]QA),HY
M&-7"7!-)`V+[/V!;9:-$`A'!T@Y1"I)*1(CK+E%2$8B.I/28K6I\*GM#+'W)
MEBGLYCAA\L?+!%9:P['\#7FFY8@LB(]'%D=]3.V"M*E:_A!(<4&)@$G*L5Q*
MT1ZV2;J,'FT_S>AIW,XR?X/$!IM?K2^8QS8+\16=-<J[!,`C3EX-\\Q5O@F?
MAP,H*:$0)WY,@B*O4)%(SID`R%CUH8[`M<>0XW&^%"<3)@`Q;2*:%76!7,"%
M$.+]"P=;WPN/5M<3AZ&J?)="GU'A)E#/LXF3'V_97+XFCI,%AIQV7+"C)1K0
M?P*[,TJ:(]RG(B.&RRP=\4:8_Q;P&..2?"BI)PZ,%3P9:3O@[A2;%T([7;!L
M`0]`LP[8='36H:(L#1Q6;Y3Q`TBC(J_./DL/V1GX1!*+`F5AHEHNSM3IC^A/
M](F^/*TVY-(2=<D*%NB*^QS(1%>`9/7L8TX#4!/'X7ULR<^XA+_[HO&&OU^H
M[7<_YFK5#SF$':B!CSF1&4183G&6?%DDD6]'+U3K'Q(B^W:BM$Q4E)24QB,F
M>GG^.UG=WP=O=<GF&&Q"H#''-.UR=%4`]_H_NRW>GQ%N+-9W7?*K,QK'703F
MOZA9*:3W7Q'W'&H#_":K`)`)$(0;U5D8V]A+Z^-AVU,7^E[T%:AT.;IVA<.3
M!S#'JIIZ?E$\EZV!YY`_869%S!B[P(P8DNP=$KLB?T25HN^]4F:T4]3J@"$\
MZ%__8EF$M-LC7@DIH/?/S8P.QN+7@DYZH_C`(6VX)>YD&;T^4/Z]T!8N,3K#
M'XGMN'."F;UZBT6,-AS3IQ8BPCD3L6.6(FE%XT-!*YHSPLHE$KG>"Q-?8%-_
MLY3IP^$XJ7>&A?J'@GYT6%@MACD83R@.(K7$R%I]C0<&ED-*'/OD"?>-_B.#
M_<D%;@,$QX6!HP\+1\[0$<LY1^`#MUC?V0FUQ0BA5C"*Y5A2>?C08=KP4!WH
M^T:0#@@RWPJ"CC7R''@.]L7RT/#D<0^\O50K1?U#H3[F=`_(@H<;I[YOV-3T
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MR#O>97D1IO5`-!@ET8WM-T>CS:R'#9TW&1-4\N7R&P@*CF$JZ7*Z]X\Z_O>%
M_@.<5M6U?,-X0^W@N'J(!Q(M0UDX^@::3%_N>@[$.OSO86:T2D4FKX19E)\:
MT"$U("G27^J&;AS1_HI4+2O)/1PD)8>/LRM^E='(0N&6OSIOH"#'>C,RF.8-
MZO;/;D;1H^SP$X'O=)8E&N75O1NW=3A1KU[-F[6WM%APU$[)!"]A>T'+(;OQ
M2BGYK>*6U.5!3TZ.GP(13MT%/>`*A<2A#FV/]508AEM>X,>SDU[BG+W(IXUF
M)#<XMN30YR#KY17G(%=M5!%A0]_?H0]I>.]#C\5]?OI\[3F;'K>8LWT=CEMB
M%-\S:JELXSG3I[M=`SN6Y/?$$9RQ=M%14O$=[,LW&"J)EQ9%8`=A_8.MW.U7
MZ!_AZ4.Q.DUU#%%\XX'T,!7;K9)U&GUF.<`.^D+;!/TDOKVV>$7B6*R^VR85
M^B89N"0,_$=R>F6?!IT5\ZXRQ;5%#(=C&GE8M[EOG+VKN288O56KM2,=O>TK
M\V1K+>#6BZ4BKWVJ#L:+[]DS3U0Y-8]3\]CX[*_M@5HKZM5:XP3;76[?->MY
MPZ@?*6[?G%O7BFLOAY[@_V[A?[#QN5[4U][Z?,+Q)@;/PWCH2%'\YISXK8?B
MD!R=(O%36SBV0!S\]RD.V2EFRWG=*.<-[5B7Q]^<$S>*I^G%4PMX&\%X>>U$
M[1.4-SFHJ9K7R\<*XS?GR/7BVL/[$_K?*_H/)OZNG4"[2]`V\F5=RYOZL8X;
MWYS7%J<<'I:NIP9PR`W@8*-OXQ1][Q;)E;Q9KN=-[5@7==Z<*]>*:V^+.#6`
M=]P`9KGR767:K/;".TCZR]1>6ZN(50FG*;?64'`M+4^.+64HU<@;6CE?KQSK
M-KL]HN($SA,XWT6W>^QIK<?1\;Z+JDBT"'4991@KLX;?0C\O!;S0P;A_=D48
M'6!??+ZJZ=J?,66_BR.'GLBK?^%XUO=//_Z`T'E<>D`<KR^^*?_HXPZY%N.N
M/J.<7)$VM:C?M*R@%SCB4^]7`:-N9_(-9$&[!.(/I/TQU^3/=^UGW7@V]6=Q
MM%<.!2Y5C[[!!?RVB45[V`$_43!SGTRMT:B6P6Q)^3>5:`<:FJ&"QE(%C5JU
M6M^N@I1;CL<#1N[:EUZO3UPN]WP]$$GBTN,^EU^!N,"<V/=X*.CP$1[&M`-^
M\MUG_5GI]_SD)93])"`7(@Z-M82Q[/;Z#E+9!9F6N*@5T>/3W>5OZ/+NZ_WU
M[6/SZ>;N5K6-UJC1C/4TRU/3J_-2T\?.##$^;$<C<4'%Q:,\2?FN+VJ$*Y7H
M2(NUE`LSVV<J$VN\^P,);ES4(2YAV,F'YT9[H;8=D7Q(;`0-0QR,ZHW.#XQ.
M'=#00'RTV1O`+1R>FBJ^W16>-YU'+]3O(L\E!;]+F1V=PYKX$`I7GT819.19
M_BXBV.HB[+K@/!G';"A>DH+DX:Z-NGA`!"_B*D[0;GM%=#'Z&@!UT:_8#<2+
MPOG-4RG4V!F.:=#V`C9'`?%(7*Z@@2C0I@S(3J@A'D@!I"9ZJ3P],;-1?<9)
MI3R(8>=Q*G0_0TPX(Y#G9S2"4K%.`&`@HD\M[!1D=WN&6N"D'.J&G:??E5("
MR9EHSP"!RZTJC^*%RH)2C.`V5'I>'=WK=[$_Y]T7ZCBH!5411-4,]1Y5CZK-
M>?531$TN;HP?L9'_?_:NK;EQ&UF_;]7^!]2<;&5FBU9$ZF9EDZGRV$[6IV;L
M*=N3/6\NFH0D5"A2X<4>[:\_W0`I4A8I2[8L$5)G'B+))-#H_M`7H-%@9LMH
MMIM&M]?-.H&'G&`,Y*4X"^4Y:68_V,*3%3&PI/`@B<$R9$V_1!GNKI*R*DTR
M8P\:-]N?_AC-S2MF.P`LK!`GYPLP!B^50XVQ6C7E_:^CW+?6K*/<M=:OH]S>
M73D3ZGK#79<$X=7!MBZ%J^><J6<]J#=8J-J_RA'?9G9/_I06CE`WSBWC<'T6
M``^HS,>LT$JU8#();KKKK*++]GN>U5W:?M<U*_!$RHOF0SQ?2FG+?1<J-NV@
M]UN(U6DVUG8VG@R'(1]FAU2W"XT+P*7P(^'LH&^Y-K]S7)8X_'I5D;^:+T]*
M=XW4=H?:;!N=9D?C'>HZF(B]J<6M[ZUTM5`3;YEYMO<#+#%Z=39QOZO=(S)@
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M_$,=8:^.,F59`?X=SU[#<W$@#[U3Z+GK:*.%=YD8[=;:U\C4Q(>@T'.3H6>_
MY/S#0<&@#H"HH9J`T).0L7MDU$=5@,GH]2CTI*B$0D\2,H6>>Q]ZZK7OF6:,
MRXI9M.]96Z^R8YCMOM'I'+IK20XE7D#46?LJK3V#01T`44,MT6X<_.)4'9!1
M'U71;?8I\J2@A")/$O*!1)[J8W:OP_,%A[=?B_EVQ-EC6C#OR%;EZ]C`%B&.
M,N%8LEQ5I<9:S;(Z\Q$6\G:9_6B';E[Z/`X8'T^\8,JA8U=>;K!BF6;<7L0"
M3NS1CM@/S4;?E#_]8()C:615G\4#]Z8-=O:2A@WU?!#;'A-91;!T>-F@9J7<
M>79F69%C'3<5-<TY2E35^+Q957_=M>,YWBTT+NN*IS7#9?.FT6];:!/3(1O-
M8VDBGXZ[(N)=7MV[ZK*&+=]U\`?P0EX]P4ZB*!EOX,Z#&EQO<%.8"4[A:@[X
M$L41P_FB_IB5AL]1X=B>H^X`88,P&,L_?_)L:.[&&04>EG^7/#J:A,)19>I=
M[F4-28QEEQ?(.O!S$&NPVU$Y!N4+$1-`W#@(8Q@+S.%HGGC<Y?<CCGW9\%IH
MHUXXPJ+].!IX5=YH@&1D)?35C09S9>XCO8K1S_,K6IRTF88K*#4UZHA-8)9R
M^<='#A(?<QLO:W'+995$V>O/2SN](D)=*H!5[.5!@'SZ['%-^UYWS9KVO6.J
M:;].YM$.UKKJ5OBTNXW"I[?HH.3C^B(]E?S[.;HLA3\O+'4OLXM;6<8D.-6I
MCNYLXV.7D-A6\QH)Q=RY4);/TUWM=)90I==>Y+6(_CP:8)`I$#]XH5>8E;&F
MS<?=K2*;C3IM._ZC/DKSH%!@->JTZ[@""E;SIFJC_<ZSA']7/`CHU653P3TJ
M@;1KW#=+(O\ZPYZ4'X%`?U]PI@T]O'V;E.".\=]IM'*J\&;=$I%HD5-`VO%-
MT-'>#W3HZC(^!'@EM"?B*6G*'<^%7K]1I\+/Y##N!@;'9J-.U_&LYS*JCRLE
MT=0EYZ&8'G!:W&$_3W?8Y9CT37]8N,$]JLJ'R%(*0NX$0U]F'0@_?<6.^9AC
M4@(T$DQX:*L-=TQ1B`[@]O;U=[J[Z^]T+]D<W]3O.^AZ-<^HGGM?M---.]VZ
MPHEVNDD\&NQY[PLD=JO6WTM'+4@BVW>C#W44N5Z+R-<\XC)#'7.]7?[`O6""
M_F^%@ULGY&V0"_4YCF9UZ'@BX2&GI-73%0^K6</:*,+?N0_!OB?UH.V.A2_P
MK`&>=3DL55C#A<)VIZ/I'"!@O.U&0D_7.P[*_$:MSVT?Q%4]Q+F%X6L?`-WB
M6=G#,O'U\6Y[S3I=FGBHEKT^>#`-LZVKK[=W)IVJ=!PN[PI@5A]7RW38T7'Y
M$[E;/U]I0Q;8"+DJ:=$S.NIN&WPN\0O[_@MU$EC(51V$.`#%XA^EE3%DN9&R
M7`([#&U_F.8,I,?R#29\QTOD37GSY_9Q=0%/;85")J7)/\KR"!$O5&DH7FQP
M/Y>F(&L=V(O%4?*2!ZV&R61^8:/"J5'JQ14/^.67GY+H:&C;DY_/1.1X`98*
MN!H4LT.N%3M.D;@;9,(GY,%7>RI'?`NR_N3!(#[^_6^,_9(U=FZ'/@P^^LK#
M[!WAP`!]Q,8U'_SZ[BQ1F15W)OS#W9N[V^"N===27]Z!D(1Z\!M\,%OOF,L=
M,;:]"&7^L=EH6CGII;V]EB"K2)#U'$%'S8;9>A5%9\)+8@FN[3`I[>_U1&V4
M42M1-0/=.G1]1-BGJ&?5&JPJ5VNC7H67[5HVV.7Y+;NX/+WZ<L[>?[ZZN?G`
MOIY?LYM_GUR?JXE:L;M5VRPL-;-\'J,.#,:<O0>M$GTHU&P2JL"+!-;]5)WE
M0DVY^`[\-2XK!>4GXWMH#K0=/#T&)2P;!B.0WU#:8!EV=T.*W$Y#"L0#G_U)
MF@+^5R+`S'/D=`G9+Q'UGF:6==;/+.OM+K/L#;LN"2V6AQ#K1*"U"7`ILXSR
M5.H%)\HLVW3S&@F%\LD.))\LIW666&;DO_'O#I_$^7=P'O,OTH'+O[IV;%-.
MVJM#B,NGWG>%3UPGV&YP^/59CG]O]HQ>LTXU33[4QY0=`@!,XUC;ZQ)6LYZU
M47K_J5Y9R)8)!O,+";C$4+&R4`A'"HL+/VNB1W=6]OYMM<.6+Q;3R^8O@7_E
M&I^L-*W6[_#;O5QYY.EB<;[*IPGJ-Z\B:V-%6AVCU];5CNCO3]01$J9EM(_W
M*'NSSKKU+-N'`"/`G1AUZJ/<MH[5/L63+>I!C'O,DXDG'+7%G1ZGCT-92GZ:
M/C_F$"Z[_R3MNN.I)$GZGV/+M#:S_E*/*49:]RTJKAC'35W-<)F'JW5ZG=YY
MWRMR;N<#J`N_*$`;JGP([E*(5C_+0"$:0>(I)"S3L/8I1-/;7=`]HWS[#H/N
M'"N!<)T=A(5=VT*>Y9%:G#TL,U^?;;SWF'1=I_+LM(V[5?GC28`:29_LN,96
MB>SX!NRX7J'_<LN>G7(@XT[&G8P[&7<R[OJ:*C+NKS#NZN-*!^6U.+!G-IO_
M>%><FQ4^2O:\E9_O0S]DDTJE),N@`@^2H#>BXC_521-QP"9)Z(SLB+.V9?0[
M+:/?[,L'3<OH]."G;KLRD3,O7Y"+.JMC(-O`XR@&%@[`N@#@:WE3@SUR62D`
MZPQPEPW"8"RS-)8==W5LSTF\M&Y!A(^+,$L*>0P2SV4C^X&S>\[A[WXLCC+?
MKJ26P#/PKZ@R4'F4^\F)[_'$"Z:<I\4'/@O['J_N$3PZ3<(0C\X63WZ?1'=7
M@SO3JCH87SR"?M1Z]]&RVFW0!06JGNON]=15'I!_2IQYW+%>0]QOM@C_L+V$
M?Y'9.K(PQ84_2>(HK_#PA@?HJS3;1ET,+SV\TVJPWTXNKMD?)Y^_G;,OYR<W
MWZ[/OYQ?WMYLXNS\&X_B%B8K%MJP_2D;*UF!9HG9``2(ZBR!^<K#V!8^&PC?
M]AV!U4FCB*<*R,N!@+>7V(X#&AX>XZ"/XQ&SV4CP$'6*O`\%&U03/^;.R!=_
M)?":*F<"OSV..%9+D0I$2+"@1HM'`:BSTC=1FP3W$0\?I/T)0D!U_KW!KO*_
MI>V%?."AG@&N_@DJ"H]*00LXO$Q[840[X3*L95$`VI1'H.5&`MHH-OZTP3CG
MXX]1UCSP*1DKW2S+JP"Y2'*,1W>9AV6NI<[-QCJRD;`I%EM)(E5W)16)%,>1
M%,?;W?K2K;&E3Q])S^*_17"V)1]"Y<F9[?[+*#/?F`%/1YV#ZHWX\1EG`3-9
M(7^0_94$F*`Q"05,/IF]@=<LQP(<!Y@K41PFJLZ1U#<RI53-M^A?57-C*ZXR
MS1^:/SN:/]8S\R<2T*X=+I\]QM*)5]U*^KJR7VC?_"!.FS:DCS`.7.X=`9KA
M%S>WY/)EL*QX[8/G0>M#7PR@+S_.+**,<`H_*W_$Q7;"!>M?H@WP?=((I!$.
M4".TYC1"8<YETU`ZNZ5>]6Q6!K[TJ<<!3+3ETW#>[7ZK*;>KPHZW<[Y]1?"3
M>NKND^`)USBP="($R=GI0*SVY</_4-6FAUK4C8[X@%J%P=\@-D&EYN+Y%^[N
M\66/?6MI2:ZL4P]BM*.1S/_%04#X_R`B(?D/TAP)%Q#Q+R8W-']&`,=\;KT^
MJX^UY.K%JII:K?5K:BW=VGBV'$@S_6_9\L&*=-"0:$C;'%)!LR]9L->]6M`&
M"DB9[6T4%L)U6"878EEA)7;Y6O_JPJ>*4P=0&2Z_FF*7F"#Y5,E'^OOYN'9?
M,(Y$M:*H=J]I250KBJJU<U$=AE%<(O2:C:G^+#O$FY!KQ'Y=$%NB6/1*##^U
M(W5QM(,?BN7G%D9,N>#;R`5N-8V.MA<&$R0($@2)+4"BL#^U$<-+6"&LZ(65
M,L]+ZX,G>A='(LX1YXASNG"N1'G6.4B5NRAI[@C%I12$D&-)D"!(U!$2^QEK
M$%8(*P<;E^I^O)]X1[PCWNG%NX(251_WIR0')>Q3*C@-:4^&5.+L+7?JUHD6
M7A,CU"WM<'L)^_FX9.9^_K60PI__:!>O61P4'EZ\\CW//*4T?XV01VG^)!]*
M\]=65+O7M"0J2O.O%3RT3YJN$<LHS9\0>PAI_EG=TW\NCI#2)[:QV65VC59/
MUR+?!`G:_R2L$%8(*SI@16M34^9I:9T^H7>B,'&..$><TX5S)<JSSD&I2NLO
MU(&DX)0\!G(B:P$)"C@(*X05P@J9FGT.3G7/$R;>$>^(=WKQKJ!$U4?*[:?<
M_H/*&J<AZ3"D$F=ON5.W3E#PFE"@;KF&NN7VGW&'C^]YH;6GZ?V[SP\F\-4I
MT972^^LM'TKOUU54E-ZOC:@HO9^2I75C&:7W$V(/(;V?JOC7;)NKU3?ZS?;:
MY-1CFXL@09`@2%#B!&&%L$(9%8>40$R<(\X1YW3A7(GRK'.02E7\=^]%4!!"
MD"!($"0.,=8@K!!6#C8NU3UKF'A'O"/>Z<6[@A)5'RG3_T69_L=-RO2G(=&0
M*-.?,OTIT_]0P4>9_B0?RO375E24Z:^-J"C3G_*F=6,99?H38@\ATY\*^:\(
MS;?:[^H8[79W;6KJL:M%B*`=4,(*886PH@-6=+8T97Z6UOD3>F<*$^>(<\0Y
M73A7HCSK'))2&7]R&,B%K"4B*-P@K!!6""MD:?8X--4]39AX1[PCWNG%NX(2
M51_W)[7?;*;I]L_$WMGSA9,`&%]OTJR5;/)6X$$2]$94W'#.WET&,6<=5G`2
M6;85_0[$%S)D9"P"W_:8\.&'L8W?6,@].^8NBP,6CSAS><S#L?#5'X,!&]@B
MQ%$D'+_A(X]IL[*>G0T-.('O"$_,7G%&MC\$VH5?>+O!5K#W:T!5PI#-+:6T
MK`KX;G0Q!3C@``>F@$IFCX,$.1'R21`B%V7^"6?WMF?[#N!_Q#G\6;+?<;)G
M'2X><(Q&_N/$GJ:_`$\#:")D3A*&,"PV#GP>V^$T+<P@GRBLY3![,@F#[P+$
MR8O"NN>.G40SH8GQF+L"GP%:HA%0>X2"!F[%22CB:?H<O#``X8,\)4RB.$PP
MDSMJ+`IODKM8KGC`+[_\E$1'0]N>_(P9XC(OO)`-?N%/DC@Z$Y'C!?C;+8CN
MDQ<X?W[\^]\8^V7VJO!%S#^+!^Y>^#$`20!?3N303QPG&2<2KB=C&('XKX(<
MX`]Q<,T'O[X[B>ZN!G>F==<R[S!]_!U+H#WYIV_P`;Z[W`%F>2#;H]:[CY;9
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M`Y"O/V4CVV7@T0(.!AP\7(@\[.^9;PM.:,&=]:;L!]/L-HX94.&!,!L,O>^J
ME^V0LTD(;X9`,X!A/`DB>`+:_-:X:;`!=U&Y2_]9H1C?Q<:""4>P@#\/B(J4
M=P\N.\0Y;F14O1R"KVR'CJKJ[>+YC&""V&4.D"7B^5;4>R.@\.C>1J*0.C`I
MRO_CRKPTV!GX[1"')1`ZA+$M?.G?`\9#"!(P"B[R\4=H5)U3QU>&TG)A!)"`
M/R^')@-P(><+/A'"C`(YI4Z^8AF$&_""Y\F00=%B>U[P*&.7D1U!$,&!O`@C
M,@&QC(P2@\$`WF4".%XNB08[F86:WE0)_P)3_C'TO`9.^0F.P@4>)AY'(Y!X
M&-*,@6OX;#J$-'C)^GDB)&3H>B+(22_GD1(,1K"/P,MH)":S0!;;1\KFPN!<
M#E$,VF?-"&F9(GNJ\H!U((.OMG`W:9\ZYA/7HM#/NA2\R!19K4WWOY[IL:P5
M^_^<1]O@&MZ@M$>!!PHA.O\KP0GXFJBHTVYUY[WZY[I[-7&KAT;=+D1'&Z'M
M-%W->%6LWNP^<8<7.W@!`:L#IM]_@MDU^K\,?&<#/.CW*RG(>W@9$2OSH=^M
M!$4E#8$_O.7A^!1Z#6TGCJ["KV$P#.UQV8J0[IY<MZ&\AM^O_CB_OOQR?GG+
M3J\N;Z]/3F\U=>MN"PX<+O@.??@CKF5*:QZQ01B,U9B'P0-8>FF&9_;9R:3.
MW"3,_!BPYR*0*Z:/(P$/X6_98K3TB,"$`RB47R<4K%QIBB?8,(:/RI>9$:%\
M@D(+$?PX#-%=2-=E@1"9!B@?R1<ZI4>GUCG!4RE0%V5]<==`URBS_6F7,[?+
M9??3.2?W$9PGT(JXAJ1X4\*+1Q$KUV6HEM/E<]C($SZ"/R4]XR_R_=2IMA:=
M:O0I/8[$I)2*-,(N=%?2/+#*X9-8+E+CG_\W`>\9>F@R>QARR9;9WXI.EF)%
M:$]X$@L'N#^T<<&8G=\'GBW'!03?)^&P;.7_>:!7SMCY7,GV/]YF"N,'@1]R
M=IS,V/%^88P?U!C%;("Z3?`K7PG>;$MX-8T%.-OH1B.X9IAZ`JDS/K'#.,/&
M&<0%,`$-W&\X"\X,=CKB8^&D,=0G$7C!4'Y-'V2I/8#V(-P9%MH]"<=3=C.Q
M(2:1'!=1),!MS]X#&L?X>X91VWW`^,4M`6O!9P=B@C`<V4`#!'<P%]B#").H
M"&F('T`'H:Z`0.GDCXNC;K-I21+2+RUC!GIL?`$4JDE\&V;_A#NXE.A-I8KY
MC=^'"6[J+$YEV_>#1`X@'MD89Z4[1LAZC(TA",E5Q6]G)QC8P,\.YVZJ4D"P
M_A`X!)IN"$%&J![/B<9//>OX&,B7`V8>MU&K!F[BQ/FH9X.;&PYN'N)0LFA\
M!@:!@5`(+22AW`@#L@9!$K*(#]5B'PJ(VTK3+_)8,@YC3AN"T"%,M2'^F!H)
M$!]\DIN6<EL-&.7+_;>YQ8)(?&=3T+)`XP`Q!YJ-AXY`*X"J,)@@U>EN'&C(
MC#!`&(I&[:9!H,T5C@8BA+&G#T$D/`3"A%]4CSX.T_$2B&2_`N40Y0('$E>H
MK<\1!-SQ:,H>`B\!`P(N,K+[D7M88AWMBN,)7\Z`["5E!]'<10X$VQ`<RX#[
MGA=4>VK((MQT==E?@"&(6I`_0%)+223GGOU@"T_&N(-T`2&;))D7.!..B!96
M7JQNHY.MO&`/BKP?NJU&?_;S;)%@YA1(DE&@+U3[.]K6/1D@'U,^IP->0(':
MGI48CA+'X:"('GC^1X3<*)U2"FS%N9ENL/LPM!FJY)00<KL7/L'81HN*!F<J
MZ(Q5$+TXWZJ;9$8^=>T<_X]R,2:#-38Z@ZG:>'9`Z>+J2>$=GR,K4)OA&LL]
MKEQ)Q00HQ.W&`/>N9YKK>26@2,#G!9`@QP8-XQ&&#,72%&4,S?0F""R9X(\_
M(,.:.7)1N=L%33)3$T8!U6;7+*`]Y&-4?>GLPVZYJ[L;X_,%-^;?YJ7YTX4_
M\!+N_]?>#Q\&AEGJPLBB(YEA*O-A,G_B=A1RL+O7'*TA@N$$O'Q'8CMU+<I<
M83FMS&83=;O-,-<"IXS,[H"P5V5!S'D+0)2+#A%#(:!154*8&5EX-UWR!!)F
M1-Y"J!#-DG>@AR]I3[?<&?G2I^)H7)0K%4BEH:Q"N255]D#D<0+PR57+H)*5
M+;6"C_-2>@O2L7MF>3\J&H,L4H(7P:(T6K,I)M=L`]0>02RC->A;+E-+7X=)
M3RC/6$J;T<NF(-L'`2ZHRYA79<2E^4!Q%O`J]LS48FIV5@C;,E,._C+GF"44
MCZ)4>O.1HF0U"NIEW-,B)[#775KNMY`A^(J2O>WU*Z>N^_L.NBZDW^UQ*:\-
M5'K;2@4KM#[%:JIR6N??SW%^%_Z,$SW_BL53EQANJ@Q7)SAMI7`@ZO^=0X+$
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M`!"D2$FD*-E*\G!.$DD$/@"+W<42^VV]`ZB4>7W>>TW8RV5M'V/6]N[`,V',
MSB3GN-/OG+<W&4`.D'H'4$ERCKO=C61G7^C+RDZOLTOT8\51L2OAZ9YW>MU-
M1I"#I-X15),>D/S>1O*S+_PEY>>\=7I>%WQF`/DW,<[4*"/=3K^7(91(=58:
M1Z65;@^Z2W*Z/8:2J]7N9ZG]5J'P/4TQP[_9"8=?NY_1_D7=;H6NTIKUNQE^
MQIUB*[N6K4&W507=./V;^O=;MS_HII5"3I<5,573LF=GW?9N`95<O-Z@?UH2
M4/!@>9*@]$*3-L`_AM[TABD9Z)_CV95B<;C3)`[[81391P81-D/W1-LGC?'M
MI^'UZ+_#^]'XNC&\_MCX,+P;W37&5XV;V\N[R^M[_H9.W`5W2U]MYM[P]Q%2
M`MP\6L&3U6R`5)PTWF)RTY%,*SOZC3*4&Q/AS^E'-F6.4HH=YYTABU<P]YF-
M0V9)DTA@2M4X<!XP%52E;W>:#=SIG!FG,M<$)F;9L60!HQP_$"1,N%HL,8QA
MLJDG_HR=QNWU4'*ZI=@P='86)A.J1P+,[>:T<<ZACT/LPX'',0M]/G<7RRQO
M\\"?!X(IH.>N%6'N'BQ1DNZ7SK_#:<(T*\R.A45S(IRUP+>FT+OW0+.ANN11
MB9`B1*$F7H!/8&O:D3&T)P>IT$3XQ!1]1OI__N3!/(BINY`)DVI,F0G$#.:/
ML?WH>)[3>(I#.W:MH#%=A!&,^''1F`;Q0XJ#@;.2L35\-)^TH-EP(F?NB@!4
M!#$M#&'RW)4T"Z!.8E?QKV#+,IE_-,'YMIV)S^EXODL)^0%38Z?ZN=)9?MD,
M<F)%B*>+S"*!FA0DJ9:'S'9>P[4FCMN`C0<6#!^FAY+DO]!ZPI31`&1+S--L
M,7X@8&L"IO6PEY8,5+1OKIM<(;E@:Z0Y1XASUVCY=RI!%0"`BH!)B/+D([/^
M&L0RST8!F8=\)J$7,G-4864BF#H;.0H-A@UO*I-1*?D;)U!XL6-FIH;BP1,S
M>!!S,!,*H7B.%/";$B$=7B(K4M73[.':QIX%BQP1D24"84K+-=Q*,`TSE])\
M97/$?)]F9F'MR+Q%26MA/`G%5%B@!D/)<5$*38J.'\DIK*)<YF7B)M5T[H@P
M=UER)4BC(U0Q@"HX<_OXYA"O*9+K<"?P"-H`Y/9COA>>2NP!=!T\/T=63::F
M0N&&[YVY81711X-_D7&D61@^.;@1&F^//@V'-V!J%=\E\W,RK191.1#;A%PQ
M$O([Q\;R`4+^[/([4V82*0_R](!.>7MT=WD!C<Z9TY1TBX]I^-#I4P$)UQ"&
M%*`6D?RA8`Q\<[)-+BZSF`7S`/D1_)38R?Z,1<#D7#@RT@:*2J6@YT/:EI\M
MSWK@&]R/)+9<ND,Q!Z7(,<CA9F(:W].<)>_S]&[&P9(F-D3[0*0CW[S&Q'FT
MW!EREI`\NF"]?).J@"I8'-ALUJSD4$*MZ1^QHCJG)8$MW%3;$,VL=!.>]$(V
M#3(59CZADAYSX\B3,-.HWN=^2#P)3>W*P$\T>03O3-L*'QLS<%(2.ZJVH*2Z
MJTUAA8]$X#)!=@-+::P_P-=*4UGD/JLT#V]@E"*'E(6I8E,4R)X7$ST$&5]H
M_@J]XW;K^%]ZF$CU(GD1EM0]CSE_U@JF*6$$)*8F5$IJR9!V&D06=@TR?25<
M@=PZ<\FP<^$D=&7$OXP8#VNWW`DTJ*@/\"],=@2K@Z>J93X0S=Z(U,U.'LUW
MM],_Z2MND"89_`@<+,$&C)4]^W$\G<HZIX@BC5)&1=303647N7A1JLH#TCT'
MBN[9LJ7M@#DD!J<P+.:;9DS$KT5>^3>?G^=M&:;=;IP0E)J$.Q(_Q8F@DX5F
M!,&6U/$FM-`02V*MIMHE`58B0F4,[2'U=AQ(=AHKRC!SIMOY!M.,3UGVHX"?
M34\:G_W`07<53D_P&-*GF4M(-"WRQROP9?AV$B^:EC]#X(U2\"R9UB0EUC.M
M"S$S'=9>**8,]6`PB0#7QAQJD(86T<-L2AJ*_Z5WV^NE$;V)@S#&8Q<Q?^'Q
M5;6LN(E6C19)CO@*@4ML4")RE:[@@QVSAZ7H!YFUR.3!PR'DQ#&6XA`I<K&U
ME'F6IM*E$;_I=4YZ!AF92ZX;;G^C9]KF2IDLG(@;-59/\BGBU_351%`D``:0
MVS-%2Q3E4E/I@*55=M6N5E1T)"8F&UU"H6BNCV?2.67HUK!0G*1VPU55K(5X
MO%"5[7JIRG;,KIR@TA>)5I6Z.RRE,HR6I)E\..W,X>'F&?2N/B.^Z;82J4G9
M'(HBTLD0O2T_#FPVPJZ`-J9XD'RTGAU9[8%9XV?J_H0Z_QE:'Q=[DQ!'$8)8
M^@`TC*3G0O.JN)Q7&F]-^)Q4T/OF!U\I)F?-142FE6SZ`9[T3/]AXKAHB)$!
MDO9W&,]FPA9T^PHG%'E78YP#XP`0822.B.<2;MV$F:S=D?1A:4<%+0(N&!^E
M44=R@)-#8M.$4[2`MYK(+U%EYQ+FB2C<4/$W$VI8\'$P7BC+HV2<'%G9A*M]
MP+?,(,FQ3%`K#R#JZ!^!5N$#2OHDL78T-D4ND5,3Q^):"S3PL`9,5TEB;*6"
M@Q[:$!1-`7W8D7JI8'2I3T!XO!(Z@N%[:<3Z5*1]!%DQY2OZSA-BC[/9EAG]
MHRF/<9Y8.Q?OKAG2T:':=M')-72GFA)T29C6$WW%O!"RA)(L>$XK2O;F\<05
M-DXD:(1G*XG$*%U#4ISX1^SGJQHT+()&P"'$EIB65$6=]<L1)B0E7<"G6HH?
M5MKXKX3&\S*,Z,S$,_4E52B(AG*X[)U$4DEA3AWFR`T1Y$1`*;@GM7MH1%-P
M^9^LKPZ*CS%MI$:DL\)AF=E,Q:5U)5=5VA7/J@6%5^6NG.K7S6342#\^8.]%
MS\FW'=+!7!L+R8-D>HO:\AG%%?@9"@G3J80XKCE2PM$(+KHT%3#R0.D\/S1F
M"M2DH<L$@$)3,_E#\G2&,:B2XFE5<=I(5DW22ZHF8L%R`.TC;;E949BJ*<GW
MCI:LP>7Z>&SD-S0A59_2M>*:*?]$>K9;N'NO9*-3`#U*!.%"B97]`VSUH7Z)
MD&P"_>)DZ=2&!QB+7GXR":\9+7'!QKJ*8ILL""D$R;=/P8<H=-Q9DPR#^1Z)
M"A-(WFC\3C>)[]M!JY*ID"=[#X\0Q.8;<%&R20S&!JQE&NN3M9!;27#--?H3
MPS/6$Q^UC&$\`PI\)<HC@)D23UB/S39"MGB40^6>>JT*."-\6R^\9]\EC\R!
MG_D+W@L8K'3QB!8G(UDTT<;3L4T[-TEEZ,0!@_^[XG_+1K2)#<T<>IN#&LH)
MG@4=(`(=YQ\1_;_`BGNAD+</YEB$31$L*SL%"OO1(8/,E614W"Q1"REW2B^*
M-04_#-43:^H5KM2Z8#B^`M*Q\,/6$;>.TJ&V'-R!ZX4+Z=<G(649\M2FSSPM
M&@:$7]7SS1A?%S>@R+_YZH2<U]#1=?VF8DK:)<=Y+_+9L10AQB^;NH2B8=J;
M7.-15D3[FSI+IT6N8#T*4J7JO@B7N6:'6Y%+6]>12]7.EHM;;K]"_YO?KCWO
MG%;MOJY<JK.S(@1%*4R;@M@\.ZG5JX0!A1R$%P]2STYR,?/:B<:S>^O[#3F2
M\'F`!^&/#O_9^!Z*]YYP_W$4!;%SM-W5VG=[1;7AY=H7`;7N@FT>J)JK+;8[
M.6*TKN#AYD`VW]7MG$V]#L>-10Y1>.4'M\X\#FR\&S>>H5?M>U2VLM9\P$'Z
M`OCZWNM!NVT%\#WCK%P9O"K.>W_(KW%'8"6]!_1,60_6N?CG_4R=][6]UP*V
M6EI.*U]0]P*U9'7>LVZM4#];P5>'$M.-.VMUIO:T.]G:K!MAJ`UV7<I@KVBW
M5@G;H+V1Y^,;%SQ^\*>QA+$L(%ZC7)P/!H/58E&(HU[\U8IT9_+<7QA\.7E9
MH^PVA1[($O=D:6ZL8!S0$6OZ.Y:#!U_O#@]]I7RMKHET='T%HGT"6-L&V(TZ
MK0EHX83N`R?](!S&T:,?T)6$,A/960+888Z35A'$;'=;0BN<NGT@&X5AO/6$
MK<'#?6R!I<0,U01E'$=XGVFJ7E?O;&Z,CK9%5=\L;0B*]N=6!\1"'-1TE;XK
M.0+KNZ:7`^%5X"/AT#/&]L%+0%:9.NW\(+NU"WO=$M[6?MZND57WZ:H@0Z6`
MER3`[E@N'`HO.>9:+]O/H']>N+KY`.H!7.V0U^Z])-ARR]^N#2K^"IRXSU:$
MWO]B/-O]B:_?SP2<2^/9R7#JU!`O/HI:M$FU4>0?#JZ=[>*JIYW>659H"GO:
M"M/&LW;:;E6%=.O,Y;%J/#,)V^K<:-T,9U!1G]L@JW8X;NT+5\G86;L2+KX@
M",O],;D>N`,2G.[IH-7/(ES1]]8PJUE10/D"($M:3P!Y5B_(D7<CTYUJ=:%.
M>YM,INZ\!J3;6L&](:QLX<HBC(+8CNB.(#QQR\ER"4'9?EASBJ[.[.2FS/E)
MX_;R[O[VR\7]E]O1]:?#),<9>4GBZG*]]4"OJS.5:3CZKM,$OY[&MKK3A0D1
M=%<<O^D,_@K38TJ%3H",D.D>/WC3;K9/SYK(&4PI)GB],I")N*HN?)*=RRE\
MZL*ZRL:T_5`E@W#[R0-OSDX'U/B*C$UUO943H\[.^^J!];D@.KO7&"+>94]R
MI&`:_FEY,69;IZJE8TI3,AH:`67[ZNQ=3N:=6X+;P%PWU<!A999<R*M0,K/:
MLNT`PWA\I]!Q:*Y@+OG^;G)+3]U-5LP:1NHM?IR2U\P*S%W,!4,BI%#FH(3O
M?]S"]+U!R<+T_7[YPO2=%<7LM_W<X/;^@:L#'TK!Z$QY>$[;2O[M4-B7?ATT
MWC%'B,PA3!5_?/F:X#^'6+VLL+P57H+U5_7I^HSF!VGUK$BY#\F@I1=08-!>
MDS36."&OIRC,H#,HC>755H1YS7L@[^1`R??:;_ZYML`KK'#X8Q8//GCK<:</
MEBHL^VNGO/!.>3MX377$?BLC^@==-.Q7_<J7\5KI5)B,J?O+:7U1]=,_/=3*
MEC^<1OK92O%5>2V4?K%$MPX_(%W#A1DKKO<"5BN=69'?9W5<%>]991)_=H2J
MW/O!?FM0'A1>G919RSDWO,K><.EBF9LTB*4.*@`H\5:\U>F4ZO\_#JIT$'OT
MS!^<ZQA?7HQG'X4;PZ>K[^^6$Z+.$E@XGF5J4)9$L[NAK):\Y:%TS_JGW9T/
M9>DID&YAU[HF[<[IH+/)0/*Q[&H8.UN/5</XR_'QE:141[IWQ'-\#%_]_=WW
M2>#"7_X/4$L#!!0````(`"](JD`#:4-TO0D``.6"```5`!P`879I:2TR,#$R
M,#,S,5]C86PN>&UL550)``,IO*M/*;RK3W5X"P`!!"4.```$.0$``.U=6W/B
MN!)^/U7G/_BP+V<?"!C"+97L%D.2*:K(D"(SY^S;E+!%4(V16$E`V%^_+6,2
M+C:6#8PO[%,2:,GZ^FM)W:VV<OO[V\0QYI@+PNA=P;PJ%PQ,+683^GI7F(DB
M$A8AA=]_^_>_;O]3+/[Q:=`S;&;-)IA*P^(826P;"R+'1H<S(4:$8V.X-`9D
MCJ7QPD9R@>`3KW^C=F5>F=?-J[(QEG)Z4RHM%HLKKF2%)WIEL4FQZ#WM$Q+0
M.[1S'UNY,M^_Z7A/9O3&J)5:I4K9K!AFY:9LWI@-X_GI7?`)D(Q(J*1#Z(\A
M/,T`;5!Q5]@8WMN0.U>,OT++<K6T%BRL)&_>!-F27E37LF;ICZ?>BS7&$U0D
M5$A$K8]6JAN_=F:KU2JYWX*H(#?";=]C%I(N/Z'C,@(EU%_%M5A1?50T*\6J
M>?4F[`+HP#!N.7/P`(\,=P`W<CG%=P5!)E-'#=S];,SQZ*Z`YH04E2++U57[
M7UXDT*%LXA-R%-"7,09."X;J\=N@NS5P:#TD3!&MR"@7RZUBM5Q2DJ6@;DHG
M&]_[+Z(_ZD\Q=_4JVM3NL,F4XS&F`LRQ"S-@@GM@T/$A1'_2>5!VD!@_.FQQ
M(B@;W7GCM9!CS1P77@]&YXU1]7`L[9L:P&\24QO;[Y\2J1X`\ZQ<-HK&>Q?P
MN]>+X77CCA+&Z3!KJT='S2K&MY7J#=B=.B,DAN[\@67P%:&I&K=9PHX4ZT^4
M^LUBV?2FT2_>Q]_;0FP`<-`0.^YBNO'E]WKUNE(WFXUF^=HLUYO-2GFMT23&
MVIEQ#MH[.&1/1HV\43'K9KW1J->K9J/6VACYAC6T^38(Q*UU__#KGH%L+U>>
M1$G,)A.WMR(!@M?M1YQ-M#3J/9]%P<*XC3GLA05C)F"(;*H>CYR"L<#D=2S=
M;Y)@2DT]M7[`CX<_9V2.'#4EV[*#.%_"?OT_Y,QP`(-:;=/*["&R]@F.#U6'
M^"DGC!.YO"M4$IJOEL5F`&B`+0S@A@[^@F7(]#W0)!^<1T;H45U)-=5].<9<
M9WW>%\P'K9JX/#*KJ2;SD5!03@]\/KM+(1IX)6"E*VQ@JP'$'FZ45I(U=^(8
MX*)-VX3VZ6?.P-^7RV=P0R7L1&H7FBK?-)CG0TTRSG)D:-%F<T(<;ZQ,7QBU
M=%?G#]F,LZJ/R:/S.M5T]@@:$H=(@E6$_B*9]6/,'!BX4.8JEP',AC7;4F:C
MWFI6FHGC.^Q)[`NFSU!C:7W?A#6A1@L*$K+?M?_[C);*^=4+![:%4\USO&A`
M`V`F0KZ'R=1A2XP'V%%9;^W)'-HN1YS'PYH)?[+'Z.M7S"?W>!@2Z/M(YHAB
M771G#@?W\^[JD^__1YR#ARM4>LE5P0Y'_D(YH"<"L&B^8$*K[3T>8<!M#_`<
MTUG(7NHOG`-68P#TV*VE>C%U`Q?M'31`.D?\1D'H$5Q/V\'(YL80&HW["Z>:
MT:.B''VXV7"&/M023K6?;'Z9UD:;B7RY=A+&7V&YI%@3:B92;L_<\RQ<4(?.
MKGTDT\>P)C5^^7$]=*FM2F"3":.A).Z*Y8A!+6@ZFVLBF4/;)JNA/"-B=VD'
M38E4X_)/'?I+YXC,*`AU]M%D(M@Y=MC4*]U[Q0]48@X+OL`0S1&+R+9ES28S
M-U%V/^.$ONZV"(QVC^TX1Y9R)F6$;MY%?^_LMK13B'GRZLSH%:V;!`86<%;V
M"C@_'F3T1\;'HPQXEK'U,&/U-.._ZGF_)E'JZ8/]"Y;]T5?T%KP3!K50!E%O
MMFH-L]%J-*J@FUHR*P@,:)_''1Q;,NF;UU'5O#_!PP%FXO0(@D&VFD+T=87G
MX6T*:@E:Y`/ET\=Q.$,^K$:"=V:&`\X28%P<([61K'[VJ9=?/WBX$-XJA0Q&
M8F/GT"$FX*0X!?<`"^GA6X&%#<U-P.Y7AFFUR1V?,>!FHI*W/4?$4;4(CXR_
M(`>_8`L\0I4.^JQ>FQM@Y)"_L/T9$1KXVDB$+O)C%R=#GXF<9W<R180KS[<_
MZM(Y3`77"PZPB`#I_)$?!6C$\"FI4\AM=1SPLGTD4TAP##],%UBT];V:#)\#
M+#`H3+UWM!'D'_:S#[9)'\>Z?.TS'1UHJ(>6BDG\&5-0B0.PVO:$4"*D4M`\
M)+P*:94GXN-`#9WNJ:#>WZ2[])DS"P>NY2&M\D1]'*BA+EI`YO/(P,RK;%J/
MN,,HF*DEP;%4!6T`H$<L9:Z/&.\2&[E]'B@^#>A,E`*Z@6=`=GN=3'S&,$I[
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M75:HW9[`YD7^\JL,B-+T`@PAMAK._'),@&^H/)15L'-/Q)0)Y/1'OI<+ADCG
MF-DXR,^=:3S]:;!R61^$<L(T#H,_A'/,>PS@F7@OYF6,.'9O/E;Q#P0_AU9U
M?^$+8#T"\#._EARP<G<8]6Z]5C4+J[JFMF7Q&;:_LHTW1OS6<=VV.>;Y>#WH
MO*R<JB4^3P4_YUSD-2N`&F=*[_Y3$)A.$SE5A6`SW4[AA50>G-P\CBA(:)TI
M)_!/\?])O84CWP8H_^2RD]WA=NG^)=;KVG?O4I;@R#]V9Y=F%,<I9FTKNH6)
MIUH25NG+'0#>[8:>0[R^_VXS'%H#V[A]PL]X3M=[WJWIS)I:FU>ZWV4)4.G*
M+3_B&,JG@_39T\\[AM)51UHOEH!IX<9H7UG;`DUQ''@1>("9Z'>0/C,YDM-]
M(SE2&=DHJ-\#N?MO`70M9;?=)1J(E@ZR46V_A^T)\1]8JEWW(\K7M0V_MI=H
M']IZB'A8EMP_W;`PML4CJ%&E?V!)?$)2X5KV1U'L)6H_EV`[)]%))D[?W,DA
MW!N@.DP$_P^_';$+,`(MR-'.VM(5P#P2BJAU1`#CTT'Z[.+G!3"ZZDCK+6H#
M//7VS/YH\Q;=P!2[OWCZ3.!(OOQRZQ&@9RL4>60<T,VX-589Y5'PP;U^PPLP
MB)A*.'<T$O1F#I%CFZ.%*AI[1EQ2S,683$$KP0GWL#8Y)CD^_FR4W6UZNZL*
M%*FBZ`-+_X$6.;:#N.@S$0=L@NH*,5/_4+S/5Z\*';R-/+SAA9E$!"7$C![\
MWJ6Z+:E!#6';@3_^!E!+`P04````"``O2*I`"LD=M<LD``!UV0$`%0`<`&%V
M:6DM,C`Q,C`S,S%?;&%B+GAM;%54"0`#*;RK3RF\JT]U>`L``00E#@``!#D!
M``#=/>]SX[BMW]_,^Q_XMIWI[HR=;/9ZO=M]=^UX\^/J>=DXDV3O^N:FTU%D
MVM8[67(E.=GTKW\$24F4)8J4+0O<?KA;QP8@@`)`$`3!'_[R91V2)YJD01S]
M^.KLY.TK0B,_G@?1\L=7VW3LI7X0O/K+G__S/W[XK_'X;Q_OKLD\]K=K&F7$
M3ZB7T3EY#K(5.4_B-%T$"26/+^0N>*(9N8\7V;/'OI'TR;<G9R=G?_S^Y"U9
M9=GFP^GI\_/S20*PJ00]\>/U>"R?]M%+&76&QQ_[[N2L^.5</CF./I!O3]^?
MOGM[]HZ<O?OP]NS#V7?D]E,!^(E)L@B,D&$0_?;(GD;8:$3ICZ\4]KX\)N%)
MG"P9YMMO3G/`5P+RPY<TJ$`_?Y/#GIW^[=/UO;^B:V\<1&GF17Z)!62:\,[>
MOW]_RG]EH&GP(>7XU['O9?S]&/DB6@CX:YR#C>&K\=F[\3=G)U_2^2LV!H3\
MD,0AO:,+PAGXD+ULZ(^OTF"]"8%Q_MTJH8MF+L(D.07\TX@NX=7`$][#$\[^
M!$_XG?SZVGNDX2L"D)_OIEJ!WE=H2:33P;A\B#,OW(M5%5/R&\)?UXRO"L?T
M2T:C.9WG/`.1EO?+G\'U@A,%LK%?(1B"DL1)=0R\IR`8@\J__4:\Z=_!-_^X
MD!8\B>:7419D+]-H$2=KKF23QS1+/#_+"7'V!25+O-."14"=)%4^O<3/2;./
M!K$EQ*D?,^O99.-0C*Q`7R3QNA-CDHVX`](_PL=P5Z**.`E-XVWBTR[O,7>@
M_$G[CK/@C/D3A@F^FD;CS_>O_IRC$H9+!#)1L'_-T?_^PRE_8K^25=[/,!(1
MO4@V%B+EX;(LO/21"\3FO:7G;6"R.#NE89;FWX`MG8W?GDF_^3OY]3_NV;ND
MP.2#]UCZ(3D`.J!A[:2=53"*9HBC6$"3GK0]OJ84!1#YE8.Y\.Z9CZ=3]C$U
M":8`(NM`C>5&/2B@\'1AAX4V?0!0PF$/5HJ4^B?+^.ET3@.A#^S#KAJPKPKO
M]L#([DA2_WG85ZYC#U[T[F^#O=[F!^L]/\`,]2XG[(ES>.I5Z"T;^-[Y??BW
MV<A@_CHK/P[Z/AN>7'NA!0P!H*&M\Y8F0<S"C_D%\Q4M&KD#AV>OC0SO&FX%
M",6"&SC0F[(`9G'<G`#XT#IP%:2^%_XO]9(K]LWN3-T*B:<'&J9W-6$'#$47
M&GG0:X,`)P!/.`*./@BEM-.("BRV3C0PWJP5"B"B7M2X,&J&=!>#ZH988][1
M90#KRBB[\=9-TT4SV/`:T<9NK@Q-,(/J@9Z!F@K()7X)2P!XV)=_SE0P\<)I
M-*=?_H>^:`6JP6&]?@W#U?>_`X2@`(T<Z#1``A,.31CX4#IPODV2RERFCQGU
MH,-K@HGM7!ET<(/J0SL3-960X)6`8>@84JCE51#2Y)P]=ADG>L>P`X7E%AJ9
MK3J%"@B"2VAXOLXA<%"2PPX\(\3K=1S=9['_V_W*8\,PVV:PJ0<;I7IWUXJ$
M-E=8B+(S<;1@8,PB1G:T4PK')!QU1`0R4;`=R"+/%E=!Y$5^P,+E.`U:MN2Z
MH2)GFBW$:LP]M^#A9:.-3-7T[Z,70@$`4SE*L]2)/:M)FC)6#+JU"X2C1<VL
MJOI2A1A<,YH>7\]^<B"20QUE`S:C24JO^^$43S7/O70UB>;PS^4_M\&3%S*C
M2R?9N9<D+\Q-_^R%6]TNJR4NCB)W$DS5;RO$P=6^`U=UC\C6]U'$@$B\(!N>
MYCF*16SR['2;51PB""Q#AA"!S3Y)=BPAAGH;F5(?U;L0@$18($?X!P5]1+R,
MY!0()S$BO%3K*$(^T>0Q;G?#O8CIPP=:HB/&$KX?;QD'=]2GC)O'D-[03*[9
M=1-1*PI2G&$A1B7J:($?/@8Q,E.?YR4*20J<$Z2PI!?F<5S6(;R7."/"L$9$
MXFG<TW`6/<M6-!%Q8+L=-P'B6*^>9=5FZU"#6ZJ.A9J:<$#BR]RGAQR5VVB#
M$XI@U`'<UV_SY@5,X0Z0')L%H]Q-Y6P2[(7C;1*SX#5[N64\\EIC%AQM(&/#
M?*M&R'84'`6V$4/5YS;XP=7;S$Q-B7(4'M46\",2T0S6(Y[O;]?;D)_XF=,-
MF^\#4?H-X-XZ3K+@7^(+!OS[M_SKW[_%6TT>,`(CPI%V!X*'!I<\14UD*A%S
MI7DD`<M%Z#%E-,:BV`I\]NWH_??OA!:SS]_]Z5L<]W^DMXP<V%X%49#1Z^")
MSJ=1QI@/6/`MYBW])&%"PIDF[$11)XIVC,&G"AMVZCK&S(BIUGF<0H#48&'#
MS@A&=S*0D.]&[]Y_+P1]-SI[_Q['9^PEK$`:<RQ2HI$\"';!;2AKMAMFF;9+
M8A46?55<9URS,"X!,=?&NUQHEL>%EA3@.*K?!^?(6>GN(KB1DVA=O^)F(?3I
M!Z2\0Z<MWR'S#*T)!NS$PG7@/09AD`4T99$PKQ]:Q>&<S?T0WF8OAC(*>W0<
M7>TJGJK-MKB#ZWLWQFJ*IZ#SL(I7BTD"?R""!/Z.VZWW`KL'=GMMN\"XNVS-
MK#?MKU4AT7;6FMC0;^U(:.P<;B^\(\<E^PFQ$=!X-GJYWH3Q"Z5WE*_9%(?2
M;JX6>#B6:RV0:L1&I,'MV9*C>J6/Q!LG`I$HF,AF?E21D*U_7]F8(TBV3"0J
M\8D?KS<T2GG.!#&4C*/E`TW6%_314"+3"(D4(.J9KL2"=;#APSX=#_4(CT&.
M,P9*`+90=_+)R[8)5S`<8^Y3`F3;W4>4.1<EKWK80)YS/WO5=#_[Q4O@6&D*
M-7;:%EP-0`A]S;2L%DW,:A`X'<LT;-17\RL*AW`V7O3RAY0\2RP"32*C.!KS
MBL9P9^&5E3CD.0A#!ID1^H6Y\CF![SA2%I.49EE(`3RE*I$3`D]=>$%"GJ"L
M$M+E0+-X>L!KR.)D+KI-PF^/\KQ&"N<UH'HT2-,M_X9OV3%VUU[R&X-GS^6?
M.!#U_!59Y$=#&%&NO-%25M2.1*=,?\5&A,D61"I3!0<>DYHL/?9KG)`P3CD@
M\)06/8Z8`+#/Q@<Z/4[%7I.'[?2F<SA2``Z[_;(/L_Q5((<'%W1!F>>;W]$G
M&FT-"WL=,$Z0T,ZZ&B<T0PX>*K2Q46]-(8&9I7)HG-A@/Y8EM&/EI=8+8BTT
MXI::W>)7`XJSK6:]<A)[.\H4BKBCUI'I#NM7E-T#PXK/&1VW4V\'--M:/]Q)
MUEBS7"VNO=;;XX!',^/U.LC6_+12-#^/(XAO*8MWJ6X7MA4#Z1BF68C*X4L]
M^/!'+DV\U(^+E1CB<)R*XT8:S%A1HP/&3X:UU]0T0Z*FQ(R%';N)&+XN;T_&
M#)\6ZR"%R(Q=?O'#+:^?MLZ1H<0'9E-HAD6/$@R&T`2(&2M8UC>%A1JA1\-=
MF*_$.L;RLB&[W'0LG'&O5*9;<8Q#Y3"="V":"E[(ZPNZ"/P@>_,!IYJZ%REJ
MO`]Y0DWF9+@@;8U,&B&QSJ-IF:X>0ZN!(9P^T_#0<%8ESXZEHAW8[T_>OGU[
M1C:>3,F/R+NW(_85_$=2T2O,VV:K.`G^1>?_#8$1Y?L"D+2')B#Z/F*]B&UY
M]JR[_+(=FNR+,>42N77<K"^9!CIA9CY9U9=`R/.YTHFOM2=3#0QOW=_$[NYB
M7X5!6>'7&6A<UL=1F^]J=5[B3-1;Y_Q7-^E=]UQ]2./(J=B>U/(;12U!Z0QJ
M>O;-MZ/O_OC-Z+OOO^/@^=]G[P9577/;JAY>-+(OG\SGO).E%]YZP7P:G7N;
M@#&D$5@+C513WLY\I:B\&73XJO(V/NK%C`4TLZ9@/@XBX@L$/%^]MP0`#E4M
M$L$EC]V?3([$FOT)A.R?+N@3#6/>28"]Q26]C-B<M4F"E,J4Q*0\'GVQ3=C`
M[V)H2RH.)XQ5<-/7D%2+<PZEBE#(TP_+#14T!1CA<*0D/2*2.%&H$T&>U!#[
MM?[&"Y*''AHA?*6YB1`>JA7GR@"D_0^`;=CJK/B827?KW*H[27:[Y+H#277M
M!:4E8)%,GV19$CQN,SBF!I7$M][1BE*L`KIC2.-2<'<<^1P)]*R%$U5%;AUG
M-IW5-N^):M#0]\5;Q>ERCMZY\_.VY^8;;`E]![V+0,)>G&\'4$0Q2H,Y]CFD
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M+VY9BBA/Z3`".8([%E(5P60=`MH)RU!9L58D41?E0F5K)R&JINU(4523//J;
MOZVQW#$-S=W?EBA.&(GY]F^=DK7<_#U<MNEH(KF4$SJBD([4QQXJ8=6'MQ2T
MHE3W=UR16F&BGP'HLA:U0,,\*=!QO5:ITG9F"=J3/&XM/A6A+%>>K1CH1F.S
MYFP!QS02RP5:M4C?D:7FWF*XM\BLB=*ZPM1".V()^K6E!A3?`EH79$W:GY]1
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MTI.\+73>`'\9P<+0EE_UM).8#>&TZ/,J\`7;^8TRO%-_2D63_T"T(A.G]C=`
M%,Y';1F*'$+!9@UWF2B-\!D+:1P&<PY2MMLO^N.SH9Q&Q)-'62OW!WAA&H.L
ME'F*\K5QB4/QSF%D4BD&/"A(>;]]Z(+(7,(VFO/C']L-PV&LJT@CPCAB`\R4
M*%W01'Y7#%SQ/OAX;KP7SNJ(R>BSUPB>2Q)CX@?+%1O@+&9@4+8$]Q(D\C.!
M>P]@W.$VFYCQPTADU%]%<1@O7Z"TB;*1$L]^\MAK82K"7@_3B#6_OP`28U[(
M1%P'[/]9',DA7VRS+7M!3(?F6Y^][_C%"[.7@L^!;QGHP4)SY<YID((($53X
MW"'I$"`T]!'-GB5-ZWH\8H;CY8U?ZR:,<".#2^(.V.Y>!"S1\E(Z-$-XV0*/
MU/+>)$"EZ;T.>/BV]^V<U)M^YO#%S(/8*C"W$684RIED*8E&8`,.CO)8":(J
M4"O"X$IDP4V#CY+.!SR1<A8<JPN`NS+8IE$/ED#MR"#1T!.J/_'%0@BG.N;K
M(`K`.64L%&PW<B,6CIE;"J,:N@%E<%.WXJ>F9A)+++`J>%CF[K8<MB9_N!15
M/&?,OMF73>$X%ZS>.GE`!<NEV;TFC'E^+U`<F>%W^&DX3/?/;0"YC"`:;P1D
MN>AP>MYW5S+;K8?AY4)8+(I,-N2Q3<L;%1)Y@5AGNG%I6(+A+0IW>6A9#L(]
MG$B7H/7$[7#Z>Q-'<95I.>\:DAX6>#BZ;2V0JNE&I,'UWI(CS4THD``OT,GK
MD.^N!9P,TE40A\D3R&U"+LA>61[-YN`4.LS1-%^:"L[8/,4?>T-WM=\2!V$3
MT%:08N//A("SV6?'54U+;BKZ'D@BN=K$"7DM4X1OBMVJ+&8_/S&H\K*UF.L:
MT\7@2=[&$\%5T:F\&YJ'(LH.VL"[+'L.38ZF#($<ED)D+B?"]L*A$EG)<9!S
M\!/J0?-)\>\LDE=/MUY&;X.%XB!LA5%<A`D%RTG8\=58!R"5IKR?/5AOF,G#
MMK%RUWO6>`E]64/`)EA^D[UZ<_W0[F#/07B=8[YA*RCQB<01>3;=JC[(!NO>
M4N6(Y'4NU!M5JOP]':F9G<'-[?NF?O*"Z`U?(`PGRQ--'N-C2`/"Y*$HDT88
M&Z]",6G>@)WYGKP@A)J1JSBY]T)Z3WUY[>1/4--R1[T0JFY`%-TROQL)I`Y[
M>XA9Z:+7`7_X3GF=F6O8BA(P9`DZ"R6PC`Y,`NF*Q8'BBLFT(#OV\B>.%W$R
M!EBL#.*_G^QFKX0G.S$+/V!)-`M-@@0BFMEB6BYL-(.EA48JB6YGOE(2W0PZ
M?$ET&Q_U\*2`!G52X+$\13?V?V$:3\?S^#DZR!J&237U+]I0DIG2R]TD$ZFS
MC,59Y(&N-W'B)2]$443(3O/S:B4ES6;K4"X<X\TYD&KOFC)U+K7>*:7N3BJ]
MM85XD4@G,R6Q"-C'=-D/)A?@MC"VCFP_*>)"BG@(*2P<UK'?QH#.B6;&'>P=
M&"0GU,1HQ?&H`,,[F_K3Z[L5-#O"'G571V+):/6$GNY:E>.%#>:=14M!*GN(
M2&[/&59M?%L'3>9[,'[E9"=N60-WL96CIJ4LC.G9XL'[<LMW\7;SF:;#'CT0
M1BKZZ6U(*C5"!U,=OJ2H)Y8U"ZZ6`\XC`@;#%BOL"2V'G8>R\",/1-4?'*V$
M@R\#+]@J<+:XAS7@`UL"EKF_W:Q@TY9&5PH(N[?["5GLY'9#Q]G5W8?'YIP`
MJ>0$R$Y.H,Q3\9/7D!,8>.NV1TDOI*2<#@%"I*1$)A5)[Q&2\SW+.TBV1]M'
MHMQ`F$7`Z=X.9V]2*-TE#A);:32Q%QVLGA,',-MQ6\D]_W0DZ7^2TM]+Z9WV
M64-JP+!^['.42&X@SF.R[>?#]B*#X+\.$+?P77O0P/%;>S-:T]B24E%_Y*BW
M.HK,UU)F5!_57E9V_'?M]&[:_HO7WE?#7U]&I]],SE>4P>DC<X.3YCZ2S"U)
M&J0C=.AR#MJB=U?,7$3-Z+1BH#7H-0FQTY]7!X[1GK>=EZ:6J#8N8J39*$-K
M:GV0F(Y8RZ670!O=-+]>XJ.7!KY&9`TLCH6T,J[:1B/@X%;1PD5-47)8PH!%
M^^,1X?`XDV07UFL;K7"L3W0Y)F/R>#PA3.;:R_BCMTW9E>(B"+>9]N((+;0;
M%KO#?)O-2E!TJZWP8:4W$L,-RVUGO]UVY\<4I*OU[OT>T"WX%PJ=;>E\\D03
M;TEOMNM'FD`6=*=[?-L\W)$&CK7O):CJ`SH1&-PS[,%=??=-TB"2"!%41!J_
MX9H_O!"@5VD]*6U42.O+.Q%JER'P5""L,K>\GI/'#UH?]9H?,8ZW*</%6FAC
MJ86K?DVZ7=N[<CI3<<JWF82U\&XZ$J[XMW;^#E5EU&"I9XGW]W(RTOH:_=P@
MZH'NZXJK6&:+<R]=787QLZF=>3L*CA>S$4-U66WP@_LG,S.&&W0`BW"T`V_(
MZ>VH"'!TRR\PH?./+Y]3.I]&Q5F62=%`R=1#;@]":(=.]A1YYV1*1RH8QU?V
M8K&>00:=77"=Y3<_E">VROY:B.WZ)_/_V\K3I0_Q'045"$):.?+P$/>CY<=Y
M%%+CD",.6Z7!R!&>,WPCDJ,)4>^56SX*-IN2_&&\@1VOZ6#?PF>_-,MM*AK:
M65GF,'&M*R-6#6</'+KAG-H%W3`Y`EX=QCZ'%#Y`0_9UG&3!OYJJQKJAXCB=
M+F*I3L0&;W"G8,]436555-'V7\'!65OU)`U;+^7(XB8`!?V`)92F`!9*>D7)
MW$60;N+4"V>+29K26K,<(S1".:N9^:)J50^*4YQJXJ>Q7:,HF$YR7ZS<?/CX
M4KTL,"4>](??AEG>KG$>+!8TH7"1WB/-GBD5?1UY[?4F"8K[]9Y@/2^^`.T#
MF,<X_JWL_>@QM01&H9E*1I[9H](XY-?\)4QIH4>]<KVB:!8+?Z&TB>T\RJ(O
MGSC>/8M(C@4+3X&'T@BRLQAYQ>X\YQ_>VQ'XMZK-/2+W.!W%X`##)>^9JID)
M=,#X_<3JK.O:B960J-W$=MEH:R;FK^"&6-`<*.$FE*.1^#FJIZ8'3#K*JA4Z
M!^=,H[0M\M0!(R4:6UFOI!@;(8=/+K:PT9!6C/W?QH^>N&:X!!_81?;*.T[@
MVXUU`):LJ^#]A[;G<?3$1IW1A@9JHDWZQ/>3+32$.>>;.GP<F^8L>UR$L+>K
M8$40;(N($Q)WXZXQ0+Z_/&>^GU^5E*I7(D&'\R7EIN)%<&@IBR&Z\%D<#16]
M_(IION!*`PB0`S[^\'>UU[G8\*-)!E%B\_7=#ZL@)4PT1H1]!_%OPJ\*AX`\
M9&&>_R)^X'G@YQ6M7O+-<REP&4.:;J$M.Y,6_GRBT3Q.4A5TX$#ZP'=3HL.(
M%E=2>(("B)AOL@*1(]Y:,(T8U_&6O8\[?I4Z5*3GERR<P_WN4:9?_1Y`S($[
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MW:AO1W7?<I0,@S1J'B4$5W[TD6JZK^AH`^9B;=C!!4CNUX(=5@/F<.U7B_7S
M*HFV^@BTSKL(LJ';G;A$H8>:S%9"3MFAA<@6]MA"Q16[-+)HK,D,<@INE"^Q
MZ566?LFKWYG$S,BREULF1<:FUDOV+<]M:@:J"P$<G>TNHJJK]MB#ZVA7UFJZ
M><NX6?&K*!=D(W%Y<$-S1*R;DKXZT6SGQ,,%DP1@.25)D)S&B'`J(D`M"*&?
MAZG)/&4+VF@90%C?E`3O@.>(1]$)U.I(=I'P_4<S1PTJF/$RB#C%NTKM&+PC
M6L0G+_F-\KY%92-!6\F;<1VQC#;!6JVC"1'?0O1<M<Y`ZP)-Z>SHC.FX*]3>
MLVH7D1HFU!)=Z4"*/X\FL4_I/+UB)@>=15FT\,G+@+N7V:*+!^E.!\F;["MP
MQ;-T)3*\E]F/PWK)DTRBNV28/8F6TQ%K:"XHQ+@Y+9#:39OE'B4-(&]\#C&'
M9ISJ8$AG#37L5LX)[L`,?\:OD8&&G=P"##O>L\\F'9R.<C\S>%A&T.%,H&T6
MNRD%Z%2&_LBRH=O=E2BI/#Q#WTK(*3NT$-G"'ENHN&*71A:-&?I%3L&1#+T2
M0DW3=,MXH[-$7(X".;[LQ2+VTB'BQ_7M(ND"^68LU,B]C25#/)NC$GFQ!82S
M`AWGC$A/8N5%/6K-]8@\>TGB\6OO(8+?>$D6,7Y6P89LHP"^CD1'[QC.D8(5
M\MA-0-,O-/$#D7Z(>>6\*!;*:>(O<HZB!>BKF#NZD5F2V>(ZCI9PX\D%?=3-
MEGIP'']C8E_U,CK8P7U+.R,-MUWEX*`W(4,0-\G,&0I6IM%9$6PM^R`!K@L!
M``7=AO,\YU6<,#YE'G>VT!]0ZX*(N]M@%JEIJT&/A;;/8&*IIG$?MR^/GO_;
M[BQ+&`V83#+19B=E<Z8\%"7F5.RM!RPY#[GQ.,A6\\1[AJX"MV70PE8A^H-<
M9AR,6XTM!2GO,38@(-U<;,75O^7I36C,E6SB!*R-K%ETG#.0!]-,!#@'"3^S
MKX.D.`F9YF7Y.:F=$Y$CDD(/KH+.G/JPMB91G$E0Z!A$PY?\";L$U",!0<$F
MC-$&8MU4A.MJVYAG_A[I,\YQLCVUJ$2#H5<0^75$B`?#>I%'79/!8@R[)XJZ
MOA(G?#.H\VA9@+1BX.<\-$+HDAT[X*A9CD9>Z@<MBJ7L(O<4@-$8R;N8#3XX
MY>A^]O>PK*_#V5[33L5&DH!>9J_EML6;QJ2O4WLR@THZX&V,C-%)-(=_(-?U
MY(40!G6Z0[8;":3[&O<0LW*!8P?\X6]T[,R<[<D\KL80,?(/M"2.=*<COJ#8
MECEASBE)7IC[^!D:-1JV33O2<,DV#8*:C5-#P!'K;.6N>8NT23T1]T7OMQNV
M&.4Y@C"_XF%:+M)-%V[88B.UQ.LF7*5'GAWJ\$WSNO!5KVW\?'M[??GI\N9A
M<DTNIO?GU[/[SW>79'9%SB?W?R57U[-?R/3F:G;W:?(PG=T@-5-'%G+`/J4R
MHW3K!;KK1:L@2#U)&]BL=")5?A^^_VCMX<V.=\-^5Q-K+]1+>)(Q3^OA1$,6
M[.<@!&#0=\!R@[QA>L,^EE5NT;QA=74A,K_;Q";(.8PL7MS3QW#LAD*'T$2)
MC@YGN-V3WY__]?+B\S7WXS>S&^[*IS<_7]X_3&]^(I/SA^G/TX?IY3V9W%R0
MJ^G-Y.:\^L->?EZSCW6_BI,,]K'+(OG)DQ>$4#A_%?.J%=$X"Y(.YW$441]F
M+L@0WR8L[,OH3&ZN->6?^Z2.L#?6_^`4NVC]D<;9;^N;_\:=N:+Y?Q1'8[[6
M2.&QHHI"E!:+\@H_]-(T6`14;";EC(S9K#CF96?\T@!UIRN1S`$\;'#P9N]P
M`<$3;]XM>1MX^^GH@\H?0.`)RJ$84CR#1Q&\UBQ_#"0CR@?QW3DB'T5F1ZD>
ML&H--<Q`"3TKSTR-&Q0K40;*WQDHO@>[HU%]-IG-:PO5@@DV4?TBJQ^GT3TS
MWW3A<99F"T-3P(/(832:/5S\LM7L_K20FLT>RG!S8[_<S1:.5W&9?TAY?^AR
M'T_9YE>+;J$&(.4/?]E!QVNZU_]P3:V&@CF%5"',ZQ@/:Q'7Q1<P3_AQ&X30
M*S$_J&T].(VXKEAYBV#M)MV`Z)#]:KEK#XZ\TFZU!LIL,F^QN=DFFUAVPA%/
MX9M_Y%$^V@73M!\)K1V"N+E(N:"T1XN;L`>O-])=*+7`ED;7"1W![O80KS"]
M#K@XUM>906L#S)C?3Z6S?U[1A.[<C\:>RV+%:BV[P\9Y^$"5%.I%_$>W49UO
MD7T]YO*]M%R]T(V`0_-CJXC&2;(1VZV9LH7%PZ=+4,SBPD&O;!S@R-S8179U
M@A14R'TA8TZH\%#'J%6UZ]O?LZBUUWF9^#&T">F[4W_%19:Q?1<OTYD$=CQ@
M+V9S3&#&=R`NL&72<B6MK/N*.$#-/>)[FWZDKT[X"AW'',XQI`UWI#W8Y_2S
MT3E+EEXDKW(^CZ,T#H-YWBK_5IPT\<1`7.7'4^Z+TRF&W<Z>:.-L>?8Z,.J^
M9R^$!]_\[)'KFJ&HM/GE21_9TB:%"XY5RN37G,S?OU)S*;>$'^B7[&.H/T?;
M_V.^0B-J&:[>[*GA&5^7:6D%:+6R$:D\B">F*[;&)JSB8:1\&BD?1WZ%!Q+^
MQ)I!#E-!AS!P>O>$YY,NO20*HB44E_.;;`VSLAX<QT>8V%=M70<[N,VV,])X
MS@:.XJXI>0U7R;\A#)%P3">FM5UQ3/-3"[P;2M0Z8VB!T=7(Y(IR>%5]T-UP
M5R%:C`'/`JZ\(.''&\IYP;2\:4?!L0,;,513:(,?W!K,S-1T"5`(QR&?J`<8
M(DYQP:D6XBB<3:/-MLM"H",-9*7K(FBC%MH0P%-+>^XL]90(,FI477IS'&=^
M/&$1DUSE];XFG]X(B=6)3LMTM0E=#0RA_YR&!_V5R<IUV8?Y:MW62^UF9YVK
M-8-C;*F8V2^W3_2P2%LE)H:L;M)6`]NA=SOV%^"N68"C\"^N3[[/O"33;V7T
M(0K&%LPQ^!YNQLF+1R?1_"Y8KK+T)LZH]3$Q:VR<F:FC<.IL98DZ^`S6B:]Z
M3ZR\IM>%9<<%Y<<*@B<*TA3QG&FE84;#439;<50M,^$,KEYV#-7T2D'C*7HE
ML,9/^^PITR^:_ML'Q'J?[W^*GV@205!R'D?<`'6!O@T"0KQG)4(1\;5"X\1\
M%BS55.'SR?T)*=%(@:=WH\>-^WH5PHG)("_,+;B:);=)O$R\=8<D5%<B.!/%
M?J*JTT8W"H-/(ONP5U/7LM-XJ:AQ0G)";FWP]B*QUD`1^Q'!7L='+Q5U9#1*
MK=H0&9"0N@]9B5)I.M2*,7RO(0MVZD>`>>FPBN"$MR^-@I=*%\S=T1!:`?,;
M\$IYBYM032N#0ZDB+1SZ&8S*NN(PDL,O._K@M[XJ*:<(<6Z@-`))F)R+>W@X
M[?$C$"?%W;GXT\IQAJ7N$S!;;L'V^H/WY?(+<$,_TH@N@LPPPQBQL!IS60E3
M[=75BH+0OLN"GZ8&H%`DP="H&ZN)0@S[M4,["K)"6:X+VN#Q5,D^`B[UR*WP
M_B!1,#M1WU%FBEL_XWWV^'1AW%;6(V#M+IM$J&XRZZ`1]IK;66FX:4M!:'&C
M_>B\^9JP@]B7@17Z'7\*3[!E(@*GIN9WIOEA/U(.V$Q'L;769$D'U\XZ,6E0
M8=C(R-<))36W9J9C"8]YH<FSW""'O@Q)'+&/OCR=%<W/5XQEFDXC%2:(_&!C
M+IGJA3+6%2B]#4KU;I2#R2)<FM(3SPT&X$/:M<0D5?+'J?\23]6)U%H+9HV*
ML$_84:QBQ]`2#V?OL!-S.OWR2OW:[.@7GTX>,0K)>I&LQ7(4R1!JM(XKG2J0
M_'S-.&!_L[_8!T@KLC_^'U!+`P04````"``O2*I`4YONO183``!2+`$`%0`<
M`&%V:6DM,C`Q,C`S,S%?<')E+GAM;%54"0`#*;RK3RF\JT]U>`L``00E#@``
M!#D!``#M75]SXC@2?[^J^PZ^[,ON`PDDDQ"F9NZ*_)M*7290)'.[][2E&`&Z
M-18K&Q+VTY]D&VQCRY9L.3(F3P$BM=7=OY9;K5;KR[_>YI:Q@L1!V/YZU#EN
M'QG0-O$8V=.O1TNG!1P3H:-__?/O?_ORCU;KMZO1@S'&YG(.;=<P"00N'!NO
MR)T9UP0[S@01:+RLC1%:0==XPA/W%=!?`OK&^7'GN//I\KAMS%QW\?GDY/7U
M]9BPMD[0]-C$\U8K>-H5<"AUVL][[.EQ9_N?Z^#)V/YLG)_T3D[;G5.C<_JY
MW?G<Z1K#[]N&WRDG$Y3;TD+V'R_T:0:5ANU\/8H,[^V%6,>83&G/]MG)IN&1
MW_+SFX-BK5_/-FT[)[]]?W@R9W`.6LAV7&";82]&)JU?I]?KG7C_I4T=]-GQ
M^C]@$[B>?G+'97!;L&^M3;,6^ZG5.6V==8[?G/$1E8%A?"'8@B,X,;P!?';7
M"_CUR$'SA<4&[OTV(W#R]0BL$&HQ0;;/_/X_W020V/SMV^-;VT7N^MZ>8#+W
M1G]D,/H_1O<Q-BBM%X29VIEJVJUVKW76/F$M3\2(GI0=^Y-+H<3H7P&+*>EI
M!BD>I4?+(U/1^(;46&QW!EUD`DO18'=HJAOY]H,SF`P6D'BJ<Z@^K_%\0>`,
MV@Z=!.[IO#.'#W0:*<Z/_).JX?(:.+,["[\J8B5"KO1X;Y!C6MA9$C@@4V"C
MOSP941'1Z1;19PT)=.A3"]JL%'&%O#Q"-]3J$)*G&05SB>%SZ"D<\1U`Y#_`
M6L+O$+#OGJI+C)A#3^&(^Z:)EY3H")H0K<"+54;`:<04CO570`@H)]"0A,)Q
M_7CZAJD[9#/M7&/;)<`L-4@./84C?G*Q^0>;/NG<67922*&E<*2^P3Z#-UA&
MHC$J"D<W@HY+EJ:[)-2W+C&^'3I*1V@R-\LW3$I\2+!-/YJEIZ8\P@$/B\C+
MX8$..1@X(Z;69XP*";ZYT![#\?97Y++'M=OM7MMH&1M"T8^4J.%3-:)D/28H
M&Q8V8T^PF/N.29X>V"^_9XV[_^)XYKTA9($7:/F4!/N=2`TQD+BWC'"@>3S%
MJY,Q1$SF'?:!#;_3:G>"1<1/]*?M.)XIV9UQ[O[[]XNS3]W3SD7GHMN]Z)YU
MNN>7D1%&L=`G\=$"8FYHTX\)>,37/4&+DX7GW+;,&;*VNIX0/)<28#`*+,@-
M)F-(Z*KZR%@Z=(QXP:B%KG65BNC3@8W9X.XL,$W11.S_^Z^*?'8"79QJT,6&
M(>I&(DQY&M]0SS[#.F+M]E\WXFP%.CK3J*,[^M("UG\A('?T%R=#2SLMFZ,G
M$<8"37W2KBD?5&*ZBK1MFK;R6`OT=:Y!7SY'(SA%C!';?03SM,DOK=G^:TF8
MJT!!%]H4=`W9XM&ZI[[PV[_AFJNAG79-49$(6X&.NAIT=+TD)#8U\[T(7M/]
MUY049X&R+K49U!VR(+FFPYMBPC>G6*O]5Y$H4X%V>OJF.SR?8]N+1WFA76>P
M=-DFW=@+JO#FOHQ.3=&=-(^;16Z;H\LO)[MQ'671'MZ>FU!\I]-F\9TM"?HY
MH&($9`HC<0*<%T]C2Z<U!6#APQ%:KK/Y91>7P<^_;T<SF-PAFPX&4=<..R@C
M_"/3E>GO]*)SV;ULG_;.SCN][FD9BRO.9]]QJ(1S.(HWJHU]E19X:'42G')#
M293S":3OQ?&#+STN9QY;+B0.]%KJ43S;R&2[L?3/[9]+M`(6BP#WW6M`R)K.
M,-X&%@</0GUK!Q,!W28!49Q513A90?*"MTA9T,4EH>\&;P&I9;Y(;!8^0C=P
M!WFS1T:79H!$FD-N"+3X'*(=&0-W!HDOOFP\)!LV`P6"?'%#JZ$&.SI]@1QC
M;I[>A%66C+%*FBMV@94P5TW*'A*\@,1=#ZFG[2U.Z-MMP9PH.G5Q=)_5I1E0
MD.:0&\U5,9%?Z$$&]:&1"Q_0"H[OJ<[L*:(O-%^<?&QD=VH&.@KPR`TF-^-%
M_XAM4_1='[9M!AK$6>-&J]6L!,YT>@N9;D(S%)W!"S>T7=PQT*'*!P1>D(5<
M!%F"MA=QG&&+LN:P%Z"[S@D/B7:O'1P4!HY*R:""C)CR*_PA6+.5K-C:/MZX
M=HHNI1W^>E^`ZXJC0)KF_MOYPL)K"$?08J>_(N+-ADMNOZ8CIY@`%(6+:@:B
M!VQ/GR&9W\"7G`AB2LNF`T64Y8QHDI8H,R>;>G."@X7+8ZG?T=3I1*.F*EF"
M6U6AI]0%Y"<]AG\3C'P$5]!>YG@8Z8V;BHP"7&>$H#2'&+T5LK!OP&G==$W+
ML)T13=*L:F$M'YZ"Y71;-DA4JST&EL&$7.]HF7?PVSMR!NDR&_+B1AD]FHX3
M6=8S8D^Z)X.([YH;(4YOW'1E2W#-3="4FQBLW3E!4\)91)#YV$AKVWAH"#/-
MS_<L"0U-`0'IP/,>A9H5@Z18@+FC,FE1.UR&FZ%[PLC*5TQI63N`E(:$*),5
M'(4NYR$&.>Z9":<[S9JG/2$.*TT;U!0,ZH_'R&=C"-#XWKX&"^0RGM+WF]);
M-P\/,HPJB@'7Q0VX@2MHX450>6L*;VT*6#HJ!][`"3(1*U^RG"^]#90;K_;*
M;@]N*+$LX>;AK"*9E`U;]WQ(VG#J;9/5)#,N*6UAQ[1YR!'D456&9,U39`JF
MQM0.%M4M9L7YWWBHI?V<[%CHNQ^'W*GJ&=5FQMG(\\RSD<;/,:J_-/"LI+8T
MJ.U[#U)(T)&Q0='/%@PJ:?;GF+A!84UNYC@_<4H)^=I-(#)@V,FIJDX@M5KS
M9J211X00958^YYY#J#%H4<2ZH@6UI<\OB4=]Z+M@0#R9CKTH0E@N5R`NQNO<
M&-"48%?1$EOWH>^X!/RJ$OVE.Z.NT5^A\Y&)DMU.#46'$)L5)&?5!17WCK.4
M0H3?H=%HR&!1T2JW-B^2O$H\@KT:#0?!<CPJS_YIWJ*1="\$>C8&($5Y597V
M51^0"'H5&3V:"`H9?Z+T<<*Z@2'3F>"T;BX(\MV(LKE>M0-`OB.Q%P7]E$.A
M>$6_LH!XC^"W_!500B'QTT2YP/!!QF!BA(_R[H>(/<SPGV;\S)ZG)5CN#V`[
MXISX.*<U`\O%9>^\V^GVNIU.KW<AG;W!.:@5'#@94110>YAM+[+YYIU5HO)\
M0"85);R#B1QNZ?ZULVL9:8?6K8;OAI05#(S/GMZ^L:N%8%YI26[[AH"C&)^U
M*@BPP30%<23W(^"#H];,/K53K9QRDLJ5YU:1M2=2MKIZ(/(-VE2"%MNC&\^1
M[978=^GK-ALD.;T:!Y,B_*K=H=(.E'1+N6?;N29T>*?"<GHU#BA%^*U@ARI$
M2T^S,Y%<(_#<B+!EXU`ARF,3JU4^8AO'V0^$F.->YO9K'$J*<5QI'4OI/'+.
MVO2>Y29#9^-8^=S1.=([0I\L32G4IW;Z+Z:_G=5H(:XK6(&6.%W"Q8!)(&#9
MZ?[?@1W44<FL+)/?JZDX*,1WQ?6F-'D3_15`%JO7=H?)$[#@$S27Q$M-_D;H
MNW0$@<5V9KX!9'/+6DJ0:!RBE`FAXII5F@ZRW<\7`!%_5^#>7M'9-[A3.3VP
MF]ZZL:"1X;?BPT.:IA^N)&5=U\9B1([C"@X6:9]#J&N6N]2-M6DN%G*Y5)5>
ME:I_G:75.;NC5"*#R3-X\R^8W?7L\K992A-N+-(J$DW=BK[S"G-2<O`&O]J#
MR=,,$Y<5)0H=NEU7+VUM)4>A=C"J2/T["S$%0JI;)6EN`D'H_@]LQDUA9!4D
M=:`04RFMNA6<YF#MATT"IIDH*=/%<%:`S(%B3)6D*MVLTE2VI+@&E/MLAX?.
MBF16Z5;:I1Z<IDAG(QE^;BZOQ^$B358H30Q7W`)BT]67LSGA<@4<9')`E-JV
M=O!1M:@4Y[:",Q_:7X6[W-\@:^ER#X!P6A\,-K+XK>!`B'9T_`K1=,:J,]#E
M`9C"Q^7\!1*V5MDY$9$UFTC1:"R2RDNAB@,F=0588&>B)Y(DJ1P:R*3D\$[U
MA]_[4-,U<&9W%GX5/;ETEG-RB=$S?()ZRWAM&1,OWY7HPH!P>G':/3L];_>Z
M%YVS<UVY@]!E@QL2O$)4*U?K'PZK&K1-M.N;+EKYL8N<9$)I0K6;%*05EKHS
MIT(*M2K)U8!]5S5:*;$16\W<KBE(TA__;QFDJ#SC$32Q;2(+QF3QC-7,*E4\
MZG#@^6[2:V+M=9%"BQS4BG2M'0K?#2Q)G!:65U4G!:6O_^'LP;'M1G\SZ`8Y
M"^P`:S!)O1H^I_4'6(J)J.R\E),LJ6D)?^BYVAIG*NWIW?6L_=_,]&Z-.'O/
MC/"<?!1-BXRH!)A9W3IL=2Z`J+#Q!Z`*24C@SF1-UR-N=@NA5R0)VDZ6$Y[>
M^`,3A2140;E.]<<?KS&=*8E#1\8F3?^09]\TR1*.J0C#\F)IOK=HWP_\J!"8
MHOSOQ+I-T\F$PRC<H7&F*E'SHYK<$>EC<H=^8EO7-%7ND'?AU)*<95I5!_[O
M;3H%XR45,A4Q1"NV4MU4-KCV+TOFAY\*$_L`6R42+)U^HOJH+P>$OEQW&!Z"
MM<>M[Q'<SA<67D,8]3,W@HC<@I:&2G74/V#Z/B*M-I]%4X1+?(^N='[$!TZ5
M2:W:RQ(UA?\Y,O'#A`I2=C((U0Z:U:7LR$JA5E5IZ60>F&O?_'.)")2]@5&<
M0.T@H4B?2:"4E$G9O>H<;TY32#8AE-T;!T4!MMOO@'$E)(IF;FTG9/$=D#^@
MRSS3<*M5%%)I?0\85L+BJ'B/6M=,Q6*%<.S<4?&SK7LZ87\'+I/#>C"1@9DL
MG0."G!+1*-K/+I_4I2A;AUF??_W--7:X+\3=9H>#&B'.Z[LI+2Z7TLNPP\%$
M29E44/ZL1M`*KM4JO]+/(%0[J%6WTI>5`M<]TNW5L+OS*"=P0/P"1VP]ZJX%
MW)CTCK6#@"+]9?LM$K*H]&R/I@78""Z"=<-@\H#M*:M?=`-?>!,+K_GA8$=*
M`A4OVC7'@.XPH=)8$G/&-MHG_(PK\8Z'@Z."LJAXK:ZLDB9R9V,"7MEYC2$@
MKDWGO!E:4&GR\Q'R^C0?&\7%4'&5<$U'\J+O:3__T&51THSW4T:/YL.GJ!#V
M;JV=(J+2"Z'#@4=)F31DK<U$P&Y?IG^8R[^BSC_+BI&I22E#XG#@55HJBI+%
MTW,X-$UDZ4+I4Q40LJ;29MFI>67KI6@<.MYDQ)*1.;X/L"D#E]K!I+PV"R*D
MRHC/PIO\GESJS=?E<@T=R.I\0"LB"D4U5'QLW=K)19LF9#TM%PO+B]P#:Q.Y
MO[<GF,Q]9><441/K'1/I)1-IMWG@*B.+2HO*Z[I4+CAV.`2(5SXWVJ1V&"FC
MSR0Z<EG->'G5P*UAS#]BVZ0?PUU>>YSB#]X@Q[2PLR0B#G(9L@T'3"7BR7B+
MJ2ZN)'"_AG_LBJTKKK%M0Y,-AL53AX3.R"X<3.C4ERQRJYAZ[6!4B>)WHM85
MBZ]>6Z^\TYF;K>3H+@X5<G`"U;FWGZC:G0GP6!],<D["E2!WD!!4+2]%#GIE
MQ>92^:6V=K6D:J#R'`:;BL+82NG[`219X2ARO"M#39\R-U\$%A#)7Q`$CD3W
M@\1.6?G4)AE:<M()SAQXE86`O<ZH.B!#X"`A5%Y"JJY7JK1Z4\Q2PE>Q#)8D
M21PDFE3(Z'VJ@55X844HN@&9`CLH,4S%S"Z#<0:38>011S'-<ZZOZ-`'=(R6
M$1*F7Z*T#4K<\*BSNRQB]'5<QQ@9&5U\.=A"XXT(HF,;3`+<`2N\C"/O-FTU
MM+7<4EEFZ*'JGRE(KBQ^VJ/JQ]1N'E,*K]@-EN\AN0IB"^\XH<7*<FQN41.<
MPTZ3<Q@E9_CTC)\9Q5\,2M/PB=;@\KR<N8C?O`XW_^7-$]SVM3/X/+5DW?#7
M9&.\`XAX.WW?(6#?8U6Q<XSQ+&F,C)SAT3-B!#5@><M9.,`\QR"[BPZ#3%//
MO;U8RKS,I6C4SG!%U!@UWO+<[K=!)^OY"5KSIZ0U;V@9$6):3GQMGIYGP*DM
MU:S]$V+EF5U>\]I96(9XPS6Y)#_[;4.;_1=!RSE/6LZ6@H[[4X-GTQ7'B-W]
MZ3QB%PJG)`CWUG/CE;?SBE:0C6\[U>>]`?.ZU<XD)548OZFJ`*_[;:X_GK[A
M%20V>]73-;<G&E';O4C:[H_CIV,CI&B$)%6\2%('R[%)D0XZS'"S3;0=SH`,
M"9X2,)=P2^6(U,9$Q948M4H%S.ZWC7I;0FEWHN389S=IGQXI(T:K-C>]Y.4*
MYW32\DX-=QHFT5&-H,5.UGH%C\)Q;VNVY;URRU&MC;G+J3OV(JY``OL]!_A1
MVF?P!D7?SI=)ZP]"O3X5+2G=`1.W;TRE\`K:<(+<',//[:4G.ST8E/A+.ZM+
M[6Q64%7Q%'5)_O;;(D>0BF)IL@*(88YQCDWVDC89)Z/G>J-P`-[,FALHXG?0
M=#]3.!ZVZO-?$FFI%'DF6H14[4PW7Z$[ER^I87G?K=FDM()0'4O;(]BF'TV9
M39U..\V\&5TC)&SL4-929^.5QR@[U#8#]A0ZV[M#O#;(-M$B/X:LA+*2F'.V
M/C/CSX)=:V?W"M6ZC5V7D<7[3@A?3MC(7^AZ@'[Y/U!+`P04````"``O2*I`
M'K:B_'`'``"--P``$0`<`&%V:6DM,C`Q,C`S,S$N>'-D550)``,IO*M/*;RK
M3W5X"P`!!"4.```$.0$``.U;WV_;-A!^'[#_@=-3!TR6E33=;,0M\J,)#*2U
M$:?KW@I:.MM$9=(EJ3CI7[\C)=FR)2M2EZ(NYI=&ENX^WMW'(T\\]?3-PSPB
M]R`5$[SG^*VV0X`'(F1\VG-BY5(5,.:\>?WK+Z>_N>X_Y[<W)!1!/`>N22"!
M:@C)DND9N9!"J0F30,:/Y);=@R8C,=%+BG=2?'+2\EO^R[]:;3+3>M'UO.5R
MV9)&5J6BK4#,73<=[9PJ1$<].^Q1RU\]N4A'%KQ+3KR.=]3VCXA_U&W[7?]/
M,GRW$GR'GDS8DY(JF,&<$HP%5STG9]SRN"7D%+7:OO?/NYN1E7,2P>[#6$9L
M0]S<R12./<:5ICR`3#YB_'.%N'D\1I=7\`7YU!J_T^EX]JE#-)53T._I'-2"
M!K`A3N_9F`D34NMV^_C81W8C,.1="3F_A`F-(]USOL0TLF%R"-5:LG&L84,@
MYCF1Q#H$9T^/ELCR>%[N=ZBEIQ\7X*$$2!:L%`2OH2.XNZ6'$]8\6G,XH6IL
MM;(GQC;?;?ONVCJ#'.J52IZ4$R]YZ.`D(>24<BXTU3B5[6]S9[%@?"+2GWC#
ML-*5(H(['(V8BP^W_8HXM=UVQSUN>T;2&R&X9>><1F;BC&:`J>$0%O:<'<]6
M(V=CAS!AG%D;<=*VV\0E*U6\3K5)HG[J;>MLP\68@@/^VEXO)"A$L0&XP1NI
M=BI2I1G0*(BC;U!<6[9;+[V;!?VYN5A=J,%DL`!IO5!G/+P0<XS(#+C"%:R/
MB^8<;G`-W**KL7HUHT<%1M<#D,&$K(<@.`;9&(0DHY`79IS?#]PWX_Z"JME5
M))95!*]EJED\?H)%@T,LT(&EG2Q=IG5(]A?G^UNNF7[LXXHLY]:7A*M:DM6,
MM3N&L0P@?VG2+$$C.;@#;PUWN2%6?US/0#-TJ6K+VQ1\:O\[J=S_R(L-M,.:
M6)%M3`614+&$@9Q2SKY:ZW'R8Y7.<.D;YH*19ET3C2H>?33%-RFW`L0?>4R;
M@Q;5+)YYW`.A-0A]#WI=?PQ!CF:8%-L<E@M5TW94I`UA-LL0@EC$@AVXJL'5
M%67R;QK%\`ZH^6U+AFVNRH6JN3HN<F5@B,4A>:`#3S5X.@L"$6.P;B$`=D_'
M42&A2B2J&7I99"C#(&N0`SLUV/E(I:0EB;.Z7\W$29&)3/,0_AKA_S"Z%O<@
MN5E.+@37D@9%+LJ%JHEY523F0VO4(FLDLH(Z,%6#J9$6P6=SB`!<E99V18%J
MAOXL,F0A2![C0$T-:I(JZHX^0"%U\H^JZ?BK2$=:G5GM`Q$UB+@%I64<Z%@R
M/MVF8O-A-1F=(AD;Z@<V:K$1F!.>I##"H`VEX'@9E%?*3TA7\N6WR_@*[)G0
M"I!L(OX/*#3_F#;6+4R(;5)U3>.EYR@V7Y@J.+DWDS#I.::)Y&;=HD_H;NMA
M'F4B!K^B769YWXY0.G`&06500"DTT1!$+$!J!BK?@TM,9]JHYX\4B!E'_4%H
MA)9ZS^8\,M;4^2V2OY/O%^M1OI/K$1TW=1U5(/J.3M\8_%)W3[U\SP]_;?8$
M3]%;(37AI1W97?WAI/]\(P(+5*%B?KF9GFMNN?Z1>^RW'E28V=C$A+7[S4S(
M]/ZS"9V$3PY3T]"O9T8DY8:6,:)CC/!?U3/"(BD(6E-Q[X7`-IK".RPHU3$7
M[EKY&T)0WLVN$X6\YOM$L7$@\NWQ*:6+VH$H5?0@TBJ[LRLLZ?<'=A\VR\"G
MJJ;,V5C9ES7'VKYNY#PARZ+('(7T'*R=<&HGZY#]6J.+,K@K]S7,S=:%3L:H
MQG1L$*ZEB!>9($,1A]`4-(-*GN'BP41X9V'#6*8O1KL<S(X&S$E:*IIX4_:@
MPO2YX*"I?*QM?-'89.70V:-QT@SI.8&$D.G=+N`[@01,]TM(_@YX:GO!IUJ2
MW]?)-2,-O;P0//U2:3#I<PVXZ9O2$&T,[P2^GZ)M]ETU\[6!_`_R.(1Q$UK[
MO'@HB:DVT#.0%[$TG;(SI>PG*>5L-P'8TTGPD>E9*.F21H/)D$K-D>$96[R'
M+==KR.VIAVA?/%]H.VUO&!VSB)E2Z$K(L^!+S%#;G,50_KCI<'.U/?6_CXX8
MR<$DEZ,X2[/EN,]'"*PFN.QO.[N:]_\)XF>*"])['K/(?`\ZC&4PL[5B11#*
MY7\RCROSH*G2GOJ^D<Z"3^_`?.\YUA6$-U/94[]+VPK;=>930OM58&:UQ]L'
M<X*>GOYFVRYN2.O=^DFY/25M-,/W%S/=1A#$TJZC9_>465MQ]HUH!$G!`6&?
M(V$<[,)K]NBAQ#)$8[9.(#F?36+QK(A[&K7DDXVMPFQ('VU5EM2I;^>+2#P"
MY+LOV8PHV?>>%7$_:^);N`<>FW-[H+B6K;+_VF[LZ,D-"TSV7,$Z+`UU]G2Z
M7%/&S2<Y`W[)U$(H4]EN;GV5$GOJU0>.TS5B7R%,+*^1^*M=X)M4]S0.Q1>S
M.WC0YU'N?;9:I-2OY#]J='4F]RR>[4[-JF9-P9WZXC_>M8\XG>!2++&R:C!!
M&VOMZ=R\3=/,K"^89FAKHS!\N_H>Q./42\Y9\?)?4$L!`AX#%`````@`+TBJ
M0`GO>WH?00``45T#`!$`&````````0```*2!`````&%V:6DM,C`Q,C`S,S$N
M>&UL550%``,IO*M/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`+TBJ0`-I
M0W2]"0``Y8(``!4`&````````0```*2!:D$``&%V:6DM,C`Q,C`S,S%?8V%L
M+GAM;%54!0`#*;RK3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"](JD`*
MR1VURR0``'79`0`5`!@```````$```"D@79+``!A=FEI+3(P,3(P,S,Q7VQA
M8BYX;6Q55`4``RF\JT]U>`L``00E#@``!#D!``!02P$"'@,4````"``O2*I`
M4YONO183``!2+`$`%0`8```````!````I(&0<```879I:2TR,#$R,#,S,5]P
M<F4N>&UL550%``,IO*M/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`+TBJ
M0!ZVHOQP!P``C3<``!$`&````````0```*2!]8,``&%V:6DM,C`Q,C`S,S$N
M>'-D550%``,IO*M/=7@+``$$)0X```0Y`0``4$L%!@`````%``4`OP$``+"+
$````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>8. INCOME TAXES </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">At December 31, 2011, the Company had net deferred tax assets of approximately $116.8 million. The net deferred tax assets are primarily composed of U.S. federal and state tax net operating loss carryforwards, U.S. federal and state research and development credit carryforwards and share-based compensation expense. Due to uncertainties surrounding the Company's ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset its net deferred tax asset. Additionally, the Internal Revenue Code rules could limit the future use of its net operating loss and research and development credit carryforwards to offset future taxable income based on ownership changes and the value of the Company's stock.</font></p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefitAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Restructuring<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
        <td class="text"><div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>9. RESTRUCTURING </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In December 2011, the Company restructured its operations by reducing its workforce by 28%. Restructuring charges totaling $1,145,000 were recorded in 2011 and included severance and related costs. The charge included $548,000 to research and development expense and $597,000 to general and administrative expense. The restructuring was completed by January 31, 2012 and all severance costs are expected to be paid by July 31, 2012. </font></p>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Changes in the accrued employee compensation liability and the balance related to the December 2011 restructuring plan are as follows: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
<tr><td width="77%"> </td>
<td valign="bottom" width="20%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three&nbsp;months&nbsp;ending<br />March 31,&nbsp;2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in&nbsp;thousands)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Balance at January&nbsp;1, 2012</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">828</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Restructuring charge for severance</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Severance payments</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">(86</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">)</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Balance at March&nbsp;31, 2012</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">742</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCostsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENWBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements Of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">380 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">$ (17,704)<span></span></td>
        <td class="nump">$ 1,833<span></span></td>
        <td class="num">$ (327,668)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flows used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">353<span></span></td>
        <td class="nump">239<span></span></td>
        <td class="nump">20,798<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_GainLossOnDisposalOfAssets', window );">Loss on disposal of assets</a></td>
        <td class="nump">65<span></span></td>
        <td class="nump">26<span></span></td>
        <td class="nump">2,336<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gain on sale of short-term securities-available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(3,863)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Write-down of short-term securities-available-for-sale</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">17,001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment charge on real estate owned</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,445<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">708<span></span></td>
        <td class="nump">1,145<span></span></td>
        <td class="nump">29,703<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_ConversionOfInterestAccruedToCommonStock', window );">Conversion of interest accrued to common stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">8<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">29,461<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IncreaseDecreaseOnWarrantValuation', window );">Increase (decrease) on warrant liability</a></td>
        <td class="nump">10,926<span></span></td>
        <td class="num">(7,274)<span></span></td>
        <td class="num">(14,044)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets', window );">(Increase) in accounts receivable, other current assets and other assets</a></td>
        <td class="num">(1,830)<span></span></td>
        <td class="num">(11,226)<span></span></td>
        <td class="num">(7,004)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities', window );">Increase (decrease) in accounts payable, accrued employee compensation, and other liabilities</a></td>
        <td class="num">(1,567)<span></span></td>
        <td class="nump">5,191<span></span></td>
        <td class="nump">12,564<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(9,049)<span></span></td>
        <td class="num">(10,066)<span></span></td>
        <td class="num">(239,263)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(9)<span></span></td>
        <td class="num">(227)<span></span></td>
        <td class="num">(19,888)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
        <td class="num">(253)<span></span></td>
        <td class="num">(109)<span></span></td>
        <td class="num">(9,745)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(112,993)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">117,724<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(2,389)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(262)<span></span></td>
        <td class="num">(336)<span></span></td>
        <td class="num">(27,291)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and warrants</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">116<span></span></td>
        <td class="nump">297,879<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
        <td class="num">(21)<span></span></td>
        <td class="num">(20)<span></span></td>
        <td class="num">(366)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Buyback of common stock pursuant to rescission offering</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(289)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_WithdrawalOfPartnershipNetAssets', window );">Withdrawal of partnership net assets</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(177)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible debt</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">80<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="num">(20)<span></span></td>
        <td class="nump">96<span></span></td>
        <td class="nump">297,127<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(9,331)<span></span></td>
        <td class="num">(10,306)<span></span></td>
        <td class="nump">30,573<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Beginning of period</a></td>
        <td class="nump">39,904<span></span></td>
        <td class="nump">33,589<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">End of period</a></td>
        <td class="nump">30,573<span></span></td>
        <td class="nump">23,283<span></span></td>
        <td class="nump">30,573<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the year for interest</a></td>
        <td class="nump">22<span></span></td>
        <td class="nump">23<span></span></td>
        <td class="nump">511<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING ACTIVITIES AND FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering', window );">Short-term securities-available-for-sale received in connection with the private offering</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">17,897<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities', window );">Issuance of common stock and warrants in satisfaction of liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">644<span></span></td>
        <td class="nump">1,188<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IssuanceOfCommonStockForBuildingPurchase', window );">Issuance of common stock for building purchase</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">750<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_AssumptionOfLongTermDebtForBuildingPurchase', window );">Assumption of long-term debt for building purchase</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,200<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_IssuanceOfCommonStockForAcquiredCompanyAssets', window );">Issuance of common stock for Ercole assets</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">8,075<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets', window );">Assumption of liabilities for Ercole assets</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 2,124<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The non-cash value of liabilities assumed as part of an asset acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_AssumptionOfLiabilitiesForAcquiredCompanyAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_AssumptionOfLongTermDebtForBuildingPurchase">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of a non-cash transaction where the Company assumed long-term debt to for the purpose of purchasing a building.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_AssumptionOfLongTermDebtForBuildingPurchase</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_ConversionOfInterestAccruedToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The SEC requires development stage companies to disclose information since inception of the Company for certain financial statements. This line item represents a legacy item from when the Company used to issue stock to vendors the Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_ConversionOfInterestAccruedToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_GainLossOnDisposalOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gain or (loss) recognized by the Company as a result of the difference between the sale price or salvage price and the book value of an asset that was sold or retired during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_GainLossOnDisposalOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services, including accounts receivable and other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IncreaseDecreaseInAccountsReceivableAndOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IncreaseDecreaseOnWarrantValuation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The income statement impact of changes in the fair value of the Company's noncash liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IncreaseDecreaseOnWarrantValuation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The non-cash value of the Company's issuance of common stock and warrants to satisfy the Company's liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IssuanceOfCommonStockForAcquiredCompanyAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of a non-cash issuance of common stock for an asset acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IssuanceOfCommonStockForAcquiredCompanyAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_IssuanceOfCommonStockForBuildingPurchase">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of a non-cash issuance of common stock to for the purpose of purchasing a building.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_IssuanceOfCommonStockForBuildingPurchase</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net increase (decrease) during the reporting period in the amount due to customers for the credit sale of goods and services, including accounts payables, accrued employee compensation and other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_NetIncreaseInAccountsPayableAccruedEmployeeCompensationAndOtherLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of non-cash short-term investments classified as available-for-sale that the Company received as part of a private offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avii_WithdrawalOfPartnershipNetAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The SEC requires development stage companies to disclose information since inception of the Company for certain financial statements. This line item represents a legacy item from when the Company Incorporated most of the partners converted their interests in the Company to common stock, some partners decided not to completely convert to common stock during the incorporation process and as a result withdrew assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>avii_WithdrawalOfPartnershipNetAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>avii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 10<br><br> -Paragraph c<br><br> -Subparagraph 3(ii)(A)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 932<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-10.(c)(7)(ii))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6949603&amp;loc=d3e511914-122862<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AcquisitionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 21<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15C<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 16B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6956420&amp;loc=d3e25351-111560<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-2/124-2<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 26<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfRealEstate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 4<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Warrants</a></td>
        <td class="text"><div> <div>

<p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>5. WARRANTS </b></font></p>

<p style="margin-top: 6px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Warrants issued in connection with the Company's December 2007, January 2009 and August 2009 financings are classified as liabilities, as opposed to equity, due to their settlement terms which require settlement in registered shares. Additionally, the settlement terms may result in cash settlement upon the occurrence of certain specified transactions set forth in the warrant agreements. Warrants classified as liabilities are adjusted to fair value each reporting period with the fair value adjustment recorded in the statement of operations. All other warrants issued by the Company were recorded as additional paid-in capital and no further adjustments are made. </font></p>

<p style="margin-top: 0px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The fair value of the warrants classified as liabilities was recorded on the balance sheet at issuance and is adjusted to fair value at each financial reporting period, with changes in the fair value recorded as a gain or loss in the statement of operations. The fair value is determined using the Black-Scholes option-pricing model, which requires the use of significant judgment and estimates for the inputs used in the model. The following reflects the weighted-average assumptions for each of the periods indicated: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"> </p></div>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr><td width="68%"> </td>
<td valign="bottom" width="14%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="14%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Three Months Ended March&nbsp;31,</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr><td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>2011</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Risk-free interest rate</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.2%-0.3 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.8%-1.3 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected dividend yield</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0 </font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected lives</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.7-2.4&nbsp;years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.7-3.4&nbsp;years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Expected volatility</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">65.1%-82.4&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">71.4%-88.5</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">%&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Shares underlying warrants classified as liabilities</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">28,948,962</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">28,948,962</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Market value of stock at beginning of period</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.75</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">2.12</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Market value of stock at end of period</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.54</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1.86</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr></table>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">A reconciliation of the change in value of such warrants for the three months ended March 31, 2012 is as follows: </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
<tr><td width="88%"> </td>
<td valign="bottom" width="6%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td valign="bottom" nowrap="nowrap">

<p style="border-bottom: #000000 1px solid; width: 48pt;"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in thousands)</b></font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom" colspan="2"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Balance at December&nbsp;31, 2011</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,446</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Change in value of warrants</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">10,926</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Reclassification to shareholders' equity upon exercise of warrants</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">&#8212;&nbsp;&nbsp;</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr><td valign="top">

<p style="text-indent: -1em; margin-left: 1em;"><font style="font-family: Times New Roman;" class="_mt" size="2">Balance at March&nbsp;31, 2012</font></p></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,372</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table>

<p style="margin-top: 12px; text-indent: 32px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The following table summarizes information about warrants outstanding at March 31, 2012. </font></p>

<p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;">&nbsp;</p>

<table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="84%" align="center">
<tr><td> </td>
<td valign="bottom" width="21%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="21%"> </td>
<td> </td>
<td valign="bottom" width="21%"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr><td style="border-bottom: #000000 1px solid;" valign="bottom" nowrap="nowrap" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Exercise&nbsp;Price</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Outstanding&nbsp;Warrants&nbsp;at<br />March&nbsp;31, 2012</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Weighted&nbsp;Average&nbsp;Remaining<br />Contractual Life (Years)</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Exercisable<br />Warrants</b></font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">$0.0003</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,667</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">No&nbsp;expiration&nbsp;date</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">16,667</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">0.1679</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">238,228</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">0.6</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">238,228</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">1.14</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">No expiration date</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">1,000</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">1.16</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">14,124,202</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">2.3</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">14,124,202</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">1.45</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">66,142</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">1.8</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">66,142</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">1.78</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">9,410,310</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">2.4</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">9,410,310</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr bgcolor="#cceeff"><td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">2.45</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,348,308</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">0.7</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">5,348,308</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 1px solid;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td></tr>
<tr><td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">29,204,857</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"> </td>
<td valign="bottom"><font class="_mt" size="1">&nbsp;</font></td>
<td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;</font></td>
<td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">29,204,857</font></td>
<td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">&nbsp;&nbsp;</font></td></tr>
<tr style="font-size: 1px;"><td valign="bottom"> </td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> </td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td valign="bottom">

<p style="border-top: #000000 3px double;">&nbsp;</p></td>
<td>&nbsp;</td></tr></table> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivatives and fair value of assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesAndFairValueTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsNoteDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>102</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements Of Operations And Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/StatementStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Statements Of Operations And Comprehensive Income (Loss)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements Of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization And Basis Of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization And Basis Of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureNetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureAccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - U.S. Government Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureUSGovernmentContracts</Role>
      <ShortName>U.S. Government Contracts</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureStockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avibio.com/2010-09-30/role/DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 00100 - Statement - Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 00105 - Statement - Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00200 - Statement - Statements Of Operations And Comprehensive Income (Loss)</Log>
    <Log type="Info">Process Flow-Through: 00300 - Statement - Statements Of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>avii-20120331.xml</File>
    <File>avii-20120331.xsd</File>
    <File>avii-20120331_cal.xml</File>
    <File>avii-20120331_lab.xml</File>
    <File>avii-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
